

Is There a VA Advantage?

Evidence from Dually Eligible Veterans

David C. Chan

David Card

Lowell Taylor*

October 2021

Abstract

We study public vs. private provision of health care for veterans aged 65 and older, who are eligible for care in private hospitals and in hospitals operated by the US Department of Veterans Affairs (VA). Utilizing the ambulance design of Doyle et al. (2015), we find that the VA reduces 28-day mortality by 46% (4.5 percentage points). Survival gains persist for at least a year. The VA also reduces 28-day spending by 21%; reported care is strikingly different between VA and non-VA settings. We find suggestive evidence of complementarities between continuity of care, health IT, and integrated care.

JEL Codes: I10, I18

Keywords: VA, Medicare, mortality, dual eligibility

*Chan: Stanford University, Department of Veterans Affairs, and NBER, david.c.chan@stanford.edu; Card: UC Berkeley and NBER, card@berkeley.edu; Taylor: Carnegie Mellon University and NBER, lt20@andrew.cmu.edu. We thank Steve Asch, Marika Cabral, Joe Doyle, Amy Finkelstein, Josh Gottlieb, Kate Ho, Peter Hull, Bob Kaestner, Chad Kessler, Tim Layton, Carol Propper, Michael McWilliams, Maria Polyakova, Jim Rebitzer, Adam Sacarny, David Silver, Anita Vashi, Todd Wagner, and Chris Walters for helpful comments and suggestions. We also thank Sophie Andrews, Sydney Costantini, Kaveh Danesh, Akriti Dureja, Johnny Huynh, Kevin Kloiber, Uyseok Lee, Chris Lim, Matthew Merrigan, Kevin Todd, and Justine Weng for excellent research assistance. Finally, we thank Melissa Taylor for valuable insight with regard to our research design. Chan gratefully acknowledges generous support from VA HSR&D I01HX002631, the Laura and John Arnold Foundation, and the Stanford Institute for Economic Policy Research.

1 Introduction

A key question in the design of health care systems across the world is whether care should be provided by government or by the private sector. In the US, the choice between public and private provision has become a top policy issue for the Department of Veterans Affairs (VA). Seeking to improve veteran access to health care, policymakers have debated whether the VA should expand the capacity of its own system—the Veterans Health Administration—or shift health care delivery to private providers.

An extensive descriptive literature (e.g., Reid 2010; Blank et al. 2017) has compared health care outcomes in public vs. private systems. More generally, economists long have debated the appropriate size and role of the public sector in the economy, highlighting theoretical arguments about competitive pressure, ownership structure, and differences in the objectives and constraints in the public vs. private sector (Alchian 1965; Stigler 1965; Hart et al. 1997). Nevertheless, rigorous empirical evaluations of the performance of public vs. private health care providers have been relatively rare, in no small part because public and private providers of health care usually serve different patient populations, either by statute or by patient selection.

In this paper, we focus on “dually eligible” veterans aged 65 and older who can receive health care at both VA facilities and private hospitals that accept Medicare. We use the ambulance design proposed by Doyle et al. (2015) to study the causal effect of receiving emergency care at the VA vs. a non-VA facility. Our approach compares veterans sharing key characteristics—zip code of residence, prior VA and non-VA utilization, and location of pick-up (e.g., their home residence vs. a nursing home)—who receive the same dispatched level of ambulance service (i.e., advanced vs. basic life support) from different ambulance companies. Our main analytic sample includes 401,319 911-dispatched ambulance rides from 2001 to 2014, for veterans with prior attachment to the VA and in a zip code served by at least two ambulance companies. As in Doyle et al. (2015), we show that the leave-out share of dually eligible veterans transported to the VA by the assigned ambulance company is a strong predictor of hospital assignment. Under the plausible assumption that ambulances are quasi-randomly assigned within zip codes and in cells of key characteristics, this design allows us to study the effect of VA vs. non-VA emergency care on health outcomes.

We find that in the high-mortality population of elderly veterans with emergencies, there is a VA advantage—a 46% reduction in 28-mortality relative to baseline (4.5 p.p., with a 95% confidence interval of 1.1 to 8.0 p.p). Importantly, we show that our instrumental variables (IV) estimates of the

VA effect are robust to the inclusion of a long list of characteristics of the index patient and of other patients transported by the same ambulance company. The latter set of ambulance co-rider controls can account for unobserved patterns of selection across ambulance companies (Altonji and Mansfield 2018). The IV estimates are larger in magnitude than the corresponding OLS estimates, which center around 2.4 p.p., with tight confidence intervals. A possible explanation for this difference is that VA “always takers” (patients who go to the VA even with an ambulance company with a low VA rate) in fact have worse health than VA “never takers,” a pattern suggested by the medical literature and one that we examine in greater detail below (Agha et al. 2000).

An important question for interpreting the survival benefits of VA care is whether these effects fade over longer horizons—as would happen if VA emergency care only temporarily displaces the mortality of fragile patients under “harvesting” (Schwartz 2000). To address this, we use an insight from Abadie (2002) to estimate the weekly potential death rates in the year after the initial ambulance ride among compliers of the quasi-experiment, i.e., patients whose destination hospital is determined by the ambulance company. With this tool, we disentangle the short-term vs. long-term effects of the VA in the setting of competing risks. Despite a high long-term mortality rate (close to one in three veterans will be dead within one year of the ambulance ride), we find that the mortality impact of presenting at the VA is concentrated in the first week, suggesting VA survival gains from care addressing temporary emergency conditions. We find no evidence of harvesting; the survival gains appear to be long-lasting. Relying on intuition from Kitagawa (2015), we also use this potential outcomes framework to develop a sharper test of IV validity than the tests typical in the applied literature.¹ Finally, we use this framework to document systematically *larger* long-run mortality hazards for VA always takers than for VA never takers, based on the fact that differences between OLS and IV estimates of the VA advantage consistently widen with longer time horizons.

The key potential threat to our research design is that veterans who are taken to the VA are healthier than veterans who are taken to non-VA hospitals. While this runs counter to the selection that we demonstrate above, this could arise if the choice of a specific ambulance company from among those that serve a given zip code is correlated with the risk of death. We present three additional pieces of evidence to address this concern. First, we show balance in characteristics of patients assigned to

¹Specifically, we use the fact that, under IV validity, all indicators for potential outcomes must occur with positive probability among compliers (Balke and Pearl 1997; Kitagawa 2015). In the setting of survival, this implies that the incremental mortality risk must be positive for compliers in every week after the ambulance ride and in both VA and non-VA assignment. This prediction may fail if there are violations of monotonicity that may arise, for example, because ambulance companies with higher VA propensities are *less* likely to send veterans with certain potential mortality outcomes to the VA. Chan et al. (2019) show that this approach may detect violations in IV validity that remain hidden under standard “judges design” tests of monotonicity (e.g., Arnold et al. 2018).

companies with different propensities of taking patients to the VA. Second, we conduct an extensive analysis along the lines suggested by Altonji et al. (2005), evaluating the stability of our estimates as we add controls to the models, including controls that measure the characteristics of *other* patients transported by the company. Third, in heterogeneity analyses, we show that the VA advantage is highly stable across VA and non-VA hospital characteristics that may be related to selection of high-risk patients.

In the final section of the paper we turn to an evaluation of the mechanisms behind the VA advantage. We consider three broad classes of mechanisms. First, we assess heterogeneity in the VA advantage according to patient and hospital characteristics. Second, along the lines of Doyle et al. (2015), VA hospitals could achieve better outcomes by spending more. On the other hand, the VA may utilize and report different sets of procedures relative to non-VA hospitals, in part because VA and non-VA hospitals are subject to very different financial incentives. Third, better access to patient information and coordination of care may improve the productivity of VA-delivered care, particularly in high-uncertainty and high-stakes environments such as emergency care. This last mechanism is consistent with a descriptive literature that highlights integration of care and health information technology (IT) as distinguishing features of the VA relative to the private sector since reforms in the mid-1990s (McCarthy and Blumenthal 2006; Jha et al. 2009).

In the first class of mechanisms, we find evidence for moderate selection on gains. Compliers in our quasi-experiment—veterans with more prior VA utilization who are medically needier and socioeconomically disadvantaged—tend to have higher treatment effects. However, in no set of patients or location do we find that the VA actually worsens health outcomes. While the VA hospitals differ from non-VA hospitals in their characteristics (e.g., they are more likely to be academic), we also find a consistent VA advantage regardless of VA or non-VA hospital characteristics. This suggests that the VA advantage is fairly broad, though disadvantaged veterans with complex medical needs may particularly benefit from the VA.

We evaluate the second explanation by examining VA and Medicare spending, using information on actual spending by taxpayers and veterans. Spending following VA care is *lower* by \$2,598, or about 21%, at 28 days. This suggests that the VA is more productive, achieving better outcomes at lower cost. We generate these results on actual spending from the perspective of taxpayers and patients. Alternatively, if we measure resource utilization by applying fixed prices to procedures in both VA and non-VA settings (Finkelstein et al. 2016), the reduction in spending following transport to a VA hospital almost doubles. We find evidence suggestive of “upcoding”—in which cases are

more likely to be coded as complex (Dafny 2005; Geruso and Layton 2020)—in the Medicare setting relative to the VA. Meanwhile, services that are reimbursed little by Medicare (e.g., telephone calls) are much more likely to be documented in VA utilization. While some of the striking differences in reported utilization likely reflects coding practices, it is also likely that a substantive portion reflects true differences in care, driven by differences in financial incentives in the VA and non-VA settings.

The third explanation centers on the idea that coordination and continuity of care in an integrated delivery system may improve health outcomes—an explanation consistent with the larger impacts of the VA on medically needy patients and those with greater prior attachment. Unfortunately, as is the case with the prior literature, we cannot show direct quasi-experimental evidence of this joint mechanism among veterans who use the VA: The VA had integrated care from before our data, and veterans with no prior attachment with the VA are almost never transported to the VA. Instead, we study this indirectly among veterans who only use *non-VA* hospitals in the setting of two policy reforms to stimulate health IT and integrated care within non-VA hospitals.

Specifically, through a parallel ambulance quasi-experiment, we ask whether these patients benefit from being assigned to their most-visited prior (non-VA) hospital (i.e., their “modal” hospital) relative to the following reforms: the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 and legislation to spur participation in “Accountable Care Organizations” (ACOs) beginning in 2011 (Blumenthal 2010; Greaney 2011). We find that the modal-hospital survival benefit increases from a negligible effect prior to the policy reforms to about 1.9 p.p.—approximately one-half of the VA survival benefit—after 2010. We also find tentative evidence linking the increase in the modal-hospital survival benefit to hospital-specific health IT adoption and, to a lesser degree, ACO participation.

Our findings contribute to three sets of related literature. First, the public vs. private provision of health care is a central question for the field of comparative health policy, which compares health care systems across the world to inform the design of health care systems (Blank et al. 2017). The literature in this field has been mainly descriptive.² Comparing the performance of health care systems across countries is intrinsically difficult for obvious reasons: Countries differ in their populations and in other determinants of health. Evidence comparing public vs. private health care provision within the same country has also been scarce. To our knowledge, a recent working paper by Frakes et al. (2020)

²As an example of the amount of material devoted to such comparative studies, the European Observatory on Health Systems and Policies (www.euro.who.int) produces policy commentary and “health system reviews” on the health care systems of individual countries.

provides the only other quasi-experimental examination of this question.³ Studying military mothers who give birth in two different hospitals due to a move in between births, they find higher spending but lower rates of complications in private hospitals.

Second, an important literature has sought to measure the quality of care in the VA, which budgeted \$84 billion for medical care in 2020 (Department of Veterans Affairs 2020).⁴ Following a well-known reorganization and investment in health IT in the mid-1990s (McCarthy and Blumenthal 2006), this literature has documented favorable VA quality, compared to care outside of the VA, in terms of process measures and health outcomes (e.g., Jha et al. 2003). The question of performance in the VA health care system has become particularly relevant in recent years, as the Department considers ways to improve access to care for veterans and as Congress has sought to increase private health care delivery for veterans (113th Congress 2014; 115th Congress 2018). So far, however, this literature has mainly compared outcomes of veterans receiving care in the VA system to those of non-veterans outside of the VA.

A third and very large literature studies why health care in the US appears to be a low-productivity outlier among developed countries, spending more as a percentage of GDP than any country but with poor outcomes relative to this spending (Garber and Skinner 2008). Experts have drawn attention to fragmentation in the US health care system, which could increase spending and potentially worsen outcomes (Cebul et al. 2008; Cutler 2010; Agha et al. 2019). Policymakers have responded by incentivizing adoption of health IT and coordination of care, but whether such policies improve health outcomes remains an open empirical question.⁵ Our results are consistent with a productivity advantage (better outcomes at lower cost) at the VA, the nation's largest integrated health care system. We find striking differences in reported services in VA vs. non-VA settings: VA hospitals are much more likely to report utilization of low-cost services that improve coordination and continuity of care; non-VA hospitals are much more likely to report highly intense services. We also find suggestive evidence that government regulations to incentivize private hospitals to adopt health IT and integrate care may

³A related but distinct question of the impact of competition on government-provided health care is addressed in several important papers studying the British setting (e.g., Gaynor et al. 2013; Bloom et al. 2015; Gaynor et al. 2016). Within this strand of research, Cooper et al. (2018) and Kelly and Stoye (2020) also study the impact of private competition on public performance; both papers also document selection of healthier patients to private hospitals.

⁴Spending continues to grow. The 2019 enacted budget allocated \$77 billion for VA medical care, and the 2021 proposed budget requests \$94 billion for medical care. For the last ten years, spending on medical care has nearly doubled (Department of Veterans Affairs 2020).

⁵A recent empirical literature documents modest reductions in spending and improvements in patient satisfaction among provider forming ACOs (McWilliams et al. 2014, 2016; Trombley et al. 2019). Finally, a mixed literature on health IT adoption has shown health improvements in some cases (e.g., Miller and Tucker 2011) but null results in general (e.g., Agha 2014). To our knowledge, our paper is the first to assess the complementarity between health IT and continuity of care.

achieve better outcomes, at least in our setting for patients with continuity of care at these hospitals.

The remainder of this paper proceeds as follows. Section 2 describes the setting and data. Section 3 presents our main analysis of the VA survival benefit. Section 4 discusses our survival analysis over time. Section 5 presents evidence on mechanisms driving the VA survival benefit. Section 6 discusses policy implications and concludes.

2 Setting and Data

2.1 US Health Care and the Veterans Health Administration

The US health care system is marked by a high level of complexity involving multiple private and public (federal, state, and local) parties. The US spends more on health care per capita than any other country—50% greater than the second-highest country, Norway—but has lower life expectancy than most other high-income countries (Rice et al. 2013). Compared to other high-income countries, the private sector plays a greater role in the US health care system.

Nonetheless, veterans in the US have access to an important system of public provision: the Veterans Health Administration of the US Department of Veterans Affairs (VA). The VA provides health care for 9 million veteran enrollees, a number that has grown dramatically in recent decades (Chan et al. 2021). The VA is the nation’s largest integrated health care delivery system, including 170 medical centers and more than 1,000 outpatient sites of care, with a budget of \$84 billion in 2020 for medical care (Department of Veterans Affairs 2020).

Key institutional features distinguish the VA from private providers in the US. The VA has a well-defined patient population—enrolled veterans—while most patients in the private US health care system receive care from multiple, unaffiliated providers (Cebul et al. 2008; Agha et al. 2019). Relatedly, financing in the VA is allocated primarily according to the needs of enrolled veterans (Wasserman et al. 2005); in contrast, private providers receive financing largely through fee-for-service contracts tied to the cost of services and inpatient hospitalizations (Rice et al. 2013).

Finally, compared to non-VA providers, the VA functions as an integrated system. It directly employs all of its physicians and health care workers, while physicians outside of the VA are mostly independent of the hospitals at which they work and can affiliate at will with multiple hospitals. Care in the VA is also integrated across inpatient, emergency department, and outpatient locations, as well as across different services and specialties of care. Since the mid-1990s, when the VA implemented one of the first and most widely used electronic health record (EHR) systems in the US, VA providers

can communicate and access records across different settings. In comparison, prior to the Affordable Care Act (ACA), only 1.5% of private US hospitals maintained a comprehensive EHR system (Jha et al. 2009). In the wake of the ACA, federal policies have attempted to spur care coordination and health IT adoption in the private sector (Blumenthal 2010; Greaney 2011). Nevertheless, “interoperability” (i.e., the ability to share electronic records) across private hospitals has remained low (Holmgren et al. 2017).

2.2 Comparing VA and Non-VA Care

Over the past decade, lawmakers have enacted major reforms that allow veterans to receive VA-funded care at private facilities (113th Congress 2014; 115th Congress 2018).⁶ These reforms broaden the role of the VA to that of an *insurer* of care for veterans (similar to the role of Medicare for the elderly), with concomitant functions such as authorizing care, processing claims, and *ex post* monitoring of claims for waste and fraud.

Related to these initiatives, the quality of VA vs. non-VA care has been a longstanding subject of interest to policymakers and researchers. The health services literature has documented that the VA provides care that is of the same or higher quality than that of the private sector, as measured by a wide variety of process measures and health outcomes.⁷ However, these comparisons are potentially confounded by differences, due to eligibility and self-selection, between the populations that utilize care in the VA and in non-VA facilities. Indeed, the vast majority of existing research has compared the care of veterans in the VA with the care of non-veterans in non-VA facilities.⁸

We use two key ideas to extend the literature on comparisons between VA and non-VA care. First, we focus on dually eligible veterans who are aged 65 and older. These veterans are eligible to receive care in the VA and at non-VA hospitals using Medicare (Hynes et al. 2007). A large and growing proportion of dually eligible veterans use care in both VA and non-VA settings (Liu et al. 2018). Patient cost-sharing is significantly lower for VA care than under Medicare: For most VA enrollees,

⁶There have been additional well-funded efforts to shift care further into the private sector (Rein et al. 2018; Kefe 2018; Shulkin 2018; Gordon 2019). According to an official recommendation to the congressionally established Commission on Care, some have even proposed that “if veteran choice dictates it over time, the long term goal of the transformation is the total transition to community care” (Blom 2016).

⁷See Shekelle et al. (2010), Trivedi et al. (2011), and O’Hanlon et al. (2017) for systematic reviews. The literature includes dozens of studies on hundreds of quality of care process measures, as well as several studies on health outcomes.

⁸Two studies are noteworthy for having better identification. Nuti et al. (2016) compare outcomes for veterans in VA hospitals with outcomes for non-veterans in non-VA hospitals but restrict comparisons between VA and non-VA hospitals in the same metropolitan statistical areas. In an older study, Wright et al. (1999) look at 47,598 dually eligible veterans with a myocardial infarction. These studies find no difference or slightly better mortality outcomes in VA hospitals. Of note, a related literature suggests that veterans generally have poorer health than non-veterans (e.g., Agha et al. 2000).

care is essentially free in the VA setting; in contrast, the average Medicare beneficiary spends more than 40% of Social Security income on out-of-pocket health care costs (Cubanski et al. 2018; Hynes et al. 2021).

Second, we build on the ambulance design strategy of Doyle et al. (2015) to sidestep concerns about the endogenous selection of where to obtain care. Specifically, we study veterans who arrive at a hospital via a 911-dispatched ambulance, comparing veterans from the *same zip code* who could have obtained services from different ambulance companies with different propensities to transport patients to a VA hospital. Importantly, Doyle et al. (2015) document that the company dispatched to serve a given patient may be chosen independently of the patient’s characteristics, due to rotational assignment, direct competition between available providers, or software that may consider the placement of available ambulance units at the time of the 911 call (Chiang et al. 2006; Ragone 2012). Ambulance companies also exhibit different tendencies to transport patients to different hospitals, based on their ownership, headquarter location, and other characteristics (Skura 2001). We further describe our quasi-experimental design and assess its assumptions in Section 3.

2.3 Data

We use data from two main sources—Medicare claims and VA administrative data—for the universe of enrolled veterans in the VA from the years 2000 to 2014. We observe all Medicare claims for any dually enrolled veteran. These claims data include the beneficiary’s zip code and demographic information (age, race, and gender), as well as a record of medical services, each defined by an encounter date, Current Procedural Terminology (CPT) code(s), diagnostic (International Classification of Diseases, Ninth Revision, or ICD-9) codes, and provider identity. On the VA side, we have a complete record of clinical encounters in the electronic health record system that we transform into a corresponding set of encounter dates, CPT codes, ICD-9 codes, and provider identities.⁹

We begin by selecting ambulance ride events for dually eligible veterans, as recorded in the Medicare claims.¹⁰ We restrict attention to “lights and sirens” emergency ambulance rides that originate from 911 dispatch calls.¹¹ As in Doyle et al. (2015), we extract the date of the ambulance ride and

⁹The VA system includes patient home address information. However, we use the zip code information from the Medicare claims records as our source of home location, since this information is updated frequently and has been widely used in previous studies, including Doyle et al. (2015).

¹⁰VA policy is that patients with outside insurance should have ambulance services paid for by that insurance. In our dually eligible population, therefore, ambulance rides will be recorded in the Medicare claims.

¹¹We select ambulance rides with Healthcare Common Procedure Coding System (HCPCS) codes A0322, A0328, A0330, A0362, A0368, A0370, A0427, A0429, A0433, or Q3019. We restrict to modifiers “RH”, “SH”, “NH”, and “EH”, corresponding to rides to a hospital from a residential location, a scene of an accident or acute event, a skilled

the identity of the ambulance company, based on its tax identification number (TIN). We use the ambulance company identity to develop our instrumental variable for the propensity of the ambulance company to deliver patients to the VA or to non-VA hospitals. We also extract information on interventions provided by the ambulance (e.g., intravenous fluids, intubation), the level of care (advanced life support or basic life support), the pick-up location (e.g., private residence, nursing home, skilled nursing facility, accident), and the ambulance diagnosis (ICD-9) codes assigned by the ambulance personnel.

We then link these ambulance rides to emergency department (ED) visits at VA and non-VA hospitals. This constitutes our main treatment of interest. For each patient we collect information on medical conditions and outpatient, ED, and inpatient utilization over the prior year, as recorded in the Medicare claims and VA records. We use the ICD-codes for past medical conditions to identify 31 Elixhauser indices (Elixhauser et al. 1998) of comorbidities, noting the source of each condition (i.e., from visits to the VA, to non-VA facilities, or both). These comorbidities range from common conditions such as hypertension to rarer conditions such as lymphoma.

Our main outcome measure is mortality. We obtain information on exact date of death from three sources: records of inpatient deaths from the VA and Medicare claims; records of death from the Veterans Benefits Administration (VBA), and records of death from the Social Security Administration (SSA). The latter two sources are particularly reliable, as they determine whether the veteran will receive payments from either the VBA or the SSA, and draw on reports from family, funeral directors, post offices, financial institutions, other federal agencies, and state vital records agencies.

To construct our main analytical sample of 401,319 ambulance rides, we make the following restrictions (see Appendix Table A.1). First, we remove patients who live in zip codes more than 20 miles away from either the nearest VA hospital or the nearest non-VA hospital. We also drop patients who traveled more than 50 miles from their zip code to the hospital. Second, we require that patients live in zip codes served by at least two ambulance companies with at least 20 rides, at least 5% of rides transported to a VA hospital, and at least 5% transported to a non-VA hospital. Finally, for our baseline analysis of VA vs. non-VA care, we drop veterans with no VA primary, ED, or inpatient care in the prior year, since fewer than 1% of these veterans are ever transported to the VA. In our secondary analysis of veterans who may be transported to modal or non-modal hospitals outside of the VA, in Section 5, we study an analogous sample of 1,414,217 ambulance rides of veterans who did not use VA care in the previous year and who live in zip codes with at least two non-VA hospitals nursing facility, and an extended care facility, respectively.

within 20 miles. Appendix Table A.13 describes the selection process for this sample.

Table 1 describes the characteristics of the veterans and the episode associated with their ambulance ride at different steps in the creation of the main analytical sample. The average 28-day mortality rate is stable across steps and relatively high, between 26.9 and 27.2 p.p., reflecting the illness acuity of elderly veterans who arrive by 911-dispatched ambulance. Similarly, the weekend rate, which is the proportion of ambulance rides arriving on a weekend day, is remarkably stable and close to two-sevenths, which reflects the unplanned nature of these health events (Card et al. 2009). The main impact of our sample restrictions is to increase the share of rides going to a VA hospital. Notably, rides transporting veterans with both VA and non-VA ED visits in the prior year comprise about a third of the rides transporting veterans with any ED visit in the prior year. In some of the steps, such as the step imposing zip-code distance restrictions, the sample becomes more concentrated in urban areas with shorter distances to nearby VA and non-VA hospitals. Black veterans also comprise a larger share of the sample. Patient characteristics otherwise remain stable across sample restriction steps.

3 Benchmark Analysis

3.1 Quasi-Experiment

Following Doyle et al. (2015), our main empirical strategy relies on the assignment of ambulances to patients in emergencies and the role of ambulance companies in determining the hospital that a patient is taken to for emergency care. As detailed in Doyle et al. (2015), several companies typically serve the same narrow geographic area. The assignment of a particular company may be quasi-experimentally determined such that the identity of the assigned ambulance company is plausibly unrelated to patient characteristics. Furthermore, ambulance companies exhibit “preferences” for delivering patients to certain hospitals, due to their ownership or the location of their operations.

We define conditioning sets within which ambulance assignment may be as good as random. First, we condition on the origin zip code $z(i)$ of ambulance ride i , so that we compare patients from the same zip code who are picked up by different ambulance companies. Second, we categorize the ambulance by whether it offers advanced life support (ALS) or basic life support (BLS) based on ambulance Healthcare Common Procedure Coding System (HCPCS) codes. We further categorize rides by the pickup site category (e.g., residential address, nursing home, scene of an accident), the day of the week, and month-year interactions (e.g., January 2010). Finally we condition on measures

of the patient’s primary care, ED, and inpatient utilization over the past year at VA and non-VA facilities.¹² For simplicity we refer to the joint set of controls for the type of ambulance, pickup site, date of pickup, and patient prior utilization as \mathbf{X}_i^0 .

Unlike Doyle et al. (2015), we do not include patient demographics, prior medical conditions, or ambulance diagnoses in the set of baseline controls. Instead, we “hold out” these variables—many of which are highly predictive of mortality—and show that they are balanced across local ambulance companies with differing propensities to send patients to the VA, conditional on $(z(i), \mathbf{X}_i^0)$.

Our treatment of interest is delivery to a VA hospital, which we denote by the indicator $D_i \in \{0, 1\}$ for ambulance ride i . Transfers are rare in our sample.¹³ Ride i is provided by company $j(i) \in \mathcal{J}_{z(i)}$, where \mathcal{J}_z is the set of companies that serve zip code z .¹⁴ Associated with each ride and company is a potential treatment indicator $D_i(j)$; thus $D_i = D_i(j(i))$. Our main outcome is 28-day mortality of the patient, denoted by $Y_i \in \{0, 1\}$. The associated potential outcomes, $Y_i(d)$, depend on whether the patient was transported to a VA hospital ($d = 1$) or not ($d = 0$), with $Y_i = Y_i(D_i)$.

Under the assumptions that different ambulance companies have systematically different tendencies to transport patients to the VA, and that the assignment of $j(i)$ is as good as random, conditional on $(z(i), \mathbf{X}_i^0)$, the identity of the ambulance company can be used to construct a valid instrumental variable for D_i . More formally, we consider the following conditions for IV validity (Imbens and Angrist 1994):

Condition 1 (IV Validity). *For a random sample of ambulance rides i provided by ambulance companies j , the following conditions hold:*

- (i) *Relevance: $E[D_i(j) | z(i), \mathbf{X}_i^0]$ is a nontrivial function of $j \in \mathcal{J}_{z(i)}$.*
- (ii) *Independence and Exclusion: The vector of potential outcomes, $(Y_i(0), Y_i(1), D_i(j))$, is independent of the assigned ambulance company, $j(i) \in \mathcal{J}_{z(i)}$, conditional on $(z(i), \mathbf{X}_i^0)$.*
- (iii) *Monotonicity: Conditional on $(z(i), \mathbf{X}_i^0)$, for any j and j' , $D_i(j) \geq D_i(j')$ for all i , or $D_i(j) \leq D_i(j')$ for all i .*

The compliers in this quasi-experiment are rides with dually eligible veterans who could be

¹²The latter set of prior utilization measures may capture ambulance service areas within large zip codes, which may in turn account for correlations between prior use of VA vs. non-VA care and the identity of ambulance companies.

¹³Of the 132,535 rides that go to the VA, 828 (0.6%) have a non-VA hospital ED visit on the subsequent day. Of the 268,784 rides to a non-VA hospital, 2,191 (0.8%) have an ED visit at a VA hospital the next day. Of 79,684 VA admissions, 418 (0.5%) were transferred to a non-VA hospital within 7 days of the ambulance ride. Of 157,682 non-VA admissions, 1,774 (1.1%) were transferred to a VA facility within 7 days.

¹⁴We define an “ambulance company” as the interaction between an ambulance company tax identification number (TIN) and the health referral region (HRR) of the ride. This accounts for a few large corporations with a single TIN that serve multiple regions.

swayed to a VA or a non-VA hospital depending on the identity of the ambulance company. Because only veterans are typically treated in VA hospitals, these compliers are patients who may state to an ambulance (but possibly not to all ambulances) that they are a veteran and who would be open to care at the VA. By definition, they likely exclude veterans who would insist on either being taken to a VA hospital or to a hospital outside of the VA. Nonetheless, in the next subsection, we estimate a sizeable share of compliers, consistent with the high share of veterans in the baseline sample with both VA and non-VA ED visits in the prior year (Table 1). We also estimate and report complier characteristics in Section 5.1. As expected, compliers are more likely to have had prior ED visits at the VA; almost three in ten compliers have had ED visits in both VA and non-VA hospitals in the prior year.

As is standard in the judges-design literature (e.g., Kling 2006, Dahl et al. 2014), to deal with finite samples, we construct a leave-out (or jackknife) instrumental variable that reflects the propensity of the ambulance company $j(i)$ assigned to ride i to transport *other* patients to the VA. We compute this as the average fraction of other patient who were picked up by company $j(i)$ and went to the VA. Specifically, for ambulance ride i transporting patient $k(i)$ we define the leave-out probability Z_i of transport to the VA:

$$Z_i = \frac{1}{K_{j(i)} - 1} \sum_{i' \in \mathcal{I}_j(i)} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}}{N_{k(i'), j(i)}}, \quad (1)$$

where K_j is the total number of patients transported by company j , $N_{k,j}$ is the total number of rides taken by patient k with company j , and \mathcal{I}_j is the set of rides transported by ambulance company j . We estimate Z_i using the sample of dually eligible veteran ambulance rides (Column 1 of Table 1).

Under Condition 1, an IV estimate based on Z_i , conditioning on $(z(i), \mathbf{X}_i^0)$, recovers a local average treatment effect (LATE) of the VA on mortality among compliers. For comparison, we also consider the observational “treatment effect” of going to the VA on mortality of patients who arrive at hospital in a 911-dispatched ambulance, controlling for $(z(i), \mathbf{X}_i^0)$:

$$Y_i = \beta D_i + \mathbf{X}_i^0 \delta_0 + \zeta_{0,z(i)} + \varepsilon_{0,i}. \quad (2)$$

where $\zeta_{0,z}$ represents an unrestricted fixed effect for rides originating in zip code z . As in Doyle et al. (2015), zip code fixed effects imply that both our observational and quasi-experimental concepts of the VA treatment effect involve comparisons between veterans who live in the same zip code.

Estimating Equation (2) by OLS yields $\hat{\beta}_{OLS}$, while instrumenting D_i with Z_i yields $\hat{\beta}_{IV}$.

The gap between $\hat{\beta}_{OLS}$ and $\hat{\beta}_{IV}$ will depend on differences in the potential outcomes between never takers (i.e., patients who go to a non-VA facility regardless of the ambulance company) and always takers (i.e., patients who go to the VA regardless of the ambulance company), as well as on differences in treatment effects between compliers and non-compliers. In the setting of a VA advantage, if sicker veterans are more likely to select into VA hospitals (e.g., Agha et al. 2000), then $\hat{\beta}_{OLS}$ may be smaller in magnitude than $\hat{\beta}_{IV}$. We explore this gap more directly in Section 4.

3.2 First Stage, Balance, and Reduced Form

We begin our empirical analysis by demonstrating instrument relevance, Condition 1(i), with the following first-stage regression:

$$D_i = \pi_1 Z_i + \mathbf{X}_i^0 \delta_1 + \zeta_{1,z(i)} + \varepsilon_{1,i}. \quad (3)$$

The coefficient π_1 reflects the impact of ambulance company preferences on the probability that the ride goes to the VA, conditional on our baseline controls for ambulance type, pickup site, zip code, date categories, and veteran prior utilization. Figure 1, Panel A, shows a binned scatterplot of residualized D_i on the y -axis with respect to residualized Z_i on the x -axis and reports $\hat{\pi}_1 = 0.882$ (s.e. 0.034). The first-stage relationship between D_i and Z_i is very predictive and close to linear.

To assess independence, Condition 1(ii), we test whether Z_i is correlated with patient characteristics that are correlated with mortality. Specifically, we construct an estimate of predicted mortality \hat{Y}_i using “hold-out” patient characteristics of patient demographics and 31 Elixhauser indices for prior medical conditions.¹⁵ We then fit models for \hat{Y}_i based on the same right-hand-side specification as in Equation (3). Panel B of Figure 1 shows (with hollow dots) that there is no relationship between \hat{Y}_i and Z_i , controlling for $(z(i), \mathbf{X}_i^0)$.¹⁶ In contrast, the same panel shows (with solid dots) that the reduced-form relationship between actual mortality, Y_i , and Z_i is significantly negative, under the

¹⁵Patient demographics include age, gender, and race and ethnicity. Age is captured by two-year age bins from 65 years to 100 years. Race and ethnicity is captured with three dummies for white, Black, and Hispanic; the omitted category is Asian/other. We use the 31 Elixhauser indices as described in Elixhauser et al. (1998), interacting each index with the source of the record indicating the comorbidity. There are three possible sources: VA only, Medicare claims only, and VA and Medicare claims. This results in $3 \times 31 = 93$ dummies. These hold-out patient characteristics are described in Appendix Table A.3.

¹⁶In Appendix Figure A.1, we present a simulation exercise that suggests that we have the power to reject a data generating process in which more than a 2-3 percent of patients are perfectly sorted by their predicted mortality to ambulances by the ambulance’s propensity to transport to the VA.

same controls. Specifically, for the reduced-form relationship,

$$Y_i = \pi_2 Z_i + \mathbf{X}_i^0 \delta_2 + \zeta_{2,z(i)} + \varepsilon_{2,i}, \quad (4)$$

we find $\hat{\pi}_2 = -0.040$ (s.e. 0.016). This suggests that quasi-random assignment to an ambulance company more likely to transport to the VA results in an intention-to-treat reduction in mortality.

Under independence, we may quantify the share of compliers in our sample. As shown in Figure 1 (Panel A), 24% of rides that are assigned values of Z_i in the lowest vigintile are still transported to the VA. Veterans in these rides may be considered “always takers.” On the other hand, 58% of rides that are assigned values of Z_i in the highest vigintile are still transported to a non-VA hospital. Veterans in these rides may be considered “never takers.” The remaining share of rides, or 18%, characterizes the share of compliers.¹⁷

The exclusion assumption in Condition 1(ii) asserts that ambulance companies do not affect outcomes other than through their effect on whether a patient arrives at a VA or non-VA hospital. Implicitly, however, our notation also assumes that each complier has a well-defined non-VA hospital that is stable across ambulance companies. In Appendix A.1.1, we evaluate the robustness of our results to potential violations of the exclusion condition. Specifically, we assess and find no evidence of any correlation between Z_i and ambulance treatments captured in summary charges or between Z_i and ambulance propensities to deliver patients to different non-VA hospitals. We also make use of the fact that we can observe mortality outcomes for patients taken by the same ambulance companies but who have no chance of being taken to the VA because they have no prior VA utilization: We assess whether our results are robust to controlling for mortality outcomes of these patients outside of our baseline sample who are transported the same ambulance company. In all of these analyses, we find that our main IV estimate below is qualitatively unchanged, suggesting that our results are robust to violations of exclusion.¹⁸

¹⁷Interestingly, this share of compliers appears roughly similar to that in Doyle et al. (2015). Characterizing compliers in Doyle et al. (2015) is less straightforward because the treatment of hospital spending is a continuous variable. Nonetheless, if we characterize a treatment as one standard-deviation increase in spending (0.2 log points), this is slightly more than the difference between the first and fourth quartile of their instrument (Table 1 in their paper). Their first-stage coefficient of 0.17 (Table 2 in their paper) could then be interpreted as a complier share. While we note that compliers in our setting need to reveal that they are a veteran (to at least one ambulance), which may reduce the share of compliers, our sample of veterans is substantially more disadvantaged, which may imply a *higher* complier share (Card et al. 2018).

¹⁸Following Kolesar et al. (2015), the analyses in Appendix A.1.1 correspond to the weaker assumption that there are no systematic correlations between our instrument and other ambulance-specific treatments that impact our outcome of interest. Specifically, under this weaker version of exclusion, we require that ambulance companies with higher values of $E[D_i(j) | z(i), \mathbf{X}_i^0]$ do not also (i) apply observed treatments during the ambulance ride that affect mortality, (ii) deliver patients to higher- or lower-quality non-VA alternatives, or (iii) have direct mortality effects on patients in a way that can systematically explain our results.

To assess the monotonicity assumption given by Condition 1(iii), we follow the standard practice in the judges-design literature to show that the first-stage relationship between D_i and Z_i remains positive for subgroups of patients defined by different observable characteristics (e.g., Arnold et al. 2018; Bhuller et al. 2020). We detail these analyses in Appendix A.1.2. In Section 4, we present a stronger test of monotonicity (and IV validity) based on *potential outcomes*. Following the reasoning in Kitagawa (2015), this test amounts to showing a positive density for the potential outcome of death in a given week among compliers.

3.3 Mortality Effect

With this background, we now move to our main results on patient mortality. In Table 2, we show both OLS and IV estimation results for Equation (2). Panel A of the table shows $\hat{\beta}_{OLS}$ from Equation (2), while Panel B shows $\hat{\beta}_{IV} = \hat{\pi}_2/\hat{\pi}_1$ from the first-stage and reduced-form regressions in Equations (3) and (4). Column 1 shows our baseline specification, controlling for zip code and the variables in \mathbf{X}_i^0 . The OLS estimate is $\hat{\beta}_{OLS} = -0.024$ (s.e. 0.001), while the IV estimate is $\hat{\beta}_{IV} = -0.045$ (s.e. 0.018).¹⁹ Relative to the mean 28-day mortality of 9.7 p.p., both estimates imply a sizeable reduction in mortality for compliers who are taken to the VA.

In the next section, we will put our IV estimate in context with Doyle et al. (2015), which examines mortality outcomes following ambulance rides at the one-year mark. We find a one-year mortality effect that is similar in magnitude as the Doyle et al. (2015) effect of being treated at a hospital with higher spending by one standard deviation. However, in Section 5.2, we show that the VA saves lives while also substantially *reducing* spending.

The other columns in Table 2 show OLS and IV estimates as we include additional controls to the models: (i) patient demographics (age, race, gender), (ii) ambulance diagnostic (ICD-9) codes, (iii) Elixhauser comorbidity indicators, and (iv) ambulance and co-rider controls, which are all described in Appendix Table A.3. Following the reasoning in Altonji and Mansfield (2018), the latter co-rider controls can capture patient selection at the ambulance company level beyond the observable characteristics of the index patient, by using characteristics of *other* rides and patients under the same ambulance company. Specifically, these controls address the potential concern that sicker patients tend to be allocated to certain ambulance companies that may be more or less likely to take patients to the VA.

¹⁹Appendix Figure A.2 shows the IV estimate visually, by plotting the predicted first-stage probability of treatment from Equation (3) on the x -axis and predicted reduced-form effect on mortality from Equation (4) on the y -axis. The slope of this visual IV relationship corresponds to $\hat{\beta}_{IV} = -0.045$.

Reassuringly, both $\hat{\beta}_{OLS}$ and $\hat{\beta}_{IV}$ remain stable as we add additional controls. Figure 2 illustrates this stability as controls are added in a more granular fashion, and Appendix Figure A.3 shows stability of the IV estimates as we permute the order in which the extra controls are added. The stability of both the OLS and IV estimates suggests a lack of selection based on a wide range of observable patient and co-rider characteristics. If anything, the inclusion of co-rider controls (shown as control sets 11 and 12 in Figure 2) slightly *increases* the magnitude of $\hat{\beta}_{IV}$, though the difference is not statistically significant. Under the reasoning of Altonji et al. (2005), this stability suggests limited scope for selection on unobservable characteristics that predict potential 28-day mortality. However, IV estimates are larger than OLS estimates, suggesting either that never takers are healthier than always takers (i.e., selection runs counter to treatment effects on mortality) or that the LATE is larger than the unconditional average treatment effect (ATE).²⁰ We investigate these possibilities in the next section and in Section 5.1.

4 Survival Analysis

In this section we develop and apply a survival analysis framework to understand the dynamics of potential survival outcomes following the ambulance ride. We use this framework to draw several insights. First, we determine the time course of VA effects on mortality. Second, we use the empirical results of this framework to provide further validation of Condition 1, beyond the standard benchmark analysis in Section 3.2. Third, we investigate the implications of heterogeneity in mortality risks between compliers and non-compliers of our ambulance quasi-experiment.

4.1 Approach

Consider a set of potential survival outcomes $S_i(t; d) \in \{0, 1\}$ under VA care ($d = 1$) and non-VA care ($d = 0$) for each week $t \in \{1, \dots, 52\}$ following the ambulance ride.²¹ By definition, if $S_i(t; d) < S_i(t - 1; d)$, then the patient in ambulance ride i would die in the t^{th} week following the ambulance ride if exposed to treatment d . Of course, potential survival outcomes must weakly decrease over time, i.e., $S_i(t; d) \leq S_i(t - 1; d)$ for all i, d , and t .

²⁰We note that a Hausman test for equality of the two estimates has a t -statistic of only 1.0, so based on this evidence alone, the gap between OLS and IV could be simply due to sampling error. In the next section, however, we show a dynamic pattern of IV and OLS estimates, over the year after the initial ambulance ride, that points more definitively to systematic differences. That is, using additional data over time, we infer with high confidence that the causal VA advantage is larger than the (precisely estimated) OLS effect.

²¹We adopt the convention that a death within the first 7 days is a death in week 1. Thus a death within 28 days is a death by the end of week 4.

As with mortality outcomes, for each ambulance ride i , we can only observe the set of survival outcomes corresponding to $d = D_i$: $S_i(t) = D_i S_i(t; 1) + (1 - D_i) S_i(t; 0)$. However, appealing to Abadie (2002), we can recover the expected survival outcomes for the set of compliers C whose hospital choice depends on which ambulance company picks them up. In particular, under Condition 1, we can estimate $s_{IV}(t; 1) \equiv E[S_i(t; 1) | i \in C]$ by two-stage least squares using the first-stage Equation (3) and a reduced-form equation similar to Equation (4) but with dependent variable $S_i(t) D_i$. Similarly, we can estimate $s_{IV}(t; 0) \equiv E[S_i(t; 0) | i \in C]$ using the same first stage model but replacing the reduced-form outcome variable in Equation (4) with $S_i(t) (D_i - 1)$. Note that by construction, the IV estimand of the VA treatment effect on 28-day mortality in Section 3, satisfies

$$\beta_{IV} = s_{IV}(4; 1) - s_{IV}(4; 0).$$

Given the potential survival outcomes, we can then estimate potential hazard rates for mortality, under VA and non-VA assignment:

$$\begin{aligned} h_{IV}(t; d) &\equiv E[1 - S_i(t+1; d) | S_i(t; d) = 1, i \in C] \\ &= \frac{s_{IV}(t; d) - s_{IV}(t+1; d)}{s_{IV}(t; d)}, \end{aligned} \quad (5)$$

for $d \in \{0, 1\}$ and $t \in \{1, \dots, 52\}$, corresponding to weekly mortality hazard rates up to one year after the initial ambulance ride. Under Condition 1, differences between $\{h_{IV}(t; 1)\}_t$ and $\{h_{IV}(t; 0)\}_t$ can be interpreted as the causal effect of VA assignment, among compliers, on the set of mortality hazard rates.²²

As in Section 3, we calculate risk-adjusted OLS survival functions and mortality hazard rates, conditional on D_i . We estimate $s_{OLS}(t; d) \equiv E[S_i(t; d) | D_i = d] = E[S_i(t) | D_i = d]$ by OLS, replacing the outcome variable in Equation (2) with $S_i(t) D_i$ for $s_{OLS}(t; 1)$ and with $S_i(t) (D_i - 1)$ for $s_{OLS}(t; 0)$. Our OLS estimand of the VA effect on 28-mortality, β_{OLS} , is similarly equal to $s_{OLS}(4; 1) - s_{OLS}(4; 0)$. Corresponding mortality hazard rates can also be calculated based on ob-

²²We emphasize that any gap between $h_{IV}(t, 1)$ and $h_{IV}(t, 0)$ at some later time horizon (e.g., $t = 12$) could arise because treatments at the VA affected the population of compliers who survive to week $t - 1$ and are therefore at risk of death in week t , or because of a treatment effect on the week t hazard, holding the population fixed.

served risk-adjusted survival:

$$\begin{aligned} h_{OLS}(t;d) &\equiv E[1 - S_i(t+1;d) | S_i(t;d), D_i = d] \\ &= \frac{s_{OLS}(t;d) - s_{OLS}(t+1;d)}{s_{OLS}(t;d)}. \end{aligned} \quad (6)$$

Compared to the potential survival functions and mortality hazards, the OLS analogues also incorporate outcomes for the always takers and never takers whose choice of hospital is unaffected by the specific ambulance company that picked them up. Specifically, $s_{OLS}(t;1)$ and $h_{OLS}(t;1)$ reflect survival outcomes for a combination of always takers and compliers, while $s_{OLS}(t;0)$ and $h_{OLS}(t;0)$ reflect survival outcomes for a combination of never takers and compliers.

4.2 Time Course of Mortality Effects

Since we examine potential survival outcomes one year after an ambulance ride, for the analysis in this section we restrict analysis to ambulance rides of patients with no prior ride within one year.²³ Figure 3 shows the estimated potential survival curves and potential hazard rates in weeks 0 to 52 for compliers assigned to the VA and those assigned to a non-VA hospital. The potential survival curves, shown in Panel A, reveal a high risk of mortality among compliers. Mortality at 28 days among compliers assigned to a non-VA hospital is greater than the sample mean of 9.7 p.p., and cumulative mortality at one year is approximately 30 p.p. However, despite the substantial mortality risk over the subsequent year, the gap in survival between VA- and non-VA-assigned compliers (i.e., the mortality treatment effect) is fully realized at 28 days and remains stable for the rest of the year.

In Panel B, we examine the implied hazard rates and show that the differences in mortality are concentrated in the first week following the ambulance ride. Thereafter, though the hazard rates for both VA- and non-VA-assigned compliers remain relatively high, they are indistinguishable from each other. This similarity suggests that the VA advantage results entirely from events within the first week following the ambulance ride.

The potential hazard profiles in Figure 3 suggest that mortality risks for the compliers in our

²³This restriction attributes survival for a given patient in a given week to the “upstream” ambulance ride, rather than attributing the survival event to both upstream and downstream ambulance rides. This changes (decreases) the sample in Appendix Table A.1 to 254,782 rides and 188,299 patients. In Appendix Figure A.14, we show that this restriction (or any other restriction on prior rides) does not lead to qualitative differences in our estimated OLS or IV treatment effects on mortality over time. Qualitatively, regardless of the number of days within which we require no prior ride, the IV estimates are larger than 4 p.p. at 28 days and remain mostly stable within the year following the ambulance ride; the OLS estimates are between 2.0 and 2.5 p.p. at 28 days and essentially disappear by one year following the ambulance ride. We evaluate the implications of the long-term difference between IV and OLS treatment effects in Section 4.4.

analysis comprise two separate risks: (i) a relatively high short-term risk component that is affected by VA vs. non-VA assignment, and (ii) a relatively stable long-term risk component that is the same between compliers who go to the VA and those who go to a non-VA hospital. If the latter risk reflects underlying patient health and is independent of the risk that led to the ambulance call, then we would expect the long-run weekly mortality rate (after, e.g., three months) to be the same for veterans who were quasi-randomly assigned to VA and non-VA hospitals; we formalize this as a test in Section 4.3.

The potential hazard rates allow us to assess whether excess mortality at non-VA hospitals involves “harvesting,” or mortality displacement, in which deaths for patients at the VA are simply delayed (Schwartz 2000; Honore and Lleras-Muney 2006). Under this hypothesis, survival gains from VA care observed at 28 days are temporary and will fade in the long-term. Such mortality displacement would imply that the hazard of dying *increases* among VA-assigned compliers after a time. We find no evidence of this in the potential hazard rates in Panel B of Figure 3. In Appendix A.2, we formally test that $h_{IV}(t; 1) \leq h_{IV}(t; 0)$ for all t and cannot reject this null hypothesis of no harvesting.²⁴ This suggests that the VA *prevents* rather than *displaces* deaths, leading to a persistent survival benefit, as shown by the stable gap between potential survival curves in Panel A.

Finally, we can use the results in this section to put the magnitude of the VA advantage in context with the results in Doyle et al. (2015). Doyle et al. (2015) find that transport to a hospital with higher log spending by one standard deviation decreases one-year mortality by 3.7 p.p., about 10% of average one-year mortality in their sample. In the sample of ambulance rides with no prior ride within a year, our estimates imply that the VA reduces mortality by 2.2 p.p., about 7.7% of average one-year mortality in our sample. The lower relative impact on mortality at one year, compared to the benchmark impact on 28-day mortality, is a consequence of much higher cumulative mortality at one year and the concentrated impact on mortality in the first week following the ambulance ride.

4.3 Extended IV Validity

We can also use the estimated potential survival outcomes to test the validity of our IV strategy based on ambulance assignment. Under Condition 1, the density of any characteristic, including characteristics defined by potential outcomes, must be positive among compliers of the quasi-experiment

²⁴Our test builds on the suggestion of Wolak (1987) to form a test statistic based on a quadratic form that represents the deviations of the data from the predictions of a constrained model that imposes the inequality restrictions. We use a simple bootstrap procedure to derive critical values of the test.

(Balke and Pearl 1997; Imbens and Rubin 1997):

$$\Pr (X_i = x, Y_i = y | i \in C) \geq 0, \tag{7}$$

for all possible characteristics $x \in \mathcal{X}$ and all possible potential outcomes $y \in \mathcal{Y}$. Kitagawa (2015) proposes a formal test of this implication, and Chan et al. (2019) show that applying this test to *potential outcomes* can provide a stronger test of the conditions for IV validity, particularly the monotonicity assumption in Condition 1(iii).²⁵

In our setting, we partition survival potential outcomes into weeks of potential mortality for 52 weeks following the ambulance ride, for both VA- and non-VA-assigned compliers. Since survival can only decrease over time, the potential mortality hazard rates for any week must be positive (i.e., $h_{IV}(t; d) \geq 0$ for all $t \in \{0, \dots, 51\}$, $d \in \{0, 1\}$). This prediction may be violated if patient risk of death in some week t is correlated with the assigned ambulance’s propensity to take patients to the VA (a violation of independence), or if there exist “defiers” (i.e., patients that are *less likely* to go to the VA when assigned to ambulances that transport more often to the VA overall) with higher risk of death in some week t (a violation in monotonicity). In Appendix A.2, we formally test the joint inequality constraint that $h_{IV}(t; d) \geq 0$ for all $t \in \{0, \dots, 51\}$, $d \in \{0, 1\}$, and cannot reject this null hypothesis, with a bootstrap-based p -value of 1.00.

If the short-term and longer-term mortality risks facing veterans are independent (as is typically assumed in a competing risks model) and treatment at the VA only affects the short-term risk component, then Condition 1 also implies that $h_{IV}(t; 1) = h_{IV}(t; 0)$ for $t \geq \bar{t}$, for some \bar{t} after the acute ambulance episode. Specifically, if the short-term risk component disappears after some time \bar{t} , and if the assignment of compliers to VA and non-VA hospitals is as good as random, then the death rates of the two groups of compliers should be the same after \bar{t} . Visually, it appears that the potential hazard rates of the compliers are very similar in weeks $t \in \{1, \dots, 51\}$. Consistent with this impression, in Appendix A.2, we show that we cannot reject that $h_{IV}(t; 1) = h_{IV}(t; 0)$ for all weeks $t \geq 1$, with a bootstrap-based p -value of 0.31.

²⁵Specifically, testing Equation (7) with respect to potential outcomes $y \in \mathcal{Y}$ may be more likely to detect violations of Condition 1 than standard tests of monotonicity, focusing on patient characteristics, that we employ in Appendix A.1.2. The intuition behind this is that testing Equation (7) with respect to potential outcomes will reveal violations in Condition 1 that relate not only to observed patient characteristics but also to unobserved patient characteristics correlated with potential outcomes. Violations in quasi-random assignment or monotonicity may be more likely to occur along potential outcomes if agents act according to an objective function based on potential outcomes.

4.4 Heterogeneity in Mortality Risks

Finally, we take a closer look at death rates during the year after the ambulance ride to better understand the differences between our main OLS and IV estimates of the VA advantage. As shown in Panel A of Figure 4, we find that, remarkably, OLS survival curves cross about nine to ten months after the ambulance ride. This reflects a reversal in the sign of the OLS-estimated VA treatment effect: While patients arriving at the VA experience an immediate survival benefit that peaks at 14 days after the ambulance ride, the survival benefit eventually reverses, such that patients arriving at the VA are *more* likely to die within a year.

Consistent with this observed survival pattern, Panel B of Figure 4 reveals a cross-over in the observed hazard rates of death for patients who are taken to VA and non-VA hospitals. In the first week after the ambulance ride, the death rate is lower for patients at the VA, though the gap between the VA and non-VA hazards is smaller than the corresponding potential-outcomes gap for compliers shown in Figure 3. Thereafter, the hazard rate for patients at the VA, $h_{OLS}(t;1)$, is consistently higher than the hazard rate for those who went to a non-VA hospital, $h_{OLS}(t;0)$. This gap suggests differences in baseline risk between always takers and never takers that are initially offset by the short-term VA advantage but reemerge, soon after the first week. These differences in baseline mortality hazards accumulate over time to generate large differences in long-term survival.

To identify differences in the baseline mortality risk between VA-assigned compliers and always takers, we compare $h_{IV}(t;1)$ and $h_{OLS}(t;1)$; to identify differences between non-VA-assigned compliers and never takers, we compare $h_{IV}(t;0)$ and $h_{OLS}(t;0)$. In Appendix A.2 we show that we cannot reject the null hypothesis that $h_{IV}(t;1) = h_{OLS}(t;1)$ for $t \geq 1$. However, we can strongly reject the null hypothesis that $h_{IV}(t;0) = h_{OLS}(t;0)$ for $t \geq 1$. The average value of $h_{IV}(t;0)$, for $t \geq 1$, is significantly larger than the corresponding average value of $h_{OLS}(t;0)$, for $t \geq 1$, which implies that never takers are healthier than compliers. This survival analysis shows, with substantially more precision than that afforded by the benchmark analysis in Section 3.3, that the VA advantage is in fact larger than the (precisely estimated) OLS effect would imply.

5 Mechanisms

This section probes further into the mechanisms behind the large VA mortality advantage. We divide our analyses into three sets. First, we explore heterogeneity in treatment effects along patient characteristics and hospital characteristics. Second, we ask whether the VA produces superior health

outcomes by spending more; spending less would imply mechanisms that improve productivity. Relatedly, we investigate differences in services reported by the VA vs. non-VA hospitals. Third, we indirectly assess the mechanisms of continuity of care, health IT, and integration of care among veterans who only use non-VA care. In this sample, we ask whether the adoption of health IT and integrated care by non-VA hospitals produces a survival benefit for patients routinely use those hospitals.

5.1 Heterogeneous Treatment Effects

Complier Characteristics. We perform a standard complier analysis examining characteristics of compliers relative to the overall sample.²⁶ Table 4 shows results for various characteristics. Compliers are more likely to be Black, to have lower income, to have a prior VA ED visit, and to suffer from mental illness and substance abuse. Compliers have slightly fewer recorded Elixhauser comorbidities and are less likely to receive Advanced Life Support (ALS). In Appendix Table A.7, we show similar patterns comparing always takers and never takers, following an approach from Dahl et al. (2014) that we describe in Appendix A.3. Consistent with our analysis in Section 4.4, we find that VA always takers have higher predicted mortality, based on observable characteristics, than either compliers or never takers.²⁷

Researchers and policymakers have noted greater incidence of mental health and substance abuse issues among veterans (Tanielian and Jaycox 2008). Recognizing this need, Congress allocated \$152 million for increasing mental health care programming in 1999; in the following two decades, VA stations expanded mental health services and hired thousands of mental health providers (106th Congress 1999; U.S. Government Accountability Office 2015). This capacity to treat mental health disorders contrasts with the non-VA health care sector, where mental health services have long been underfunded and underprovided (Huskamp and Iglehart 2016).

Selection Model. We consider a structural model of selection, both to assess how VA treatment effects vary with a veteran’s propensity to go to the VA and to infer the ATE. Following the “marginal treatment effects” (MTE) literature (see, e.g., Heckman and Vytlacil (2007) for a review), we exploit our multivalued ambulance instrument in order to characterize the relationship between treatment

²⁶Specifically, we employ the same approach from Abadie (2002) that we introduced in Section 4.1. Under IV validity in Condition 1, we can estimate $E[X_i | i \in C]$ for some characteristic X_i by two-stage least squares, involving the first-stage Equation (3) and a reduced-form equation replacing the outcome variable in Equation (4) with $X_i D_i$.

²⁷For Table 4 and Appendix Table A.7, we predict mortality using the same regression of mortality on baseline and hold-out characteristics described in Section 3.2 applied only on rides going to non-VA hospitals, in order to separate the VA advantage from coefficients used in the prediction. The intuition for this is described in Chetty et al. (2014, p. 2598). Adopting their approach of estimating coefficients on predictors while controlling for D_i yields nearly identical results.

effects and veterans who are induced to go to the VA. Specifically, we allow for flexibility in the returns to VA care among compliers who are induced into VA care, ranging from ambulances with low propensities to deliver patients to the VA to those with high propensities. We provide further details of our approach in Appendix A.4.

We find evidence of moderate “selection on gains,” in which veterans with larger mortality reductions from going to the VA are more likely to go to the VA. In Appendix Figure A.8, we show the MTE function ranging from veterans who are most likely to use the VA to those who are least likely to use the VA. Veterans induced to go to the VA by lower-propensity ambulances have higher returns to VA care than veterans who are induced by high-propensity ambulances. In Appendix Table A.8, we find a substantial ATE, only marginally smaller than the LATE, across a variety of specifications.

Heterogeneity by Hospital and Patient Characteristics. We next assess heterogeneity in the VA mortality effect by hospitals in a patient’s choice set and by patient characteristics. We consider a wide range of characteristics, in three categories: (i) characteristics of non-VA hospitals serving a given zip code, weighting the hospitals by volume of rides from the zip code; (ii) characteristics of the VA hospital serving a given zip code; and (iii) patient characteristics. Appendix A.5 provides details on hospital characteristics; Appendix A.6 describes our estimation approach.

Table 5 shows differences in hospital characteristics between VA and non-VA hospitals. For example, VA hospitals have fewer ED visits and admissions per bed and are more likely to be teaching hospitals.²⁸ However, we find at most modest treatment heterogeneity with respect to any of these hospital characteristics (Appendix Tables A.9 to A.11). Heterogeneity along any of the VA or non-VA hospital characteristics across zip codes is less than 20% of the main VA advantage, suggesting that the VA advantage pertains across the spectrum of VA and non-VA alternatives. Non-VA hospital characteristics in a zip code that are associated with a modestly smaller VA advantage include trauma center status and number of nurses per 1,000 patient-days. As for heterogeneity by VA hospital characteristics, the VA advantage is perhaps slightly greater for larger VA hospitals. In Appendix A.7, we describe complementary results from an empirical Bayes approach to heterogeneity in station-specific OLS estimates of the VA advantage; in that approach, we fail to demonstrate meaningful heterogeneity in the VA advantage across VA stations.

Across patients (Appendix Table A.12), the VA advantage is likely as large for minority veter-

²⁸VA hospitals appear to have more long-term care admissions, which explains a higher average length of stay (i.e., fewer admissions for slightly larger average daily census). As shown in Table 3, the difference in length of stay is not borne out in our sample; the IV estimate of the effect on length of stay suggests that the VA reduces length of stay.

ans (Black and Hispanic) as for non-minority veterans. The VA survival benefit appears greater for veterans who suffer from mental illness or substance abuse, who have more prior visits at the VA, or who have higher predicted mortality. However, the differences in the VA survival benefit across all of these dimensions are still smaller than the overall scale of the survival benefit. Importantly, the VA survival benefit is not limited to select medical conditions that stereotypical users of the VA might have; even patients who are less than likely to use VA care experience a similar VA survival benefit.

5.2 Effect on Spending and Utilization

In light of the important literature on the returns to spending in health care (e.g., Garber and Skinner 2008), we examine the causal effect of VA vs. non-VA care on spending. The motivation behind this analysis is similar to that in Doyle et al. (2015), who sought to understand whether higher-spending hospitals achieve better health outcomes.

Actual Spending. We calculate our baseline measure of spending from the perspective of actual spending by taxpayers and veterans, relying on internal VA cost data and Medicare payment data from claims. Internal VA cost accounting apportions costs by VA utilization data and scales the cost of each encounter so that total spending matches actual budgeted spending within each VA station.²⁹ On the Medicare side, we include total payments made to providers, including those from the veteran (i.e., coinsurance and deductible), the government, and any other insurer.

Using the same instrumental variables approach as in our benchmark analysis, we study the effect of VA vs. non-VA care on daily VA and non-VA spending over time since the ambulance ride. Specifically, we combine VA and Medicare spending in various weekly intervals since the ambulance ride. Table 3 further shows that the VA reduces 28-day combined spending by \$2,598, or by 21% of the mean 28-day spending. The reduction in spending reflects a lower probability of inpatient admission and fewer hospital days associated with VA care, although VA care results in slightly more outpatient visits in the following 28 days. In Figure 5, we show potential cumulative spending curves during the first year and implied weekly spending rates conditional on survival, for compliers transported to a VA hospital and those transported to a non-VA hospital. Differences in cumulative spending remain throughout the end of the year. Unlike survival outcomes, differences in spending accrue until at least three months after the ambulance ride.

²⁹The apportioning is based on inputs such as Relative Value Units (RVUs) associated with CPT codes, Diagnosis-Related Group (DRG) weights, patient characteristics, and admission lengths of stay. This methodology is detailed in Wagner et al. (2003) and in Phibbs et al. (2019).

Fixed-Price Spending and Reported Utilization. As an alternative measure of spending, we take reported utilization in the VA and Medicare data and apply the same prices to each instance of utilization, based on its identifying code, regardless of whether it was covered by the VA budget or reimbursed by Medicare.³⁰ According to this measure, the VA reduces 28-day combined spending by \$4,977, almost double the reduction in our baseline measure of actual spending.

Importantly, both VA and non-VA hospitals use identical systems for recording utilization and are held to the same standard of accurate coding based on clinical documentation. However, financial incentives in the two settings differ starkly. Financing outside of the VA is predominantly fee-for-service, tightly connected with units of utilization, which in turn are priced based on notions of costs. Inside the VA, financing is based on the population of veteran enrollees and less connected with reported utilization.

In Appendix A.8, we detail evidence of striking differences in reported utilization between the VA and non-VA hospitals. These differences likely reflect a combination of both upcoding (Dafny 2005; Fang and Gong 2017) and true differences in utilization. Among the most common services, some outpatient and rehabilitation services (e.g., CPT codes 99212 and 99110) are much more likely to be performed in the VA than outside of it; remarkably, telephone calls (CPT code 98966) are *only* reported at the VA. Services with high reimbursement are more likely to be performed in non-VA hospitals; in contrast, services that are more common in the VA are without exception reimbursed little. Within evaluation and management (E/M) services with different levels of complexity, the odds of reporting high- vs. low-complexity services are more than five times higher in private hospitals vs. the VA.

Implications. The result that the VA saves lives while reducing spending is significant for two reasons. First, the result speaks directly to the policy question of whether the VA should privatize its care in a Medicare-type arrangement. We show that, at least for the patients in our design, this privatization arrangement would be dominated by the status quo, as it would lead to both higher spending and worse health outcomes. Second, this joint finding suggests that the general mechanism behind the VA survival benefit is not higher spending but higher productivity.

Our evidence points to productive inefficiency, rather than “flat of the curve” spending that un-

³⁰We closely follow methodology laid out by Gottlieb et al. (2010) and Finkelstein et al. (2016). Specifically, we impute spending for physician services based on Relative Value Units (RVUs) for service procedures with CPT codes, for other outpatient procedures based on average reimbursements for (non-CPT) HCPCS codes, and inpatient stays based on Diagnosis-Related Group (DRG) weights. We scale prices by a constant so that imputed total Medicare spending equals actual total Medicare spending.

derlies the relatively low-returns to US health care. We also uncover striking differences in reported utilization between the VA and non-VA sectors that are plausibly driven by differences in financial incentives implicit in public vs. private provision. Many of the services with low reimbursement (i.e., low intensity) neglected in the private sector may nonetheless improve coordination of care and health outcomes. These results complement a growing literature on productivity differences across personnel (Chan et al. 2019; Silver 2020) and hospitals (Chandra and Staiger 2007, 2020) by showing an important productivity difference between health care *systems*.

5.3 Health IT and Integrated Care

Our final analysis investigates the role of health IT and integrated care in generating the VA survival advantage. There is much in the qualitative literature to support this mechanism. Fragmentation and poor coordination in the US health sector has long been highlighted as a potential source of inefficiency. In the VA, a qualitative literature attributes its “transformation” into a high-quality health system, achieving superior performance in a wide range of process measures, to its adoption of health IT and integrated care in the mid-1990s (e.g., Jha et al. 2003).³¹

While empirical research has focused on one mechanism or another, there likely exist important complementarities between a patient’s continuity of care and a health system’s adoption of health IT and integrated care. Patients with isolated problems or those with no prior utilization in a health care system will benefit little from health IT and integrated care. Similarly, patients who are well-informed or whose providers have time to make decisions (e.g., hip replacements, chemotherapy initiation) may overcome informational barriers imposed by the lack of health IT or integrated care. In contrast, easy access to information is likely crucial our setting of emergency conditions.

In this subsection, we can provide only indirect evidence of these mechanisms. The VA’s implementation of health IT and its reorganization into more integrated care in the mid-1990s predate our data.³² Similarly, it is not possible to examine the VA’s effect on mortality among veterans who have no prior utilization at the VA, since it is exceedingly rare for these veterans to be transported to the VA by ambulance, as shown in Appendix Figure A.14. Thus, we will examine these mechanisms in a separate setting of veterans who use only use providers outside of the VA. As Appendix Figure A.14 also shows, veterans may utilize more than one non-VA hospital system; these veterans may or may

³¹For recent qualitative research that illuminates this mechanism between VA and non-VA care, see, e.g., Nevedal et al. (2019) and Rinne et al. (2019).

³²Indeed, the VA’s adoption of a common health IT platform (VistA) in the mid-1990s paved the way for research on health services within the VA system, including this study.

not be transported to the hospital system where they usually receive care.

We detail our analysis in Appendix A.9. In brief, we construct a separate sample of veterans who only use non-VA care in the prior year and who live in a zip code with more than one nearby non-VA hospital. While these veterans will almost certainly be transported to a non-VA hospital, we assess mortality outcomes as a function of whether they are quasi-randomly assigned—via a similar ambulance instrument as the one we use in our benchmark analysis—to their modal non-VA hospital. This modal-hospital effect on mortality arguably captures at least some of the potential effect of continuity of care in the private sector. We then examine complementarities with health IT and integrated care by further exploiting two changes induced by incentives in federal laws and payment policies during our study period. First, the HITECH Act of 2009 dramatically increased the share of hospitals using health IT (Blumenthal 2010).³³ Second, in 2011, Medicare began to incentivize care integration via alternative payment arrangements to “Accountable Care Organizations” (ACOs) (Greaney 2011).

We find that, overall, the survival advantage of being transported to a veteran’s modal hospital is small. However, the effect suggestively grows around the time of the HITECH Act of 2009, when a large share of non-VA hospitals adopted health IT. In Appendix Table A.15, we also examine how the modal-hospital effect relates to hospital-specific dates of health IT or ACO adoption. Our results provide suggestive evidence that the growth in the modal-hospital effect is associated with health IT adoption, holding hospitals fixed; the relationship with ACO adoption appears similar but is imprecise.³⁴

6 Conclusion

The structure of health care delivery to US veterans provides a distinctive research opportunity, allowing us to study fundamentally different systems of health care that coexist for a large patient population. Specifically, millions of older veterans (those at least aged 65) are dually eligible for care in a public system, operated by the Veterans Health Administration, or in private-sector hospitals,

³³Jha et al. (2009) report in 2009 that 1.5% of US non-federal hospitals had an electronic health record (EHR) system in all clinical units and an additional 7.6% had an EHR system in at least one clinical unit. By 2014, 97% of such hospitals had possessed an EHR technology meeting requirements of the Department of Health and Human Services, and 76% of hospitals had implemented the EHR system in at least one clinical unit (Charles et al. 2015). However, interoperability (i.e., the ability to share electronic medical records) across private hospitals has remained low (Holmgren et al. 2017). To this day, multiple EHR platforms exist in the private sector, and they do not communicate with each other.

³⁴In contrast to dramatic rates of health IT adoption, we find that only 11% of non-VA hospitals participated in ACOs by the last year of our sample, consistent with other research (Colla et al. 2016).

financed by Medicare. The ambulance setting provides plausible quasi-experimental assignment of veterans to these health care systems. Our work has current policy relevance, as the Department of Veterans Affairs is now considering whether to bolster its existing public delivery system or to replace it, either partially or fully, with a system of financing private care.

We find a significant VA advantage: Our preferred instrumental variables estimate, based on veterans who are induced by their ambulance company to be treated at a VA or non-VA hospital, shows a 4.5 p.p. survival gain at 28 days (95% confidence interval 1.1 to 8.0 p.p.), implying about a 46% reduction in mortality relative to the overall average. These survival gains occur in the first week following the ambulance ride and appear to be long-lasting. We further use this survival analysis framework to validate our IV quasi-experiment and to demonstrate differences in long-term mortality hazards between VA and non-VA users who are non-compliers; we show that, if anything, the VA treats sicker patients in our sample than do non-VA hospitals. Although we find some intuitive margins of heterogeneity in the VA advantage, the VA outperforms the non-VA alternative in a wide variety of locations with different types of non-VA hospitals and for all types of patients we consider, not only for patients with stereotypical medical conditions.

Importantly, the VA also reduces total spending by 21% relative to non-VA providers, which points to higher productivity in the VA than in the private sector. We demonstrate striking differences in the procedures reportedly performed at the VA vs. those reportedly performed by non-VA providers. These differences relate to the underlying arrangements in which public vs. private providers are funded in the US (and in other developed countries). We also find evidence consistent with complementary mechanisms of continuity of care, health IT, and organization. For example, veterans with prior VA care (and those who are more likely to use the VA) have larger survival gains from VA assignment. Among veterans who only use non-VA hospitals, the benefits of continuity of care are weaker and seem to materialize only when their (non-VA) hospitals adopt health IT and integrated care. Still, even when accounting for private efforts to adopt health IT and reorganize care, there remains a sizeable residual VA advantage.

Our results contribute more broadly to two streams of literature on the efficiency of production. First, we contribute to the descriptive analysis that compares the performance of the US health care system to systems in other developed countries (Blank et al. 2017). By almost all accounts, comparisons of US health outcomes and health care spending are unfavorable with those of other developed countries (Garber and Skinner 2008; Rice et al. 2013). Our analysis points to a potentially large source of inefficiency in the US context: its version of private provision of health care, in which

costly but not necessarily efficient care is incentivized and where well-known information and coordination gaps may be fatal, at least for veterans in emergencies. Although several developed countries that outperform the US also feature private provision of care, the US system arguably has the most complex configuration of financing and delivery, with high levels of uninsurance, administrative costs, and fragmentation (Cebul et al. 2008).

Second, we provide empirical support in the context of health care for the general idea of production complementarities among three innovations in production: information technology (IT), workplace reorganization, and products and services (Bresnahan et al. 2002). The VA adopted a comprehensive health IT system almost two decades before the vast majority of private hospitals in the US. This reform was accompanied by an integration of care involving both reorganizing the delivery system and redefining services involved in patient care. For private hospitals, redefining health care products and services is limited by fee-for-service payment systems and the difficulty of measuring quality (Cutler 2010). Hospitals without a broad network of clinics and an overarching mandate for a population's health may find it difficult to reorganize and redefine its services. Our result that health IT in private hospitals may improve survival—but to a muted extent and only for patients that the hospitals have previously treated—is consistent with these production complementarities. Complementarities in health care production may pose barriers for replicating the VA advantage in the fragmented private landscape of US health care.

References

- 106TH CONGRESS (1999): “Veterans Millennium Health Care and Benefits Act,” Public Law 106-117.
- 113TH CONGRESS (2014): “Veterans Access, Choice, and Accountability Act of 2014,” Public Law 113-146.
- 115TH CONGRESS (2018): “Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act of 2018,” Public Law 115-182.
- ABADIE, A. (2002): “Bootstrap Tests for Distributional Treatment Effects in Instrumental Variable Models,” *Journal of the American Statistical Association*, 97, 284–292.
- AGHA, L. (2014): “The effects of health information technology on costs and quality of medical care,” *Journal of Health Economics*, 19–30.

- AGHA, L., B. FRANDBSEN, AND J. B. REBITZER (2019): “Fragmented division of labor and health-care costs: Evidence from moves across regions,” *Journal of Public Economics*, 169, 144–159.
- AGHA, Z., R. P. LOFGREN, J. V. VANRUISWYK, AND P. M. LAYDE (2000): “Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use,” *Archives of Internal Medicine*, 160, 3252–3257.
- ALCHIAN, A. A. (1965): “Some Economics of Property Rights,” *Il Politico*, 30, 816–829.
- ALTONJI, J. G., T. E. ELDER, AND C. R. TABER (2005): “Selection on Observed and Unobserved Variables: Assessing the Effectiveness of Catholic Schools,” *Journal of Political Economy*, 113, 151–184.
- ALTONJI, J. G. AND R. K. MANSFIELD (2018): “Estimating Group Effects Using Averages of Observables to Control for Sorting on Unobservables: School and Neighborhood Effects,” *American Economic Review*, 108, 2902–2946.
- ALTONJI, J. G. AND L. M. SEGAL (1996): “Small-Sample Bias in GMM Estimation of Covariance Structures,” *Journal of Business & Economic Statistics*, 14, 353–366.
- AMERICAN MEDICAL ASSOCIATION (2015): *The Physicians’ Guide: Medicare RBRVS*, Chicago: AMA.
- (2017): *Principles of CPT Coding*, American Medical Association, 9th edition ed.
- ANGRIST, J. D., P. D. HULL, P. A. PATHAK, AND C. R. WALTERS (2017): “Leveraging Lotteries for School Value-Added: Testing and Estimation,” *Quarterly Journal of Economics*, 132, 871–919.
- ARNOLD, D., W. DOBBIE, AND C. S. YANG (2018): “Racial Bias in Bail Decisions,” *Quarterly Journal of Economics*, 133, 1885–1932.
- BALKE, A. AND J. PEARL (1997): “Bounds on Treatment Effects from Studies with Imperfect Compliance,” *Journal of the American Statistical Association*, 92, 1171–1176.
- BHULLER, M., G. B. DAHL, K. V. LOKEN, AND M. MOGSTAD (2020): “Incarceration, Recidivism, and Employment,” *Journal of Political Economy*, 128, 1269–1324.
- BLANK, R., V. BURAU, AND E. KUHLMANN (2017): *Comparative Health Policy*, Macmillan International Higher Education.

- BLOM, D. (2016): “Considerations and Recommendations,” Tech. rep., Commission on Care, Washington, D.C.
- BLOOM, N., C. PROPPER, S. SEILER, AND J. VAN REENEN (2015): “The Impact of Competition on Management Quality: Evidence from Public Hospitals,” *The Review of Economic Studies*, 82, 457–489.
- BLUMENTHAL, D. (2010): “Launching HITECH,” *New England Journal of Medicine*, 362, 382–385.
- BLUNDELL, R. AND R. L. MATZKIN (2014): “Control functions in nonseparable simultaneous equations models,” *Quantitative Economics*, 5, 271–295.
- BRESNAHAN, T. F., E. BRYNJOLFSSON, AND L. M. HITT (2002): “Information Technology, Workplace Organization, and the Demand for Skilled Labor: Firm-Level Evidence,” *Quarterly Journal of Economics*, 117, 339–376.
- CARD, D., C. DOBKIN, AND N. MAESTAS (2009): “Does Medicare Save Lives?” *Quarterly Journal of Economics*, 124, 597–636.
- CARD, D., A. FENIZIA, AND D. SILVER (2018): “The Health Effects of Cesarean Delivery for Low-Risk First Births,” Working Paper 24493, National Bureau of Economic Research.
- CEBUL, R. D., J. B. REBITZER, L. J. TAYLOR, AND M. E. VOTRUBA (2008): “Organizational fragmentation and care quality in the U.S. healthcare system,” *Journal of Economic Perspectives*, 22, 93–113.
- CENTERS FOR MEDICARE & MEDICAID SERVICES (2002): “Medicare Program; Fee Schedule for Payment of Ambulance Services and Revisions to the Physician Certification Requirements for Coverage of Nonemergency Ambulance Services,” in *Federal Register*, 67, 9099–9135.
- CHAN, D., M. DUGGAN, AND A. GUO (2021): “Soldiering on: Improving policies to benefit America’s veterans,” Policy Brief, Stanford Institute for Economic Policy Report.
- CHAN, D. C., M. GENTZKOW, AND C. YU (2019): “Selection with Variation in Diagnostic Skill: Evidence from Radiologists,” Working Paper 26467, National Bureau of Economic Research.
- CHANDRA, A., A. FINKELSTEIN, A. SACARNY, AND C. SYVERSON (2016): “Healthcare Exceptionalism? Productivity and Allocation in the U.S. Healthcare Sector,” *American Economic Review*, 106, 2110–2144.

- CHANDRA, A. AND D. O. STAIGER (2007): “Productivity spillovers in healthcare: evidence from the treatment of heart attacks,” *Journal of Political Economy*, 115, 103–140.
- (2020): “Identifying Sources of Inefficiency in Healthcare,” *Quarterly Journal of Economics*, 135, 785–843.
- CHARLES, D., M. GABRIEL, AND T. SEARCY (2015): “Adoption of Electronic Health Record Systems among U.S. Non-Federal Acute Care Hospitals: 2008-2014,” ONC Data Brief 23, The Office of the National Coordinator for Health Information Technology.
- CHETTY, R., J. N. FRIEDMAN, AND J. E. ROCKOFF (2014): “Measuring the Impacts of Teachers I: Evaluating Bias in Teacher Value-Added Estimates,” *American Economic Review*, 104, 2593–2632.
- CHIANG, A. J., G. DAVID, AND M. G. HOUSMAN (2006): “The Determinants of Urban Emergency Medical Services Privatization,” *Critical Planning*, 13.
- COLLA, C. H., V. A. LEWIS, E. TIERNEY, AND D. B. MUHLESTEIN (2016): “Hospitals Participating In ACOs Tend To Be Large And Urban, Allowing Access To Capital And Data,” *Health Affairs*, 35, 431–439.
- COOPER, Z., S. GIBBONS, AND M. SKELLERN (2018): “Does competition from private surgical centres improve public hospitals’ performance? Evidence from the English National Health Service,” *Journal of Public Economics*, 166, 63–80.
- CUBANSKI, J., T. NEUMAN, A. DAMICO, AND K. AMITH (2018): “Medicare Beneficiaries’ Out-of-Pocket Health Care Spending as a Share of Income Now and Projections for the Future,” Tech. rep., Kaiser Family Foundation.
- CUTLER, D. (2010): “Where Are the Health Care Entrepreneurs?” *Issues in Science and Technology*, 27, 49–56.
- DAFNY, L. S. (2005): “How Do Hospitals Respond to Price Changes?” *American Economic Review*, 95, 1525–1547.
- DAHL, G. B., A. R. KOSTOL, AND M. MOGSTAD (2014): “Family Welfare Cultures,” *Quarterly Journal of Economics*, 129, 1711–1752.

- DEPARTMENT OF VETERANS AFFAIRS (2020): “FY 2021 Budget Submission: Budget in Brief,” Tech. rep., Washington, D.C.
- DOYLE, J. J., J. A. GRAVES, J. GRUBER, AND S. KLEINER (2015): “Measuring Returns to Hospital Care: Evidence from Ambulance Referral Patterns,” *Journal of Political Economy*, 123, 170–214.
- ELIXHAUSER, A., C. STEINER, D. R. HARRIS, AND R. M. COFFEY (1998): “Comorbidity Measures for Use with Administrative Data,” *Medical Care*, 36, 8–27.
- FANG, H. AND Q. GONG (2017): “Detecting Potential Overbilling in Medicare Reimbursement via Hours Worked,” *American Economic Review*, 107, 562–591.
- FINKELSTEIN, A., M. GENTZKOW, AND H. WILLIAMS (2016): “Sources of Geographic Variation in Health Care: Evidence from Patient Migration,” *Quarterly Journal of Economics*, 131, 1681–1726.
- FRAKES, M. D., J. GRUBER, AND T. JUSTICZ (2020): “Public and Private Options in Practice: The Military Health System,” Tech. Rep. w28256, National Bureau of Economic Research.
- GARBER, A. M. AND J. SKINNER (2008): “Is American Health Care Uniquely Inefficient?” *The Journal of Economic Perspectives*, 22, 27–50.
- GAYNOR, M., R. MORENO-SERRA, AND C. PROPPER (2013): “Death by Market Power: Reform, Competition, and Patient Outcomes in the National Health Service,” *American Economic Journal: Economic Policy*, 5, 134–166.
- GAYNOR, M., C. PROPPER, AND S. SEILER (2016): “Free to Choose? Reform, Choice, and Consideration Sets in the English National Health Service,” *American Economic Review*, 106, 3521–3557.
- GERUSO, M. AND T. LAYTON (2020): “Upcoding: Evidence from Medicare on Squishy Risk Adjustment,” *Journal of Political Economy*, 128, 984–1026.
- GORDON, S. (2019): “The VA Is Privatizing Veterans’ Health Care While Launching a Campaign to Deny It,” *The American Prospect*.
- GOTTLIEB, D. J., W. ZHOU, Y. SONG, K. G. ANDREWS, J. S. SKINNER, AND J. M. SUTHERLAND (2010): “Prices Don’t Drive Regional Medicare Spending Variations,” *Health Affairs*, 29, 537–543.

- GREANEY, T. L. (2011): “Accountable Care Organizations: The Fork in the Road,” *New England Journal of Medicine*, 364, e1.
- HART, O., A. SHLEIFER, AND R. W. VISHNY (1997): “The Proper Scope of Government: Theory and an Application to Prisons,” *The Quarterly Journal of Economics*, 112, 1127–1161.
- HECKMAN, J. J. AND E. J. VYTLACIL (2005): “Structural Equations, Treatment Effects, and Econometric Policy Evaluation,” *Econometrica*, 73, 669–738.
- (2007): “Chapter 71 Econometric Evaluation of Social Programs, Part II: Using the Marginal Treatment Effect to Organize Alternative Econometric Estimators to Evaluate Social Programs, and to Forecast their Effects in New Environments,” in *Handbook of Econometrics*, ed. by J. J. Heckman and E. E. Leamer, Elsevier, vol. 6, 4875–5143.
- HOLMGREN, A. J., V. PATEL, AND J. ADLER-MILSTEIN (2017): “Progress In Interoperability: Measuring US Hospitals’ Engagement In Sharing Patient Data,” *Health Affairs*, 36, 1820–1827, publisher: Health Affairs.
- HONORE, B. E. AND A. LLERAS-MUNEY (2006): “Bounds in Competing Risks Models and the War on Cancer,” *Econometrica*, 74, 1675–1698.
- HUSKAMP, H. A. AND J. K. IGLEHART (2016): “Mental Health and Substance-Use Reforms: Milestones Reached, Challenges Ahead,” *New England Journal of Medicine*, 375, 688–695.
- HYNES, D. M., S. EDWARDS, A. HICKOK, M. NIEDERHAUSEN, F. M. WEAVER, E. TARLOV, H. GORDON, R. L. JACOB, B. BARTLE, ALLISON O’NEILL, R. YOUNG, AND A. LALIBERTE (2021): “Veterans’ Use of Veterans Health Administration Primary Care in an Era of Expanding Choice,” *Medical Care*, 59, S292–S300.
- HYNES, D. M., K. KOELLING, K. STROUPE, N. ARNOLD, K. MALLIN, M.-W. SOHN, F. M. WEAVER, L. MANHEIM, AND L. KOK (2007): “Veterans’ Access to and Use of Medicare and Veterans Affairs Health Care,” *Medical Care*, 45, 214–223.
- IMBENS, G. W. AND J. D. ANGRIST (1994): “Identification and Estimation of Local Average Treatment Effects,” *Econometrica*, 62, 467–475.
- IMBENS, G. W. AND D. B. RUBIN (1997): “Estimating Outcome Distributions for Compliers in Instrumental Variables Models,” *Review of Economic Studies*, 64, 555–574.


- JHA, A. K., C. M. DESROCHES, E. G. CAMPBELL, K. DONELAN, S. R. RAO, T. G. FERRIS, A. SHIELDS, S. ROSENBAUM, AND D. BLUMENTHAL (2009): "Use of Electronic Health Records in U.S. Hospitals," *New England Journal of Medicine*, 360, 1628–1638.
- JHA, A. K., J. B. PERLIN, K. W. KIZER, AND R. A. DUDLEY (2003): "Effect of the Transformation of the Veterans Affairs Health Care System on the Quality of Care," *New England Journal of Medicine*, 348, 2218–2227.
- KEFE, J. (2018): "Is the VA being privatized? Critics say this Koch-backed group is fighting to do just that," *Newsweek*.
- KELLY, E. AND G. STOYE (2020): "The impacts of private hospital entry on the public market for elective care in England," *Journal of Health Economics*, 73, 102353.
- KITAGAWA, T. (2015): "A Test for Instrument Validity," *Econometrica*, 83, 2043–2063.
- KLINE, P. M. AND C. R. WALTERS (2019): "On Heckits, LATE, and Numerical Equivalence," *Econometrica*, 87, 677–696.
- KLING, J. R. (2006): "Incarceration Length, Employment, and Earnings," *The American Economic Review*, 96, 863–876.
- KOLESAR, M., R. CHETTY, J. FRIEDMAN, E. GLAESER, AND G. W. IMBENS (2015): "Identification and Inference With Many Invalid Instruments," *Journal of Business and Economic Statistics*, 33, 474–484.
- LIU, C.-F., A. BATTEN, E. S. WONG, S. D. FIHN, AND P. L. HEBERT (2018): "Fee-for-Service Medicare-Enrolled Elderly Veterans Are Increasingly Voting with Their Feet to Use More VA and Less Medicare, 2003-2014," *Health Services Research*, 53, 5140–5158.
- MCCARTHY, D. AND D. BLUMENTHAL (2006): "Stories from the Sharp End: Case Studies in Safety Improvement," *The Milbank Quarterly*, 84, 165–200.
- MCWILLIAMS, J. M., L. A. HATFIELD, M. E. CHERNEW, B. E. LANDON, AND A. L. SCHWARTZ (2016): "Early Performance of Accountable Care Organizations in Medicare," *New England Journal of Medicine*, 374, 2357–2366.

- MCWILLIAMS, J. M., B. E. LANDON, M. E. CHERNEW, AND A. M. ZASLAVSKY (2014): “Changes in Patients’ Experiences in Medicare Accountable Care Organizations,” *New England Journal of Medicine*, 371, 1715–1724.
- MILLER, A. R. AND C. E. TUCKER (2011): “Can Health Care Information Technology Save Babies?” *Journal of Political Economy*, 119, 289–324.
- NEVEDAL, A. L., T. H. WAGNER, L. S. ELLERBE, S. M. ASCH, AND C. J. KOENIG (2019): “A Qualitative Study of Primary Care Providers’ Experiences with the Veterans Choice Program,” *Journal of General Internal Medicine*, 34, 598–603.
- NUTI, S. V., L. QIN, J. S. RUMSFELD, J. S. ROSS, F. A. MASOUDI, S.-L. T. NORMAND, K. MURUGIAH, S. M. BERNHEIM, L. G. SUTER, AND H. M. KRUMHOLZ (2016): “Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia,” *Journal of the American Medical Association*, 315, 582.
- O’HANLON, C., C. HUANG, E. SLOSS, R. A. PRICE, P. HUSSEY, C. FARMER, AND C. GIDENGIL (2017): “Comparing VA and Non-VA Quality of Care: A Systematic Review,” *Journal of General Internal Medicine*, 32, 105–121.
- OLSEN, R. J. (1980): “A Least Squares Correction for Selectivity Bias,” *Econometrica*, 48, 1815–1820.
- PERLMAN, M. D. (1969): “One-Sided Testing Problems in Multivariate Analysis,” *The Annals of Mathematical Statistics*, 40, 549–567.
- PHIBBS, C. S., W. J. SCOTT, N. E. FLORES, AND P. G. BARNETT (2019): “HERC’s Outpatient Average Cost Dataset for VA Care,” Tech. rep., VA Palo Alto, Health Economics Resource Center, Menlo Park, CA.
- RAGONE, M. (2012): “Evolution or revolution: EMS industry faces difficult changes,” *Journal of Emergency Medical Services*, 37, 34–39.
- REID, T. R. (2010): *The Healing of America: A Global Quest for Better, Cheaper, and Fairer Health Care*, Penguin.

- REIN, L., P. RUCKER, E. WAX-THIBODEAUX, AND J. DAWSEY (2018): “Trump taps his doctor to replace Shulkin at VA, choosing personal chemistry over traditional qualifications,” *Washington Post*.
- RICE, T., P. ROSENAU, L. Y. UNRUH, AND A. J. BARNES (2013): “United States of America: Health system review,” *Health Systems in Transition*, 15, 1–431.
- RINNE, S. T., K. RESNICK, R. S. WIENER, S. R. SIMON, AND A. R. ELWY (2019): “VA Provider Perspectives on Coordinating COPD Care Across Health Systems,” *Journal of General Internal Medicine*, 34, 37–42.
- SCHWARTZ, J. (2000): “Harvesting and Long Term Exposure Effects in the Relation between Air Pollution and Mortality,” *American Journal of Epidemiology*, 151, 440–448.
- SHEKELLE, P. G., S. ASCH, P. GLASSMAN, S. MATULA, A. TRIVEDI, AND I. MIAKE-LYE (2010): “Comparison of Quality of Care in VA and Non-VA Settings: A Systematic Review,” Tech. rep., Department of Veterans Affairs, Washington, D.C.
- SHULKIN, D. J. (2018): “Privatizing the V.A. Will Hurt Veterans,” *The New York Times*.
- SILVER, D. (2020): “Haste or Waste? Peer Pressure and Productivity in the Emergency Department,” Tech. rep., Princeton University.
- SKURA, B. (2001): “Where Do 911 System Ambulances Take Their Patients? Differences between Voluntary Hospital Ambulances and Fire Department Ambulances.” Tech. rep., Office Comptroller, City of New York, New York, NY.
- STIGLER, G. J. (1965): “The Economist and the State,” *American Economic Review*, 55, 1–18.
- TANIELIAN, T. AND L. H. JAYCOX, eds. (2008): *Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery*, Santa Monica, CA: RAND Corporation.
- TELSER, L. G. (1964): “Advertising and Competition,” *Journal of Political Economy*, 72, 537–562.
- TRIVEDI, A. N., S. MATULA, I. MIAKE-LYE, P. A. GLASSMAN, P. SHEKELLE, AND S. ASCH (2011): “Systematic Review: Comparison of the Quality of Medical Care in Veterans Affairs and Non-Veterans Affairs Settings,” *Medical Care*, 49, 76–88.


- TROMBLEY, M. J., B. FOUT, S. BRODSKY, J. M. MCWILLIAMS, D. J. NYWEIDE, AND B. MORE-FIELD (2019): “Early Effects of an Accountable Care Organization Model for Underserved Areas,” *New England Journal of Medicine*, 381, 543–551.
- U.S. GOVERNMENT ACCOUNTABILITY OFFICE (2015): “VA Mental Health: Clearer Guidance on Access Policies and Wait-Time Data Needed,” Tech. Rep. GAO-16-24.
- WAGNER, T. H., S. CHEN, AND P. G. BARNETT (2003): “Using Average Cost Methods to Estimate Encounter-Level Costs for Medical-Surgical Stays in the VA,” *Medical Care Research and Review*, 60, 15S–36S.
- WASSERMAN, J., J. S. RINGEL, K. A. RICCI, J. D. MALKIN, B. O. WYNN, J. ZWANZIGER, S. NEWBERRY, M. BOOTH, A. RASTEGAR, M. SCHOENBAUM, AND B. GENOVESE (2005): “Analyzing and Influencing How the VA Allocates Its Health Care Dollars,” Tech. rep., RAND Corporation.
- WOLAK, F. A. (1987): “An Exact Test for Multiple Inequality and Equality Constraints in the Linear Regression Model,” *Journal of the American Statistical Association*, 82, 782–793.
- WOOLDRIDGE, J. M. (2015): “Control Function Methods in Applied Econometrics,” *Journal of Human Resources*, 50, 420–445.
- WRIGHT, S. M., L. A. PETERSEN, R. P. LAMKIN, AND J. DALEY (1999): “Increasing Use of Medicare Services by Veterans With Acute Myocardial Infarction,” *Medical Care*, 37, 529–537.

Figure 1: First Stage, Balance, and Reduced Form




Note: Panel A shows a binned scatterplot of arrival at a VA hospital on the y-axis against the ambulance leave-out propensity to arrive at a VA hospital on the x-axis. The figure is a graphical representation of the first-stage regression in Equation (3). Panel B shows binned scatterplots of 28-day mortality and predicted 28-day mortality on the y-axis against the ambulance leave-out propensity to arrive at a VA hospital on the x-axis. Mortality bin means are shown in solid circles, while predicted mortality bin means are shown in hollow circles. The figure represents the reduced-form regression in Equation (4) and the corresponding balance regression replacing mortality with predicted mortality. The sample includes 401,319 ambulance rides and 1,217 combinations of ambulance company identifiers and Dartmouth Atlas Hospital Referral Regions (HRRs). The sample selection is given in Appendix Table A.1. Baseline controls are detailed in Appendix Table A.2 and include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization.

Figure 2: OLS and IV Specifications




Note: This figure shows OLS and IV estimates of the effect of the VA on 28-day mortality, represented in Equation (2) as β , with progressive sets of controls. Numbered incremental controls correspond to categories or subcategories of variables that are presented in order in Appendix Tables A.2 and A.3. Control sets are as follows: (1) zip code; (2) pickup source; (3) ambulance service; (4) time categories; (5) prior utilization; (6) demographics; (7) socioeconomic status, combat history, and eligibility; (8) extended prior utilization; (9) prior diagnoses; (10) 3-digit ambulance diagnosis codes; (11) co-rider baseline controls; and (12) co-rider hold-out controls. Estimates are shown along solid lines, while 95% confidence intervals are shown in dashed lines. All specifications use the baseline sample, given in Appendix Table A.1.

Figure 3: Complier Potential Outcomes




Note: This figure shows potential outcomes for ambulance compliers who arrive at a VA hospital and those who arrive at a non-VA hospital. Panel A shows survival outcomes as a function of days from the ambulance ride. “Days” indicate one-week intervals from the ambulance ride. Denote $S_i(t; d) \in \{0, 1\}$ as an indicator for whether patient i survives up to time t after the ambulance ride, depending on whether the patient arrives at the VA ($d = 1$) or a non-VA hospital ($d = 0$). Observed survival is $S_i(t) = D_i S_i(t; 1) + (1 - D_i) S_i(t; 0)$. We estimate complier VA survival, or $E[S_i(t; 1) | i \in C]$, by an IV regression with a dependent variable of $S_i(t) D_i$, the endogenous VA treatment D_i , and the same first-stage and reduced-form design matrix implied by Equations (3) and (4). We estimate complier non-VA survival, or $E[S_i(t; 0) | i \in C]$, by a similar IV regression with a dependent variable of $S_i(t) (D_i - 1)$. All regressions use a sample of ambulance rides with no prior ride in the last year and the same baseline controls as described in Figure 1. Panel B presents implied weekly mortality hazard rates, as given by Equation (5).

Figure 4: Observed Risk-Adjusted Outcomes




Note: This figure shows observed risk-adjusted outcomes for patients who arrive at a VA hospital and those who arrive at a non-VA hospital. Panel A shows survival outcomes as a function of days from the ambulance ride. “Days” indicate one-week intervals from the ambulance ride. Denote $S_i(t; d) \in \{0, 1\}$ as an indicator for whether patient i survives up to time t after the ambulance ride, depending on whether the patient arrives at the VA ($d = 1$) or a non-VA hospital ($d = 0$). Observed survival is $S_i(t) = D_i S_i(t; 1) + (1 - D_i) S_i(t; 0)$. We estimate VA survival, or $E[S_i(t) | D_i = 1]$, by an OLS regression with a dependent variable of $S_i(t) D_i$ and the same design matrix implied by Equation (2); we estimate non-VA survival, or $E[S_i(t) | D_i = 0]$, by a similar OLS regression with a dependent variable of $S_i(t) (D_i - 1)$. All regressions use a sample of ambulance rides with no prior ride in the last year and the same baseline controls as described in Figure 1. Panel B presents implied weekly mortality hazard rates, as given by Equation (6).

Figure 5: Complier Spending



Note: This figure shows potential spending outcomes for ambulance compliers who arrive at a VA hospital and those who arrive at a non-VA hospital. Denote $\text{Spending}_i(t; d)$ as the potential cumulative spending function for patient i up to time t after the ambulance ride, depending on whether the patient arrives at the VA ($d = 1$) or a non-VA hospital ($d = 0$). If a veteran i dies at t_* , $\text{Spending}_i(t; d)$ will be constant for all $t \geq t_*$. Panel A shows cumulative spending per patient as a function of days from the ambulance ride. We estimate cumulative spending for compliers who arrive at a VA hospital, or $E[\text{Spending}_i(t; 1) | i \in C]$, by an IV regression with a dependent variable of $\text{Spending}_i(t) \times D_i$, the endogenous VA treatment D_i , and the same first-stage and reduced-form design matrix implied by Equations (3) and (4). We estimate complier non-VA cumulative spending, or $E[\text{Spending}_i(t; 0) | i \in C]$, by a similar IV regression with a dependent variable of $\text{Spending}_i(t) (D_i - 1)$. All regressions use a sample of ambulance rides with no prior ride in the last year and the same baseline controls as described in Figure 1. Panel B presents implied weekly spending rates for compliers, conditional on survival.

Figure 6: Modal Hospital Effect and Health IT Adoption



Note: Panel A of this figure shows the IV estimate of the modal non-VA hospital effect on 28-day mortality by calendar year. The first-stage and reduced-form equations are given in Equations (A.30) and (A.31). The overall sample is the same alternative sample designed to study choice among non-VA hospitals for patients with only non-VA utilization in the prior year. Results for the overall IV estimates are shown in Appendix Figure A.15. Details of the sample selection are given in Appendix Table A.13. Estimates are shown in connected dots, while 95% confidence intervals are shown in dashed lines. Panel B of the figure shows the percent of rides going to hospitals after health IT adoption in our analytic sample. Health IT adoption is defined from a dataset from the Office of the National Coordinator of Health Information Technology (ONC). This dataset merges hospital attestation data from the Medicare EHR Incentive Program with certified EHR product information from ONC’s Certified Health IT Product List (CHPL), and we code the use of any certified product as health IT adoption.

Table 1: Characteristics of Baseline Sample

| Restrictions | Sample characteristics | | | | |
|-------------------------------|------------------------|--------------------|---------------------|--------------------------|----------------------------|
| | Dually eligible | Add zip × hospital | Add zip × ambulance | Add VA prior utilization | Add no ride in prior month |
| Male | 0.899 | 0.883 | 0.863 | 0.962 | 0.963 |
| Age | 77.04 | 76.89 | 76.13 | 75.62 | 76.03 |
| Black | 0.111 | 0.163 | 0.187 | 0.200 | 0.194 |
| Income | \$21,724 | \$21,453 | \$20,874 | \$20,243 | \$20,905 |
| Rural zip code | 0.255 | 0.043 | 0.045 | 0.050 | 0.051 |
| Residential source | 0.610 | 0.600 | 0.652 | 0.685 | 0.705 |
| Comorbidity count | 6.53 | 6.69 | 6.44 | 6.54 | 6.14 |
| Prior VA ED visit only | 0.048 | 0.082 | 0.130 | 0.277 | 0.294 |
| Prior non-VA ED visit only | 0.607 | 0.560 | 0.492 | 0.252 | 0.247 |
| Prior VA and non-VA ED visit | 0.088 | 0.115 | 0.134 | 0.288 | 0.235 |
| Ambulance rides in prior year | 2.77 | 3.05 | 3.25 | 3.12 | 2.16 |
| Advanced Life Support | 0.696 | 0.655 | 0.655 | 0.674 | 0.684 |
| Weekend rate | 0.272 | 0.269 | 0.270 | 0.270 | 0.269 |
| 28-day mortality | 0.115 | 0.109 | 0.104 | 0.100 | 0.097 |
| Present at VA | 0.044 | 0.088 | 0.166 | 0.336 | 0.330 |
| Number of patients | 2,862,557 | 1,118,302 | 365,163 | 188,299 | 188,299 |
| Number of ambulance rides | 8,828,997 | 3,465,588 | 1,051,093 | 491,193 | 401,319 |

Note: This table presents characteristics of observations remaining at each step of creating the baseline sample, detailed in Appendix Table A.1.

Table 2: Effect of VA Hospitals on Mortality

| | Dependent variable: 28-day mortality | | | | |
|---------------------------------|--------------------------------------|---------|---------|---------|---------|
| | (1) | (2) | (3) | (4) | (5) |
| VA hospital | | | A: OLS | | |
| | -0.024 | -0.023 | -0.026 | -0.022 | -0.021 |
| | (0.001) | (0.001) | (0.001) | (0.001) | (0.001) |
| Outcome mean | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |
| | | | B: IV | | |
| First stage | 0.878 | 0.853 | 0.839 | 0.837 | 0.860 |
| | (0.035) | (0.034) | (0.034) | (0.034) | (0.043) |
| IV estimate | -0.045 | -0.037 | -0.036 | -0.038 | -0.049 |
| | (0.018) | (0.018) | (0.018) | (0.017) | (0.023) |
| Outcome mean | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |
| Patient background controls | No | Yes | Yes | Yes | Yes |
| Comorbidity controls | No | No | Yes | Yes | Yes |
| Ambulance diagnosis controls | No | No | No | Yes | Yes |
| Ambulance and co-rider controls | No | No | No | No | Yes |

Note: This table shows OLS and IV estimates of the effect of VA hospitals on 28-day mortality. Panel A gives OLS estimates, β_{OLS} , for β in Equation (2). Panel B gives IV estimates, β_{IV} , as well as the first stage coefficient, $\hat{\pi}_1$ in Equation (3), with respect to the leave-out probability of the assigned ambulance company to transport patients to the VA. Baseline controls in all specifications are described in Appendix Table A.2 and include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization. Patient background controls include demographics, socioeconomic status, combat history, eligibility for benefits, and counts of prior utilization. All additional controls are described in further detail in Appendix Table A.3. The estimation sample is described in Appendix Table A.1.

Table 3: Effect of VA Hospitals on Other Outcomes

| | Dependent variable | | | | |
|--------------|--------------------|----------------------|--------------------|-----------------------------|-----------------|
| | Admission (1) | Hospital days (2) | ED revisits (3) | Outpatient visits (4) | Spending (5) |
| | A: OLS | | | | |
| VA hospital | -0.004 (0.003) | 0.514 (0.045) | -0.036 (0.007) | 0.200 (0.017) | 840 (87) |
| Outcome mean | 0.589 | 4.380 | 0.318 | 1.443 | 12,265 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |
| | B: IV | | | | |
| IV estimate | -0.090 (0.032) | -0.468 (0.434) | 0.029 (0.044) | 0.379 (0.174) | -2,598 (820) |
| Outcome mean | 0.589 | 4.380 | 0.318 | 1.443 | 12,265 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |

Note: This table shows OLS and IV estimates of the effect of VA hospitals on various outcomes. Hospital days is defined as the number of inpatient days immediately following the ED visit; if the patient is not admitted from the visit, then this equals 0 for that visit. Outpatient visits is defined as the number of VA and non-VA outpatient visits within one month of the ride. ED revisits is defined as subsequent ED visits up to 14 days following the ride. Spending is defined as total spending over the 28 days following the ambulance ride. Panel A gives OLS estimates, $\hat{\beta}_{OLS}$, for β in Equation (2). Panel B gives IV estimates, $\hat{\beta}_{IV}$, as well as the first stage coefficient, $\hat{\alpha}_1$ in Equation (3), with respect to the leave-out probability of the assigned ambulance company to transport patients to the VA. All regressions use baseline controls, which are described in Appendix Table A.2 and include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization. The estimation sample is described in Appendix Table A.1.

Table 4: Complier Characteristics

| | Overall | Compliers | Ratio |
|-------------------------------|----------|---------------------|-----------------------|
| Male | 0.963 | 0.952 (0.006) | 0.99 [0.98 - 1.00] |
| Age | 76.0 | 74.9 (0.433) | 0.99 [0.97 - 1.00] |
| Black | 0.194 | 0.257 (0.028) | 1.33 [1.05 - 1.61] |
| Income | \$20,905 | \$16,972 (\$611) | 0.81 [0.75 - 0.87] |
| Rural zip code | 0.051 | 0.091 (0.025) | 1.78 [0.82 - 2.75] |
| Residential source | 0.705 | 0.647 (0.033) | 0.92 [0.83 - 1.01] |
| Comorbidity count | 6.143 | 5.447 (0.113) | 0.89 [0.85 - 0.92] |
| Mental illness | 0.427 | 0.444 (0.015) | 1.04 [0.97 - 1.11] |
| Substance abuse | 0.144 | 0.163 (0.011) | 1.13 [0.97 - 1.28] |
| Prior VA ED visit only | 0.294 | 0.412 (0.012) | 1.40 [1.32 - 1.48] |
| Prior non-VA ED visit only | 0.247 | 0.065 (0.005) | 0.26 [0.22 - 0.30] |
| Prior VA and non-VA ED visit | 0.235 | 0.288 (0.012) | 1.23 [1.12 - 1.33] |
| Ambulance rides in prior year | 2.156 | 2.178 (0.084) | 1.01 [0.93 - 1.09] |
| Advanced Life Support | 0.684 | 0.600 (0.024) | 0.88 [0.81 - 0.95] |
| Predicted VA user | 0.847 | 0.939 (0.004) | 1.11 [1.10 - 1.12] |
| Predicted mortality | 0.097 | 0.095 (0.004) | 0.98 [0.90 - 1.06] |

Note: This table presents average complier characteristics and the ratio between this average and the average among all veterans in the sample. Average complier characteristics and standard errors are calculated by performing two-stage least squares using the first stage Equation (3) and a reduced-form equation replacing the outcome variable in Equation (4) with $X_i D_i$, where X_i is the characteristic corresponding to ride i . Regressions use baseline controls described in Appendix Table A.2; the regression sample is the baseline sample described in Appendix Table A.1. Standard errors for each average are presented in parentheses. The corresponding 95% confidence intervals for each ratio are presented in brackets.

Table 5: Means of Hospital Characteristics

| | Hospital Sample | | |
|---------------------------------------|-----------------|-----------------|------------------|
| | VA | Non-VA | |
| | Baseline sample | Baseline sample | National average |
| <i>Volume, Size, and Capabilities</i> | | | |
| ED visits | 17,780 | 41,600 | 38,416 |
| Admissions | 6,310 | 13,676 | 12,445 |
| Average daily census | 227 | 200 | 182 |
| Total staffed beds | 322 | 283 | 258 |
| Teaching hospital | 0.59 | 0.27 | 0.22 |
| Urban location | 0.90 | 0.97 | 0.89 |
| Trauma center | 0.11 | 0.64 | 0.61 |
| Advanced cardiac care | 0.74 | 0.70 | 0.58 |
| <i>Staffing</i> | | | |
| ED staff per 1,000 ED visits | 0.78 | 0.55 | 0.73 |
| Nurses per 1,000 patient-days | 6.20 | 5.45 | 5.63 |
| Physicians per 1,000 patient-days | 5.31 | 7.75 | 8.73 |
| Hospitalists per 1,000 patient-days | 0.17 | 0.29 | 0.40 |
| Intensivists per 1,000 patient-days | 0.08 | 0.16 | 0.20 |
| <i>Spending and Relative Outcomes</i> | | | |
| Relative spending | 1.13 | 1.01 | 1.00 |
| Mortality rate | 7.68 | 12.27 | 12.23 |
| Readmissions rate | 12.33 | 18.08 | 18.14 |
| <i>Payment and Organization</i> | | | |
| Capitated lives covered | | 8,087 | 11,399 |
| Network participant | | 0.51 | 0.46 |
| Hospital system | | 0.75 | 0.62 |
| HMO | | 0.19 | 0.20 |
| PPO | | 0.21 | 0.19 |
| ACO | | 0.04 | 0.09 |
| <i>Health IT Adoption</i> | | | |
| Adoption by 2011 | | 0.25 | 0.20 |
| Adoption by 2012 | | 0.61 | 0.56 |
| Adoption by 2013 | | 0.87 | 0.83 |
| Adoption by 2014 | | 0.93 | 0.87 |

Note: This table presents average characteristics of VA and non-VA hospitals. Non-VA hospital characteristics are further presented for the baseline sample and for the national average. The national average weights hospital characteristics by their yearly admissions in the American Hospital Association (AHA) Annual Survey. The average in the baseline sample weights hospital characteristics by rides in that sample, described in Appendix Table A.1. Hospital characteristics are described in further detail in Appendix A.5.

Appendix

A.1 IV Validity

A.1.1 Exclusion Restriction

Under the standard assumptions for IV validity in Imbens and Angrist (1994), ambulance companies would be subject to the exclusion restriction, in Condition 1(ii), that they only affect outcomes by whether they transport patients to the VA, and not by other treatments that they may administer during the ambulance ride or by their choice of non-VA hospitals. Following Kolesar et al. (2015), we relax this assumption to allow for differences in potential treatments and non-VA hospital choices across ambulance companies but require that such differences that may affect outcomes are not systematically related to ambulance propensity to transport to the VA.

Specifically, we include controls \mathbf{C}_i that are related to actions by the ambulance after pickup in the first-stage and reduced-form relationships:

$$\begin{aligned} D_i &= \pi_1 Z_i + \mathbf{X}_i^0 \delta_1 + \mathbf{C}_i \eta_1 + \zeta_{1,z(i)} + \varepsilon_{1,i}; \\ Y_i &= \pi_2 Z_i + \mathbf{X}_i^0 \delta_2 + \mathbf{C}_i \eta_2 + \zeta_{2,z(i)} + \varepsilon_{2,i}. \end{aligned}$$

Under each set of ambulance-related controls, we examine the stability of $\hat{\beta}_{IV} = \hat{\pi}_2 / \hat{\pi}_1$.

We consider four sets of controls in \mathbf{C}_i . First, we control for splines of ambulance charges reflected in their Medicare claims. Consistent with the health economics literature on productivity and the returns to spending (Doyle et al. 2015; Chandra et al. 2016), we consider charges incurred by the ambulance company as a sufficient statistic for the intensity of treatment during the ride.³⁵ Second, we control for splines of the mileage of the ride. Third, we control for indicators of the number of non-VA hospitals to which the ambulance company transports patients from a zip code.

Fourth, we control for average measures of non-VA hospitals to which the ambulance company delivers its patients. For each non-VA hospital h , we measure average mortality and spending outcomes \bar{Y}_h , among veterans outside of our benchmark analytic sample who *only* have non-VA prior utilization (Panel B of Appendix Table A.13). We also measure the share, w_{jh} , that each ambulance company j delivers patients to each non-VA hospital h , also among veterans with non-VA-only prior utilization. For each ride i , we then control for average non-VA hospital measures of mortality and spending, calculated as $\sum_h w_{j(i),h} \bar{Y}_h$, weighted by the hospital-specific shares of the assigned ambulance $j(i)$. As in Section 5.2, we use information on Medicare claims to infer non-VA hospital spending.

Appendix Table A.4 shows estimates of the VA effect on mortality and on spending, using the

³⁵In principle, we also observe detailed CPT procedure codes for services rendered during the ambulance ride (e.g., supplemental oxygen, medications, or intravenous fluids). However, in 2002, Medicare changed to a simple payment arrangement that depended only on a few characteristics of the ride, such as ALS vs. BLS level, mileage, and the use of lights and sirens (Centers for Medicare & Medicaid Services 2002). Consistent with this payment policy, detailed CPT codes for extra services are usually missing in the claims data.

same baseline controls as in our benchmark analyses in Section 3 with the addition of various ambulance related controls. We find that results are highly robust to the addition of these controls.

A.1.2 Monotonicity

We test the monotonicity condition in Condition 1(iii) by tests standard in the judges-design literature that demonstrate a positive first-stage relationship across subgroups of observations (Arnold et al. 2018; Bhuller et al. 2020). We define eight pairs of subsamples based on several important patient characteristics: (i) age ≤ 80 years vs. age > 80 years; (ii) white vs. non-white race; (iii) comorbidity count above vs. below median; (iv) either vs. neither mental illness or substance abuse present; (v) VA visits in the prior year above vs. below median; (vi) Advanced Life Support vs. Basic Life Support; (vii) prediction of VA user above vs. below median; and (viii) prediction of mortality above vs. below median.

Under monotonicity, we expect that an ambulance that has a higher propensity to transport veterans to the VA should weakly increase the probability of transport to the VA for any set of veterans. Specifically, using the set of observations \mathcal{I}_m for each subsample m , we estimate a first-stage regression with respect to our baseline instrument, Z_i , from Equation (1):

$$D_i = \pi_1^m Z_i + \mathbf{X}_i^0 \delta_1^m + \zeta_{1,z(i)}^m + \varepsilon_{1,i}^m, \quad (\text{A.1})$$

and we assess whether $\hat{\pi}_1^m \geq 0$.

We further assess monotonicity in each subsample m by constructing a “reverse-sample” instrument that only uses observations in the analytical sample (Step 6 in Appendix Table A.1) that are not in \mathcal{I}_m :

$$\tilde{Z}_i^{-m} = \frac{1}{\tilde{K}_{j(i)}^{-m}} \sum_{i' \in \tilde{\mathcal{I}}_{j(i)} \setminus \mathcal{I}_m} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}}{\tilde{N}_{k(i'),j(i)}}. \quad (\text{A.2})$$

Within the *analytical* sample, $\tilde{\mathcal{I}}_j$ denotes the set of rides assigned to j , \tilde{K}_j^{-m} is the number of patients assigned to ambulance j without characteristic m , and $\tilde{N}_{k,j}$ is the number of rides by patient k with ambulance j .³⁶ In each subsample m , we also perform first-stage regressions of the form in Equation (A.1) that use \tilde{Z}_i^{-m} instead of Z_i as the instrument.

Recall that the baseline instrument, Z_i , is computed in the much larger sample of dually eligible veterans (Step 1 in Appendix Table A.1). Since the reverse-sample instruments are based on much smaller patient populations, they may be weaker predictors of underlying ambulance propensities to transport to the VA.

In Appendix Table A.5, we demonstrate a positive and statistically significant first-stage coefficient in every subsample and for both the baseline instrument and the reverse-sample instrument. Coefficient sizes are generally smaller for the reverse-sample instruments. In Appendix Table A.6,

³⁶We use the analytical sample to construct the reverse-sample instruments, so that the samples used to construct instruments are roughly the same between pairs of characteristics (e.g., subsamples for comorbidity count above vs. below median).

we show first-stage relationships using two other instruments that are both based on the smaller analytical sample. Specifically, we construct a “baseline” instrument, \tilde{Z}_i , and an “in-sample” instrument, \tilde{Z}_i^m , from the analytical sample:

$$\tilde{Z}_i = \frac{1}{\tilde{K}_{j(i)} - 1} \sum_{i' \in \tilde{I}_{j(i)}} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}}{\tilde{N}_{k(i'), j(i)}}, \text{ and} \quad (\text{A.3})$$

$$\tilde{Z}_i^m = \frac{1}{\tilde{K}_{j(i)}^m - 1} \sum_{i' \in \tilde{I}_{j(i)} \cap \mathcal{I}_m} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}}{\tilde{N}_{k(i'), j(i)}}. \quad (\text{A.4})$$

First-stage coefficients for these instruments are also all positive and statistically significant. They are similar in magnitude to the coefficients for the reverse-sample instruments, which suggests that lower signal-to-noise ratios due to smaller sample sizes explain much of decrease in coefficient magnitude for the reverse-sample instruments, compared to the baseline (overall-sample) instrument.

A.2 Statistical Tests of Hazard Functions

A.2.1 Potential Survival Rates and Hazard Rates

Following the notation in Section 4, let $s_{IV}(t; d) \equiv E[S_i(t; d) | i \in C]$ denote the IV estimands of the potential survival rates among compliers, where $d \in \{0, 1\}$ indicates outcomes under VA care ($d = 1$) or non-VA care ($d = 0$), for each week $t \in \{0, 1, \dots, 52\}$. We then define the corresponding estimands of the potential mortality *hazards* as follows:

$$h_{IV}(t; d) \equiv \frac{s_{IV}(t-1; d) - s_{IV}(t; d)}{s_{IV}(t-1; d)}.$$

We use two-stage least squares to construct estimates of the potential survivor fractions at each time horizon, $\hat{s}_{IV}(t; d)$ and then construct the corresponding potential hazard functions, $\hat{h}_{IV}(t; d)$. We also construct a set of 250 block bootstrap samples (selecting samples by zip code, with replacement), and for replication sample $r \in \{1, \dots, R\}$, we construct $\hat{s}_{IV}^r(t; d)$ and $\hat{h}_{IV}^r(t; d)$. Using these samples we construct the mean estimated potential hazard for each week across the replications:

$$\bar{h}_{IV}^B(t; d) = \frac{1}{R} \sum_r \hat{h}_{IV}^r(t; d). \quad (\text{A.5})$$

We also construct the standard deviation of the bootstrap-estimated potential hazard for each week:

$$\hat{\sigma}_{IV}^B(t; d) = \sqrt{\frac{1}{R-1} \sum_r \left[\hat{h}_{IV}^r(t; d) - \bar{h}_{IV}^B(t; d) \right]^2}. \quad (\text{A.6})$$

We construct similar objects for potential survival and hazard rates under OLS: $\hat{s}_{OLS}(t; d)$ and $\hat{h}_{OLS}(t; d)$, respectively. Using the same set of block bootstrap samples, we compute $\hat{s}_{OLS}^r(t; d)$ and $\hat{h}_{OLS}^r(t; d)$ in each bootstrap replication sample r .

A.2.2 Test of Mortality Displacement

To detect “mortality displacement” (Schwartz 2000), in which deaths of VA patients are simply delayed, we test the joint null hypothesis that $h_{IV}(t;1) \leq h_{IV}(t;0)$ for all $t \geq 1$. This null hypothesis states that the mortality hazard under the VA never overtakes the mortality hazard under non-VA hospitals, even in later periods, and it is consistent with no mortality displacement.

Restating the null hypothesis as

$$H_{0,1} : h_{IV}(t;0) - h_{IV}(t;1) \geq 0, \text{ for all } t \geq 1, \quad (\text{A.7})$$

we use estimates $\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1)$ and consider the following test statistic of the null, based on Wolak (1987):

$$Q_1 \equiv \sum_{t=1}^{52} w_{1,t} \mathbf{1}(\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1) < 0) \left(\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1) \right)^2, \quad (\text{A.8})$$

where $w_{1,t}$ is a strictly positive weight. This test statistic penalizes only negative differences $\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1) < 0$ that can be consistent with the null hypothesis that $\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1) \geq 0$, for all $t \geq 1$, only by statistical noise.

To derive a critical value for Q_1 , we use our bootstrap sample to form a set of recentered bootstrap estimates of the potential hazards at each week:

$$\begin{aligned} \tilde{h}_{IV}^r(t;0) &= \hat{h}_{IV}^r(t;0) - \bar{h}_{IV}^B(t;0); \\ \tilde{h}_{IV}^r(t;1) &= \hat{h}_{IV}^r(t;1) - \bar{h}_{IV}^B(t;1). \end{aligned}$$

We then construct the empirical distribution of the test statistic, in Equation (A.8), under the recentered bootstrap deviations:

$$Q_1^r \equiv \sum_{t=1}^{52} w_{1,t} \mathbf{1}(\tilde{h}_{IV}^r(t;0) - \tilde{h}_{IV}^r(t;1) < 0) \left(\tilde{h}_{IV}^r(t;0) - \tilde{h}_{IV}^r(t;1) \right)^2. \quad (\text{A.9})$$

We take the 95th percentile of this distribution as the critical value above which our test statistic Q_1 can reject the null hypothesis $H_{0,1}$, in Equation (A.7).

Following Wolak (1987), this distribution is formed under the data generating process implied by the “least favorable null” for testing joint inequality constraints (Perlman 1969). Specifically, we consider the least favorable data generating process that satisfies the null hypothesis H_0 , in Equation (A.7), which is

$$\underline{H}_{0,1} : h_{IV}(t;0) - h_{IV}(t;1) = 0, \text{ for all } t \geq 1. \quad (\text{A.10})$$

If we obtain a test statistic Q_1 with improbable negative deviations that reject the least favorable null hypothesis $\underline{H}_{0,1}$ in Equation (A.10), then we can also reject the null hypothesis $H_{0,1}$ in Equation (A.7).

We use the same weights $w_{1,t}$ in Equations (A.8) and (A.9) and set them as the inverse of the estimated sampling variance of the recentered deviations:

$$w_{1,t}^{-1} = \frac{1}{R-1} \sum_r (\tilde{h}_{IV}^r(t;0) - \tilde{h}_{IV}^r(t;1))^2. \quad (\text{A.11})$$

These weights standardize the statistical distribution of $\hat{h}_{IV}(t;0) - \hat{h}_{IV}(t;1)$, so that the test statistic distribution can be considered as chi-squared. Although we use critical values derived from the bootstrap distribution, we find the scale of our test statistic to be more intuitive with this normalization.³⁷

We show results in Panel A of Appendix Figure A.5. We find that Q_1 is within the distribution of bootstrapped values of Q_1^* . We therefore cannot reject the null of no mortality displacement.

A.2.3 Extended Test of IV Validity

In addition to standard tests of IV validity that are based on observable characteristics—including tests of balance in Section 3.2 and monotonicity in Appendix A.1.2—we develop a tractable extended test of IV validity using the insights in Balke and Pearl (1997) and Heckman and Vytlačil (2005, Proposition A.5) that are based on *potential outcomes*.

Kitagawa (2015) summarizes these insights as follows for a binary instrument $Z \in \{0, 1\}$, a binary treatment $D \in \{0, 1\}$ (increasing in probability with Z), and an outcome $Y \in \mathcal{Y}$. For any Borel set B in \mathcal{Y} , IV validity in Condition 1 implies that

$$\Pr(Y \in B, D = 1 | Z = 1) - \Pr(Y \in B, D = 1 | Z = 0) \geq 0; \quad (\text{A.12})$$

$$\Pr(Y \in B, D = 0 | Z = 0) - \Pr(Y \in B, D = 0 | Z = 1) \geq 0. \quad (\text{A.13})$$

Kitagawa (2015, Proposition 1.1) further states that tests of Equations (A.12) and (A.13) constitute the strongest possible tests of IV validity in the sense that no other feature of the data can contribute further to screening out invalid instruments.³⁸

We note that, given the approach in Abadie (2002), testing Equations (A.12) and (A.13) is algebraically equivalent to testing, for all $B \subset \mathcal{Y}$,

$$\Pr(Y_i(0) \in B | i \in C) \geq 0; \quad (\text{A.14})$$

$$\Pr(Y_i(1) \in B | i \in C) \geq 0. \quad (\text{A.15})$$

³⁷Wolak (1987) proposes to use an optimal minimum distance test statistic that would use the full covariance matrix of $\delta(t)$. We avoid this formulation due to finite-sample issues that would cause this covariance matrix to be poorly estimated by the full covariance matrix of $\delta^r(t)$, noted by Altonji and Segal (1996). Results are qualitatively similar when we choose a weight of $w_t = 1$ for all t , but we find that using w_t from Equation (A.11)—i.e., normalizing each $\delta(t)$ by its bootstrap standard error—affords greater power in rejecting the null. This approach is equivalent to our best estimate of a diagonal covariance matrix in place of the full covariance matrix.

³⁸Chan et al. (2019) provides an applied example, in the setting of radiologists, in which standard monotonicity tests in Appendix A.1.2 are satisfied but a simple version of this extended test of validity is not satisfied. They find that radiologists who diagnose more cases with pneumonia do so in a wide range of subgroups of patients defined by observable characteristics (i.e., standard tests of monotonicity) but that the same radiologists who diagnose more cases with pneumonia are more likely to miss cases of pneumonia (i.e., $\Pr(Y \in B, D = 0 | Z = 0) - \Pr(Y \in B, D = 0 | Z = 1) < 0$).

Thus we use the Abadie (2002) approach to define a partition of mortality outcomes \mathcal{Y} in terms of weekly hazard rates, by the date of death (if any) following the ambulance ride. Such a partition implies that potential hazard rates among compliers, $h_{IV}(t; d)$, are non-negative in every week $t \in \{1, \dots, 52\}$ under both VA assignment ($d = 1$) and non-VA assignment ($d = 0$).

That is, our extended test of IV validity amounts to testing the following joint null hypothesis of inequality constraints:

$$H_{0,2} : h_{IV}(t; d) \geq 0, \text{ for all } t \geq 1, d \in \{0, 1\}. \quad (\text{A.16})$$

Following a similar approach as for mortality displacement in Appendix A.2.2, our test statistic is

$$Q_2 \equiv \sum_{d=0}^1 \sum_{t=1}^{52} w_{2,t} \mathbf{1}(\hat{h}_{IV}(t; d) < 0) \left(\hat{h}_{IV}(t; d) \right)^2,$$

where $w_{2,t}^{-1} = (\hat{\sigma}_{IV}^B(t; d))^2$. We obtain the critical value for our test statistic by the distribution of recentered bootstrapped estimates, defined above. For the r th bootstrap replication, the test statistic is

$$Q_2^r \equiv \sum_{d=0}^1 \sum_{t=1}^{52} w_{2,t} \mathbf{1}(\tilde{h}_{IV}^r(t; d) < 0) \left(\tilde{h}_{IV}^r(t; d) \right)^2.$$

We take the 95th percentile of the distribution of Q_2^r across replications $r \in \{1, \dots, R\}$ as the critical value for Q_2 . As above, this test of inequality constraints is based upon a least favorable null hypothesis. In this case, the least favorable null hypothesis is

$$\underline{H}_{0,2} : h_{IV}(t; d) = 0, \text{ for all } t \geq 1, d \in \{0, 1\}. \quad (\text{A.17})$$

We show results in Panel B of Appendix Figure A.5. We find that Q_2 is lower than any bootstrapped value of Q_2^r . This suggests not only that we cannot reject the null hypothesis $H_{0,2}$ in Equation (A.16), but also that the realized data are significantly more favorable than the least favorable null hypothesis $\underline{H}_{0,2}$ in Equation (A.17). In other words we can strongly reject the null that $h_{IV}(t; d) = 0$, for all $t \geq 1, d \in \{0, 1\}$, which means that $h_{IV}(t; d) > 0$ for at least some $t \geq 1, d \in \{0, 1\}$.

A.2.4 Tests of Hazard Rate Equality

We finally perform tests of the equality of hazard rates after the first week after the ambulance ride. Comparing hazard rates across different groups of veterans, we aim to shed light on heterogeneity in longer-term mortality risk across these groups. To define these tests generally, consider two sets of hazard rates, $h_1(t)$ and $h_2(t)$, for $t \geq 2$. We consider two types of null hypothesis.

First, we assess mean differences in hazard rates between $\{h_1(t)\}_t$ and $\{h_2(t)\}_t$, for $t \geq 1$, under the null hypothesis that the mean hazard rate is the same between the two sets:

$$H_{0,3} : \frac{1}{51} \sum_{t=2}^{52} (h_1(t) - h_2(t)) = 0. \quad (\text{A.18})$$

We test this null hypothesis by comparing $\frac{1}{51} \sum_{t=2}^{52} (\hat{h}_1(t) - \hat{h}_2(t))$ against the bootstrapped distribution of recentered differences. Specifically, for replication $r \in \{1, \dots, R\}$, denote the bootstrap-estimate hazard rates of $(h_1(t), h_2(t))$ as $(\hat{h}_1^r(t), \hat{h}_2^r(t))$. Define the recentered bootstrap hazard rate as

$$\begin{aligned}\tilde{h}_1^r(t) &\equiv \hat{h}_1^r(t) - \bar{h}_1^B(t) \text{ and} \\ \tilde{h}_2^r(t) &\equiv \hat{h}_2^r(t) - \bar{h}_2^B(t),\end{aligned}$$

where $\bar{h}_1^B(t) \equiv \frac{1}{R} \sum_r h_1(t)$ and $\bar{h}_2^B(t) \equiv \frac{1}{R} \sum_r h_2(t)$. The distribution of $\{\frac{1}{51} \sum_{t=2}^{52} (\tilde{h}_1^r(t) - \tilde{h}_2^r(t))\}_r$ determines the two-sided critical values for the mean hazard difference. By construction, this distribution will have mean 0.

Second, we consider the joint null hypothesis that the difference between each pair of hazards is equal to 0:

$$H_{0,4} : h_1(t) - h_2(t) = 0, \text{ for all } t \geq 1. \quad (\text{A.19})$$

Using estimates $\hat{h}_1(t) - \hat{h}_2(t)$, we construct the following test statistic:

$$Q_4(h_1(\cdot), h_2(\cdot)) \equiv \sum_{t=2}^{52} w_{4,t} (\hat{h}_1(t) - \hat{h}_2(t))^2.$$

We compute the empirical distribution of Q_4 under the null hypothesis by using recentered differences $\tilde{h}_1^r(t) - \tilde{h}_2^r(t)$. Each bootstrap replication r yields

$$Q_4^r(h_1(\cdot), h_2(\cdot)) \equiv \sum_{t=2}^{52} w_{4,t} (\tilde{h}_1^r(t) - \tilde{h}_2^r(t))^2.$$

We take the 95th percentile of the distribution of Q_4^r across replications $r \in \{1, \dots, R\}$ as the critical value for Q_4 . We set $w_{4,t}^{-1} = \frac{1}{R-1} \sum_r (\tilde{h}_1^r(t) - \tilde{h}_2^r(t))^2$ to standardize the distribution of $\hat{h}_1(t) - \hat{h}_2(t)$.

In Appendix Figures A.6 and A.7, we consider five comparisons of hazard rates, for $t \geq 1$, under the null hypotheses of Equations (A.18) and (A.19), respectively. First, we test the null hypothesis that $h_{IV}(t; 1) - h_{IV}(t; 0) = 0$, for all $t \geq 1$. Under quasi-experimental assignment of compliers (Condition 1), we expect not to reject this null if longer-term hazard rates reflect underlying health. Second, we test the null hypothesis that $h_{OLS}(t; 1) - h_{OLS}(t; 0) = 0$, for all $t \geq 1$. While we show stability of OLS results in Figure 2, this test may reveal differences in underlying health between veterans assigned to the VA and those assigned to a non-VA hospital that are not captured by observable patient characteristics.

Third, we test the null hypothesis that $h_{IV}(t; 1) - h_{OLS}(t; 1) = 0$, for all $t \geq 1$. This reveals differences in underlying health between compliers and VA-assigned veterans, which includes compliers and always takers. Fourth, we similarly test the null hypothesis that $h_{IV}(t; 0) - h_{OLS}(t; 0) = 0$, for all $t \geq 1$. This reveals differences in underlying health between compliers and non-VA-assigned veterans, which includes compliers and never takers.

A.3 Non-Complier Characteristics

In this appendix section, we describe a simple approach to calculate characteristics of non-compliers, following Dahl et al. (2014), and we discuss results. In our approach, we first residualize the leave-out ambulance propensity to transport to the VA, Z_i , by our key controls, $(z(i), \mathbf{X}_i^0)$. Denote this residual as Z_i^* . We categorize always takers as rides with Z_i^* below the 20th percentile that still went to the VA ($D_i = 1$). We categorize never takers as rides with Z_i^* above the 80th percentile that still did not go to the VA ($D_i = 0$).

Among each group of always takers and never takers, we compute characteristics along the same dimensions as those in our compliers analysis, in Table 4. Specifically, for each characteristic, we compute mean values among the group of always takers and among the group of never takers, and we compare these means with the overall mean by a ratio. We compute standard errors of these means by drawing bootstrapped samples, blocked by zip code, and repeating this procedure with each bootstrapped sample.

As shown in Appendix Table A.7, we mostly find results that are consistent with our earlier results of complier characteristics and the fact that the majority of non-compliers are never takers: For many characteristics, those that are more common among compliers tend to be more common among always takers and less common among never takers. Compared to the overall population, always takers are more likely to be Black and have lower income. Always takers are more likely to have mental illness, and they have a slightly higher rate of substance abuse, though the latter is not statistically significant. Always takers are more likely to have prior VA ED visits and less likely to have prior non-VA ED visits. However, both always takers and never takers as defined by this methodology have slightly higher predicted mortality.

A.4 Marginal and Average Treatment Effects

Consider the probability of going to the VA as a function of our instrument Z_i and key controls $(z(i), \mathbf{X}_i^0)$: $P(Z_i)$, where we have omitted the key controls for brevity. Following Heckman and Vytlačil (2005), we can state the treatment rule as

$$D_i = \mathbf{1}(P(Z_i) \geq U_i), \quad (\text{A.20})$$

where U_i is uniformly distributed in the interval $(0, 1)$. Individuals with low U_i relative to $\underline{p} \equiv \arg \min_i P(Z_i)$ are always takers, while individuals with high U_i relative to $\bar{p} \equiv \arg \max_i P(Z_i)$ are never takers.

In this appendix, we estimate two objects relative to selection, as defined by $U_i \sim U(0, 1)$. The marginal treatment effect (MTE) for rides with $U_i = u$ is

$$MTE(u) \equiv E[Y_i(1) - Y_i(0) | U_i = u].$$

The average treatment effect (ATE) is

$$ATE = \int_0^1 MTE(u) du.$$

We estimate $MTE(u)$, for $u \in [\underline{p}, \bar{p}]$, using variation in the propensity of ambulances to transport to the VA. We estimate the ATE by extrapolating $MTE(u)$ to $u \in [0, 1]$ with a control function approach.

A.4.1 Marginal Treatment Effects

We first estimate marginal treatment effects using a local instrumental variables approach that exploits outcomes along the distribution of ambulance propensity to transport to the VA. The intuition for this approach is that $MTE(u)$ can be stated as

$$MTE(u) = \frac{\partial}{\partial p} E[Y_i | P(Z_i) = u].$$

That is, if mortality decreases linearly with ambulance propensity to transport to the VA, then the data would be consistent with constant treatment effects. On the other hand, if mortality decreases at a faster rate for lower $P(Z_i)$, then the data would suggest “selection on gains,” in which veterans who are more likely to benefit from VA care are also more likely to be transported to the VA given a set of ambulances. The visual IV relationship in Appendix Figure A.2 suggests a slightly convex shape in the relationship between mortality and $P(Z_i)$, which implies selection on gains.

We proceed with estimating a flexible relationship between Y_i and $P(Z_i)$ as follows. We compute $P(Z_i) = \hat{D}_i$ from the first-stage Equation (3). We then residualize \hat{D}_i by baseline controls, defined in Appendix Table A.2, and denote the residual as \hat{D}_i^* . We similarly residualize Y_i by baseline controls and denote the residual as Y_i^* . For interpretation, we set Y_i^* and \hat{D}_i^* to have the same respective means as Y_i and D_i . A regression of Y_i^* on \hat{D}_i^* yields a point estimate that is numerically identical to the IV estimate $\hat{\beta}_{IV}$.³⁹

Rather than fitting a straight line through points (\hat{D}_i^*, Y_i^*) , we fit a flexible function with Gaussian basis splines with four knots (k_1, k_2, k_3, k_4) corresponding to the 5th, 35th, 65th, and 95th percentiles of \hat{D}_i^* . Specifically, for each ride i , we form five basis functions

$$f_n(p) = \exp\left(- (k_n - k_{n-1}) (p - c_n)^2\right),$$

where $c_n = \frac{1}{2}(k_{n-1} + k_n)$, $k_0 = \min \hat{D}_i^*$, and $k_5 = \max \hat{D}_i^*$. We regress

$$Y_i^* = \sum_{n=1}^5 \gamma_n f_n(\hat{D}_i^*) + \varepsilon_i$$

and form a flexible prediction $\hat{Y}^*(p) = \sum_{n=1}^5 \hat{\gamma}_n f_n(p)$.

³⁹This regression corresponds to the indirect least squares version of IV and is also numerically identical to the visual IV coefficient that corresponds to the two-stage least squares version of IV.

This prediction yields a convenient analytical derivative for the MTE

$$\widehat{MTE}(u) = \sum_{n=1}^5 \hat{\gamma}_n f'_n(u) = - \sum_{n=1}^5 2(k_n - k_{n-1})^2 (u - c_n) \hat{\gamma}_n f_n(u).$$

For each $p \in [0.05, 0.20]$, corresponding to the range of \hat{D}_i^* , we compute 95% confidence intervals of $\hat{Y}^*(p)$ by taking the standard deviations of $\hat{Y}^*(p)$ across 50 bootstrapped iterations (with samples drawn by zip code, with replacement). Similarly, for each $u \in [0.05, 0.20]$, we compute 95% confidence intervals of $\widehat{MTE}(u)$ by taking the standard deviations of $\widehat{MTE}(u)$ across these same bootstrapped iterations. We display both $\hat{Y}^*(p)$ and $\widehat{MTE}(u)$ in Appendix Figure A.8.

A.4.2 Average Treatment Effect

In order to estimate the ATE, we adopt a control function model in order to extrapolate treatment effects to non-compliers. Specifically, we model potential outcomes as

$$E[Y_i(d)|U_i = u] = \alpha_d + \gamma_d (J(u) - \mu_J) + \mathbf{X}_i^0 \delta + \zeta_{z(i)}, \quad (\text{A.21})$$

where $d \in \{0, 1\}$ and $u \in (0, 1)$. $J(u)$ is a strictly increasing, continuous function that maps selection to potential outcomes, and $\mu_J \equiv E[J(U_i)]$. Since $E[J(u) - \mu_J] = 0$, we can interpret $\alpha_1 - \alpha_0$ as the ATE. Kline and Walters (2019) show that the control function model in Equations (A.20) and (A.21) can also rationalize the Imbens and Angrist (1994) LATE that we estimate in Section 3, regardless of the choice of $J(u)$.⁴⁰

For our baseline specification, we adopt the linear selection function of $J(u) = u$ from Olsen (1980), which we use with Equation (A.21) to state the following expectation, conditional on the first-stage error $\varepsilon_{1,i}$ from Equation (3):⁴¹

$$\begin{aligned} E[Y_i|D_i = d, \varepsilon_{1,i} = \varepsilon] &= \alpha_d + \gamma_d E[J(u) - \mu_J|D_i = d, \varepsilon_{1,i} = \varepsilon] + \mathbf{X}_i^0 \delta + \zeta_{z(i)} \\ &= \alpha_d - \gamma_d \frac{\varepsilon}{2} + \mathbf{X}_i^* \delta + \zeta_{z(i)}. \end{aligned} \quad (\text{A.22})$$

This expectation corresponds to the following regression:

$$Y_i = \alpha_\Delta D_i + \gamma_0 \left(-\frac{\hat{\varepsilon}_{1,i}}{2} \right) + \gamma_\Delta \left(-\frac{\hat{\varepsilon}_{1,i}}{2} \right) D_i + \mathbf{X}_i^0 \delta + \zeta_{z(i)} + v_i, \quad (\text{A.23})$$

plugging in the estimated first-stage residual $\hat{\varepsilon}_{1,i}$ from Equation (3). We can compute the ATE from

⁴⁰Kline and Walters (2019) show algebraic equivalence between the control function LATE implied by Equation (A.21), \underline{p} , and \bar{p} , when the instrument is binary and there are no controls. They also generalize their result for multivalued instruments. With controls, the equivalence may not hold in the standard regression approach in which controls are treated as additively separable but will hold under a propensity score approach.

⁴¹To see this, assume that the first stage regression in Equation (3) estimates a well-behaved $P(Z_i) \in (0, 1)$ such that $D_i = P(Z_i) + \varepsilon_{1,i}$. Define $\lambda_d(p) \equiv E[J(U_i) - \mu_J|D_i = d, P(Z_i) = p]$. We have $\lambda_1(p) = \frac{p}{2} - \frac{1}{2} = \frac{p-1}{2}$, and $\lambda_0(p) = \frac{p+1}{2} - \frac{1}{2} = \frac{p}{2}$. Note that $\lambda_d(p) = \frac{p-d}{2} = \frac{-\varepsilon}{2}$, where $\varepsilon \equiv d - p$. This implies that $\varepsilon_{1,i} = D_i - P(Z_i)$ is a sufficient statistic for $(D_i, P(Z_i))$, and we can state the expectation $J(U_i) - \mu_J$ conditional on $\varepsilon_{1,i}$: $E[J(U_i) - \mu_J|\varepsilon_{1,i} = \varepsilon] = -\frac{\varepsilon}{2}$.

this equation as $\alpha_\Delta = \alpha_1 - \alpha_0$. We estimate Equation (A.23) by OLS to yield $\hat{\alpha}_\Delta = -0.037$, slightly smaller in magnitude than the LATE estimate of -0.041 from Section 3. For inference on the difference between the ATE and the LATE, we recover a numerically equivalent LATE with the following control function regression:⁴²

$$Y_i = \beta_{CF} D_i + \gamma \hat{\varepsilon}_{1,i} + \mathbf{X}_i^0 \delta_0 + \zeta_{0,z(i)} + v_i, \quad (\text{A.24})$$

where $\hat{\beta}_{CF}$ is estimated by OLS and is numerically equivalent to $\hat{\beta}_{IV}$ estimated by two-stage least squares. For each bootstrapped replication, we estimate both the ATE, $\hat{\alpha}_1 - \hat{\alpha}_0$, and its difference with the LATE, $\hat{\beta}_{CF}$, in order to obtain standard errors on both the ATE and the difference.

We also examine semiparametric specifications that allow for flexible relationships between the first-stage residual and the structural error term. These alternative specifications allow nonlinear relationships of $g_d(\varepsilon) \equiv E[\varepsilon_{0,i} | D_i = d, \varepsilon_{1,i} = \varepsilon]$, where $\varepsilon_{0,i}$ is the structural error term in Equation (2). Specifically, we estimate regressions of the following form:

$$Y_i = \alpha_\Delta D_i + g_0(\hat{\varepsilon}_{1,i})(1 - D_i) + g_1(\hat{\varepsilon}_{1,i})D_i + \mathbf{X}_i^0 \delta + \zeta_{z(i)} + v_i, \quad (\text{A.25})$$

where $g_d(\hat{\varepsilon}_{1,i})$, $d \in \{0, 1\}$, are flexible functions of the first-stage residual that are non-zero when $D_i = 0$ and $D_i = 1$, respectively. To estimate $g_d(\hat{\varepsilon}_{1,i})$, $d \in \{0, 1\}$, we use a vector of restricted cubic spline functions or Gaussian basis functions, with three or five knots. Ensuring that $E[g_d(\hat{\varepsilon}_{1,i})] = 0$ by demeaning each spline or basis function, we can interpret α_Δ as the ATE.

In Appendix Table A.8, we show estimates of the ATE and the ATE-LATE difference. ATE estimates are all smaller in magnitude than the LATE estimate from Section 3. We compute standard errors on this difference with 50 bootstrapped iterations (selecting samples by zip code, with replacement). The ATE-LATE difference is statistically significant in our baseline specification in Equation (A.23), though they are not statistically significant in the semiparametric specifications.

A.5 Hospital Characteristics

In this appendix, we provide further details on hospital characteristics that we use in our heterogeneity analyses in Section 5.1. These characteristics are listed in Table 5 and Appendix Tables A.9 to A.11. For each zip code and year, we use characteristics of the closest VA hospital and a weighted average of the characteristics of associated non-VA hospitals. Weights for each non-VA hospital are proportional to the number of ambulance rides originating from a given zip code to the hospital in that year. Unless otherwise noted, characteristics are observed at the hospital-year level.

We use the American Hospital Association (AHA) Annual Survey to collect the following VA and non-VA hospital characteristics at the hospital-year level: (i) number of ED visits; (ii) number of facility admissions; (iii) number of available hospital beds; (iv) teaching hospital status; (v) trauma

⁴²Blundell and Matzkin (2014) attribute the first proof of this equivalence between control function and two-stage least squares approaches to estimating the LATE to Telser (1964).

center status; (vi) number of privileged ED staff, which we use to construct ED staff per 100 ED visits given (i); (vii) number of full-time registered nurses, which we use to construct nurses per 100 admissions given (ii); (viii) number of privileged hospitalists, which we use to construct hospitalists per 100 admissions; and (ix) number of privileged intensivists, which we use to construct intensivists per 100 admissions given (ii).

We construct a measure of advanced cardiac care, which we define as either the capability to perform interventional cardiac catheterization or cardiac surgery as measured by the AHA Annual Survey (at the hospital-year level) or listing as an ST-Elevation Myocardial Infarction (STEMI) center by the American Heart Association (at the hospital level). We record whether each hospital is certified as a Primary Stroke Center according to the Joint Commission, the American Heart Association, and the American Stroke Association (at the hospital level).

For VA hospitals, we form measures of relative spending from the average cost of an inpatient-day, available from the VA Health Economics Resource Center (HERC). For non-VA hospitals, we use data from `Data.Medicare.gov` on Medicare spending per beneficiary at the hospital level. Similarly, we obtain mortality and readmission rates from `Data.Medicare.gov` for non-VA hospitals and from the VA's Strategic Analytics for Improvement and Learning (SAIL). For each hospital's mortality rate, we take the mean of all available 30-day mortality rates, including disease-specific rates such as heart attack and pneumonia; we form similar means for each hospital's readmission rate based on available 30-day readmission rates, including disease-specific rates. Because some years are missing mortality or readmission rates, for each hospital and rate, we first form averages across years at the hospital level.

For measures of non-VA hospital organization, we use AHA Annual Survey measures of network status, hospital system status, and health maintenance organization (HMO) affiliation. We also obtain whether the hospital participates in an Affordable Care Organization (ACO) from the Medicare Shared Savings Program (MSSP) ACO provider-level dataset. We measure health IT adoption for each hospital and year from the use of any electronic health record certified products on the Certified Health IT Product List (CHPL) reported on `healthIT.gov`. Additional characteristics in Table 5 are also obtained from the AHA Annual Survey: (i) average daily census, (ii) urban location (i.e., hospital is not classified as either "micro" or rural), (iii) capitated lives covered, and (iv) Preferred Provider Organization (PPO) affiliation.

A.6 Heterogeneity by Observable Characteristics

This appendix describes our analytical approach to estimating treatment effect heterogeneity by observable hospital or patient characteristics. As described in Section 5.1, we three categories of characteristics: (i) characteristics of non-VA hospitals serving a given zip code, weighting the hospitals by volume of rides from the zip code; (ii) characteristics of the VA hospital serving a given zip code; and (iii) patient characteristics. Hospital characteristics are described in further detail in Appendix A.5.

For each of these characteristics x , we construct a binary indicator variable, $I_{x,i} \in \{0, 1\}$. For example, for the non-VA hospital characteristic of number of staffed beds, we create a binary indicator variable for whether the volume-weighted average number of staffed beds across non-VA hospitals in a zip code is above or below the median. We include a demeaned $\tilde{I}_{x,i} \equiv I_{x,i} - \hat{E}_i [I_{x,i}]$ in the following linear control function regression:

$$Y_i = \beta_x D_i + \rho_x D_i \tilde{I}_{x,i} + \pi_x \tilde{I}_{x,i} + \gamma_x \hat{\varepsilon}_{1,i} + \mathbf{X}_i^0 \delta_x + \zeta_{x,z(i)} + \varepsilon_{x,i}, \quad (\text{A.26})$$

where $\hat{\varepsilon}_{1,i}$ is the first-stage error from Equation (3). Controlling for the endogeneity of selection, this approach yields estimates of binary heterogeneous treatment effects along several dimensions. This approach enables greater statistical power than performing separate IV regressions in subsamples defined by $I_{x,i} \in \{0, 1\}$. For a discussion of this general approach, see Wooldridge (2015), Section III. Since $\tilde{I}_{x,i}$ has a mean of 0, we can interpret β_x as the LATE, controlling for $\tilde{I}_{x,i}$; ρ_x is the difference in the VA effect on mortality between $I_{x,i} = 1$ and $I_{x,i} = 0$. We calculate standard errors by bootstrap, drawing blocks of data by zip code.

A.7 OLS Heterogeneity in Station-Specific VA Advantage

In this appendix, we describe analyses related to OLS heterogeneity in the station-specific VA advantage and validating this heterogeneity with our quasi-experiment. As in our heterogeneity analyses in Section 5.1, we assign each zip code z to a VA station $\ell(z)$ based on the station that the most veterans living in that zip code use. This assignment of zip codes to VA stations matches station catchment areas for 92% of zip codes.

In separate OLS regressions, we estimate the VA advantage for each station ℓ as β_ℓ in

$$Y_i = \beta_{OLS}^\ell D_i + \mathbf{X}_i^0 \delta^\ell + \zeta_{z(i)}^\ell + \varepsilon_i, \quad (\text{A.27})$$

using ambulance rides i such that the zip code $z(i)$ maps to station ℓ (i.e., $\ell(i) \equiv \ell(z(i)) = \ell$). The ride-weighted variance of $\hat{\beta}_{OLS}^\ell$ is 3.4×10^{-4} , while the ride-weighted variance of the sampling error for each $\hat{\beta}_{OLS}^\ell$ is 2.1×10^{-4} . This implies a sampling-error-adjusted, ride-weighted variance of β_{OLS}^ℓ of $A = (3.4 - 2.1) \times 10^{-4} = 1.4 \times 10^{-4}$, or a standard deviation of β_{OLS}^ℓ of $\sqrt{A} = 0.012$.

In Appendix Figure A.9, we plot the distribution of $\hat{\beta}_{OLS}^\ell$ for 32 stations with at least 5,000 rides, forming a sample of 276,483 rides. We also plot the empirical Bayes posteriors for all stations, which we calculate as follows:

$$\tilde{\beta}_{OLS}^\ell = (1 - B_\ell) \hat{\beta}_{OLS}^\ell + B_\ell \hat{\beta}_{OLS}, \quad (\text{A.28})$$

where $B_\ell = \frac{V_\ell}{V_\ell + A}$ is the shrinkage factor based on V_ℓ , which is the variance of the sampling error for station ℓ , and A , which is the variance of the prior distribution of β_{OLS}^ℓ . $\hat{\beta}_{OLS} = -0.024$ is the overall OLS estimate reported in Section 3.3. This figure shows that essentially all stations exhibit a VA advantage, at least when estimated by OLS.

We evaluate whether differences in $\tilde{\beta}_{OLS}^\ell$ imply differences in the treatment effects identified by

our quasi-experiment. As a first analysis, we divide stations into two groups depending on whether $\tilde{\beta}_{OLS}^\ell$ is above- or below-median. We estimate by two-stage least squares $\hat{\beta}_{IV}$, based on Equations (3) and (4), separate IV estimates for ambulance rides belonging to each of these two groups. $\hat{\beta}_{IV}$ estimated for stations with below-median (i.e., larger in magnitude) $\tilde{\beta}_{OLS}^\ell$ is 0.030 larger in magnitude than the same estimate for stations with above-median (i.e., smaller in magnitude) $\tilde{\beta}_{OLS}^\ell$. However, the difference is imprecise, with a bootstrapped standard error of 0.051.

For a more systematic validation of $\tilde{\beta}_{OLS}^\ell$, in the spirit of Angrist et al. (2017), we conduct a pooled analysis by indirect least squares. Specifically, denoting demeaned $\tilde{\beta}_{OLS}^\ell$ as $\tilde{\beta}_{OLS}^{\ell*}$, we estimate

$$Y_i = \beta D_i + \gamma D_i \times \tilde{\beta}_{OLS}^{\ell(i)*} + \mathbf{X}_i^0 \delta + \zeta_{z(i)} + \varepsilon_i,$$

where we instrument D_i and $D_i \times \tilde{\beta}_{OLS}^{\ell(i)*}$ by Z_i and $Z_i \times \tilde{\beta}_{OLS}^{\ell(i)*}$. This regression reveals an imprecise and wrong-signed result of $\hat{\gamma} = -0.790$ (s.e., 1.351). The overall imprecision of these results suggests that there is little signal that we can validate in the heterogeneity across station-specific OLS measures of the VA advantage. The more precise results in Section 5.1 also suggest little meaningful heterogeneity along binary characteristics of VA and non-VA hospitals in a given zip code.

A.8 Reported Utilization Patterns

We provide details in this appendix on analyses of reported utilization patterns in the VA and in non-VA hospitals. Our analyses are all based on line items of utilization from the VA and Medicare data corresponding to any patient in the baseline sample in the 28 days following his ambulance ride. Each line item corresponds to a service defined by Current Procedural Terminology (CPT) code.

In our first set of analyses, we examine the share of line items originating from the VA across different CPT codes. Specifically, we define this share as the proportion of line items for a CPT code originating from VA records out of the total number of line items for that CPT code reported by both VA and non-VA (i.e., Medicare) providers. Appendix Figure A.10 shows VA shares for the top 25 (out of 5,167) CPT codes in the Medicare Physician Fee Schedule (MPFS), ranked by total utilization.

We find a wide range of VA shares even within this set of common CPT codes. At one extreme, only 4.1% of line items for CPT code 99223, one of the codes for evaluation and management (E/M) performed in initial hospital care, originate from the VA. Also with a VA share of 4.1%, CPT code 99239 reports E/M care lasting more than 30 minutes on the discharge day of a hospitalization. In order for this code to be reported, the physician must report that she spent more than 30 minutes with the patient. In non-VA hospitals, there is a financial incentive to do so; for clinical care, there is little reason to do so. In contrast, the complementary E/M CPT code that reports spending 30 or fewer minutes on discharge day (99238) is more than four times likelier (17.1%) to originate from the VA. At the other extreme, 90.5% of line items for CPT code 99211, which reports a simple outpatient E/M service not requiring the presence of a physician, originate from the VA. Strikingly, *all* of the reported utilization of CPT code 98966, for short calls made by a non-physician, occur in the VA.

Appendix Figure A.11 shows similar VA shares for the top 25 (out of 115) groups of Category

I CPT codes, ranked by total utilization. This figure shows similar patterns, albeit for much larger aggregations of line items. Hospital inpatient E/M services are much more commonly reported by non-VA providers. Physical therapy, rehabilitation, psychiatric services, and telephone (i.e., non-face-to-face) services provided by non-physicians are much more commonly reported in the VA. Pulmonary services—the vast majority of which comprise low-reimbursed services such as measuring oxygen levels and providing inhalation treatment—are also much more commonly reported in the VA.

We examine the relationship between reimbursement and the share of a CPT code’s utilization coming from the VA. We measure reimbursement among CPT codes on the MPFS, multiplying year-specific relative value units (RVUs) with the year-specific dollar conversion factor. In Appendix Figure A.12, we show a strong negative relationship between the median reimbursement (across years) for a given CPT code and its VA share. Importantly, reimbursement by Medicare for physician services is determined by the resource-based relative value scale (RBRVS), a system entirely based on the costliness of procedures and not on the benefit of procedures (American Medical Association 2015). Thus, services with high potential value relative to their costs (e.g., telephone calls) are reimbursed little and much less likely reported in the fee-for-service system outside the VA.

We finally focus on evaluation and management (E/M) CPT codes, which allow for reporting of complexity. E/M codes are among the most common CPT codes and reflect an integral part of clinical care, particularly for emergency patients. Reimbursement may vary widely across E/M codes reporting different levels of complexity. For example, within the set of CPT codes 99201-99205, collectively for “office or other outpatient encounters for new patients,” may range almost fivefold in reimbursement. The complexity allowed for an E/M code reported for an encounter depends on documentation, but much of the documentation is ultimately unverifiable. For these reasons, Fang and Gong (2017) devote much of their analysis in detecting potential overbilling to E/M codes.

In Appendix Figure A.13, we show the odds of reporting the highest level of complexity within a type of E/M code relative to reporting the lowest level of complexity with that type, among non-VA providers and among VA providers. We display the odds ratio (i.e., the non-VA odds divided by the VA odds) on the x -axis for seven broad categories of E/M codes. We show that the odds of reporting the highest level of complexity is much higher among non-VA providers. In only one category (i.e., critical care) is the odds ratio close to one. The (volume-weighted) average odds ratio is 5.1.

A.9 Modal-Hospital Mechanisms

This appendix details analyses in Section 5.3, where we describe indirect evidence for the role of health IT and integrated care. We perform analyses on a sample of veterans who only use non-VA care in the year prior to their ambulance rides. Since no veteran in this sample has prior VA utilization, the sample is disjoint from our benchmark sample (Appendix Table A.1). We only include zip codes with at least two non-VA hospitals within 20 miles, but we make no requirement on proximity to a VA hospital. The probability of transport to a VA hospital in this sample is 0% (as opposed to 33% in the benchmark sample), but rates of weekend transport and 28-day mortality are remarkably similar.

We detail the sample selection process for this analysis in Appendix Table A.13 and present patient and ride characteristics in this sample Appendix Table A.14.

Quasi-Experimental Design. As an analog to our benchmark VA instrument in Equation (1), we construct an instrument that reflects a given ambulance company's leave-out propensity to deliver patients to the index patient's modal non-VA hospital. Let $h(i)$ denote the hospital that ambulance ride i is transported to, and let $h^m(i)$ represent the modal non-VA hospital used by patient $k(i)$ in ride i . Our treatment of interest is $D_i^m \equiv \mathbf{1}(h(i) = h^m(i))$, which indicates whether ambulance ride i transports its patient $k(i)$ to his modal hospital. Our instrumental variable for this treatment is

$$Z_i^m = \frac{1}{K_{j(i),z(i)} - 1} \sum_{i' \in \mathcal{I}_{j(i),z(i)}} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}^m}{N_{k(i'),z(i'),j(i')}}. \quad (\text{A.29})$$

where $K_{j,z}$ is the number of patients transported by company j from zip code z , $N_{k,z,j}$ is the number of rides taken by patient k originating in zip code z with company j , and $\mathcal{I}_{j,z}$ is the set of rides transported by ambulance company j from zip code z . This is the leave-out probability that ambulance company $j(i)$ transports other patients from the same zip code to the modal hospital $h^m(i)$ of patient $k(i)$.⁴³ We use the following first-stage and reduced-form equations, similar to Equations (4) and (3):

$$D_i^m = \pi_1^m Z_i^m + \gamma_1^m \bar{Z}_i^m + \mathbf{X}_i^0 \delta_1^m + \zeta_{1,z(i)}^m + \varepsilon_{1,i}^m; \quad (\text{A.30})$$

$$Y_i = \pi_2^m Z_i^m + \gamma_2^m \bar{Z}_i^m + \mathbf{X}_i^0 \delta_2^m + \zeta_{2,z(i)}^m + \varepsilon_{2,i}^m. \quad (\text{A.31})$$

We include in these equations an additional control variable:

$$\bar{Z}_i^m = \frac{1}{K_{z(i)} - 1} \sum_{i' \in \mathcal{I}_{z(i)}} \frac{\mathbf{1}(k(i') \neq k(i)) D_{i'}^m}{N_{k(i'),z(i')}},$$

where K_z is the number of patients from zip code z , $N_{k,z}$ is the number of rides taken by patient k originating in zip code z , and \mathcal{I}_z is the set of rides originating in zip code z . This is the leave-out probability that patients from the same zip code $z(i)$ are transported to hospital $h^m(i)$, *unconditional* on the ambulance company. The modal-hospital effect may also capture hospital quality or hospital-patient match effects. We further assess the modal hospital effect both (i) while including hospital fixed effects in Equations (A.30) and (A.31) and (ii) while splitting rides i into samples based on whether the ride was before or after the hospital $h(i)$ adopted health IT or joined an ACO.

In the sample of veterans with only non-VA prior utilization (Panel B of Appendix Table A.13), we demonstrate in Appendix Figure A.15 a well-behaved first-stage relationship between D_i^m and Z_i^m and balance between predicted mortality, \hat{Y}_i , and Z_i^m , conditional on $(\bar{Z}_i^m, \mathbf{X}_i^0, z(i))$.⁴⁴

⁴³As with the benchmark instrument, we construct this instrument from data in the overall sample of ambulance rides with dually eligible veterans (Column 1, Tables 1 and A.14). For patients with multiple hospitals that tie for highest utilization in the prior year, we designate the set of these highest-use hospitals as the "modal hospital."

⁴⁴Analogously to Figure 1, this figure presents binned scatterplots of the first-stage regression in Equation (A.30), the reduced-form regression in Equation (A.31), and a balance regression with predicted mortality as the outcome variable and

Results. The IV estimate of the modal-hospital effect on mortality is -0.006 (s.e. 0.004), which is less than 20% of the VA effect on mortality. The visual IV graph in Appendix Figure A.16 shows that the overall relationship between the reduced form and first stage is not particularly striking.⁴⁵ However, computing the same IV estimate separately by years, we show in Figure 6 a stronger modal-hospital effect emerges after the passage of the HITECH Act of 2009, which led to a rapid rise in electronic medical record systems. The modal-hospital effect is close to 0 and stable prior to 2009; following 2009, the modal-hospital effect grows to about half the size of the VA effect on mortality.

To extend this analysis, we use hospital-specific dates of hospital health IT adoption or ACO participation (described in Appendix A.5). During our sample period a sizable proportion of hospitals adopted health IT and, to a much lesser extent, participated in an ACO. We construct four subsamples defined by whether or not each veteran’s modal hospital had adopted health IT, at the time of his ambulance ride, and similarly by whether or not each veteran’s modal hospital had joined an ACO. In each of these subsamples, we performed the same IV regression of the effect of transport to a veteran’s modal hospital. Results are shown in Table A.15, Columns 1, 2, 4, and 5. We obtain all of these results after adding hospital fixed effects in the first-stage and reduced-form regressions in Equations (A.30) and (A.31), respectively. Results are qualitatively unchanged regardless of their inclusion.

In Columns 3 and 6 of Table A.15, we also perform regressions in the overall sample (described in Panel B of Appendix Table A.13). We maintain all of the interactions implicit in our subsample results except that we allow hospital group fixed effects to remain constant before and after adoption of health IT or an ACO. We do so with the following control function approach. First, we estimate a first-stage regression that interacts everything with adoption status, except for fixed effects for hospital groups, $g(h(i))$, defined by whether a hospital ever adopts health IT or an ACO:

$$D_i^m = \sum_{a \in \{0,1\}} \mathbf{1}(\text{Adopted}_i = a) \left(\pi_{1,a}^m Z_i^m + \gamma_{1,a}^m \bar{Z}_i^m + \mathbf{X}_i^0 \delta_{1,a}^m + \zeta_{1,z(i),a}^m \right) + \xi_{1,g(h(i))}^m + \varepsilon_{1,i}^m. \quad (\text{A.32})$$

We then take estimated first-stage residuals $\hat{\varepsilon}_{1,i}^m$ and include them in an interacted control-function model:


$$Y_i = \sum_{a \in \{0,1\}} \mathbf{1}(\text{Adopted}_i = a) \left(\beta_a D_i^m + \gamma_a \hat{\varepsilon}_{1,i}^m + \mathbf{X}_i^0 \delta_a + \zeta_{z(i),a} \right) + \xi_{g(h(i))} + \varepsilon_i. \quad (\text{A.33})$$

As with our other control-function regressions, we compute standard errors by 50 bootstrapped iterations, drawing samples by zip code blocks, with replacement. While estimates control for hospital or hospital group fixed effects, we find that results are essentially unchanged regardless of their inclusion.

the same design matrix.


⁴⁵Analogously to Figure 2 and Appendix Figure A.3 in the benchmark analysis, Appendix Figure A.17 shows stability in OLS and two-stage least squares estimates with increasing controls, and Appendix Figure A.18 shows robustness of two-stage least squares estimates under an exhaustive set of control combinations.

Figure A.1: Balance Coefficient in Simulated Data




Note: This figure plots the balance coefficient in the baseline sample and in simulated data in which we perfectly sort a percent of ambulance rides and randomly assign the rest of the ambulance rides. The y-axis shows the balance coefficient, and the x-axis shows the percent of perfectly sorted observations in the simulated data, or $\iota \in \{0, 1, \dots, 100\}$. The dashed horizontal line indicates the balance coefficient in the baseline sample, also shown in Panel B of 1. Each simulated dataset comprises observations of residuals of predicted mortality \hat{Y}_i and residuals of Z_i , formed by regressions of each object on baseline controls. We form the simulated dataset by perfectly sorting ι percent (in expectation) of \hat{Y}_i residuals according to ambulances that are sorted by their mean Z_i residual and randomly assigning the remaining $1 - \iota$ percent (in expectation). We assign rides only within their original zip code, also holding the number of rides assigned to each ambulance company within the zip code fixed. The regression of reassigned residual \hat{Y}_i on residual Z_i gives the balance coefficient in each simulated dataset, shown in the solid black line. The shaded gray region indicates the 95% confidence interval, which we obtain by 20 bootstrapped replications drawn by zip code blocks with replacement. The upper confidence limit intersects with the actual balance coefficient between $\iota = 2$ and $\iota = 3$.

Figure A.2: Visual IV




Note: This figure shows the visual IV plot corresponding to our baseline IV regression of the effect of the VA on 28-day mortality. For each bin of the instrument, which is the ambulance leave-out propensity to arrive at a VA hospital, we plot the mean 28-day mortality on the y-axis and the probability that the index patient arrives at a VA hospital on the x-axis. VA arrival predictions correspond to a first-stage regression in Equation (3), and mortality predictions correspond to a reduced-form regression in Equation (4). The best-fit line in the visual IV plot replicates the IV estimate of the effect of the VA on 28-day mortality, which we perform to obtain the standard error (in parentheses). This IV regression uses 401,319 observations and 1,217 combinations of ambulance company identifiers and Dartmouth Atlas Hospital Referral Regions (HRRs). The baseline sample selection is given in Appendix Table A.1. Controls include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization, which are detailed in Appendix Table A.2.

Figure A.3: Combinations of Controls




Note: This figure shows IV estimates of the VA effect on 28-day mortality on the y-axis, from Equation (2), varying the number of controls included in the IV regression. Numbered incremental controls correspond to categories or subcategories of variables that are presented in order in Appendix Tables A.2 and A.3. All specifications include the five baseline controls. Therefore, the figure represents $5 + (2^7 - 1) = 132$ specifications. For each number of controls n for $n > 5$, we consider “7 choose $n - 5$ ” specifications. The mean IV estimate is shown with a dashed line; the minimum and maximum IV estimates are shown with a short dashed line. We use our baseline sample, described in Appendix Table A.1.

Figure A.4: Treatment Effects by Time and Sample




Note: This figure shows mortality treatment effects over varying days since the ambulance ride and in varying samples restricting by prior rides. “Days” indicate one-week intervals from the ambulance ride. Panel A shows OLS results corresponding to Equation (6). Panel B shows IV results corresponding to Equation (5). The vertical dashed line indicates treatment effects on 28-day mortality, our baseline outcome. All regressions use a sample of ambulance rides with no prior ride in the last year.

Figure A.5: Joint Inequality Constraints




Note: This figure shows the test statistic for joint inequality constraints and bootstrapped-generated distributions of the test statistic under the least favorable version of the null hypothesis. Panel A shows the joint inequality test of no mortality displacement, as defined by null hypothesis in Equation (A.7). Panel B shows the joint inequality test of no negative hazard rates, as defined by the null hypothesis in Equation (A.16). The test statistic for both tests is shown as a solid vertical line. The one-sided critical value, or 95th percentile of the bootstrapped distribution of the test statistic under the least favorable version of the null hypothesis, is shown as a dashed vertical line. Details of the test statistic and the bootstrap procedure for Panels A and B are given in Appendices A.2.2 and A.2.3, respectively.

Figure A.6: Mean Hazard Differences




Note: This figure shows tests of equality of mean hazard rates for different sets of hazard rates, as defined by the null hypothesis in Equation (A.18). Each panel corresponds to a comparison between sets of hazards corresponding to VA or non-VA compliers or users. Details of the statistical procedure are given in Appendix A.2.4. Hazard rates for compliers are estimated by two-stage least squares and denoted in the appendix by $\hat{h}_{IV}(t; d)$, where $d = 1$ for compliers assigned to the VA and $d = 0$ for compliers assigned to a non-VA hospital. Hazard rates for users are estimated by OLS and denoted by $\hat{h}_{OLS}(t; d)$, where d similarly denotes VA users ($d = 1$) vs. non-VA users ($d = 0$). The solid black line shows the test statistic, and the histogram shows the distribution of bootstrapped test statistics under the null hypothesis. Bootstrapped standard errors are given in the caption.

Figure A.7: Joint Equality Constraints




Note: This figure shows tests of joint equality of hazard rates for different sets of hazard rates, as defined by the null hypothesis in Equation (A.19). Each panel corresponds to a comparison between sets of hazards corresponding to VA or non-VA compliers or users. Details of the statistical procedure are given in Appendix A.2.4. Hazard rates for compliers are estimated by two-stage least squares and denoted in the appendix by $\hat{h}_{IV}(t; d)$, where $d = 1$ for compliers assigned to the VA and $d = 0$ for compliers assigned to a non-VA hospital. Hazard rates for users are estimated by OLS and denoted by $\hat{h}_{OLS}(t; d)$, where d similarly denotes VA users ($d = 1$) vs. non-VA users ($d = 0$). The solid line shows the test statistic, the histogram shows the distribution of bootstrapped test statistics under the null hypothesis, and the dashed line shows the one-sided 95th percentile critical value.

Figure A.8: Marginal Treatment Effects




Note: This figure shows a flexible fit of the IV relationship between 28-day mortality and the ambulance propensity to transport to a VA hospital. Panel A shows the visual IV relationship with residual 28-day mortality on the y -axis and residual probability of being transported to a VA hospital on the x -axis. Both objects are residualized by baseline controls, described in Appendix Table A.2. The probability of being transported to a VA hospital is calculated from the first-stage relationship in Equation (3). The data underlying the fit in Panel A are similar to those in the linear visual IV plot in Appendix Figure A.2. The fit is based on five Gaussian basis splines. Panel B shows the implied marginal treatment effects, which are the analytical derivatives at each point on the fit in Panel A. 95% confidence intervals are calculated by 50 bootstrapped iterations (drawn by zip codes, with replacement). Details are given in Appendix A.4.

Figure A.9: Station-Specific OLS Estimates of VA Advantage




Note: Panel A of this figure shows the kernel density distribution of station-specific OLS estimates of the VA advantage, or $\hat{\beta}_{OLS}^l$ estimated from Equation (A.27) for rides corresponding to each station. We include estimates from 32 stations with at least 5,000 rides, comprising a sample of 276,483 rides. Panel B of this figure shows the kernel density distribution of empirical Bayes posteriors of the station-specific OLS estimates of the VA advantage. These posteriors are given by $\tilde{\beta}_{OLS}^l$ in Equation (A.28). The figure displays posteriors from all 94 stations in our baseline sample in Appendix Table A.1, comprising 401,319 rides.

Figure A.10: VA Shares Within Top Reported Procedures




Note: This figure shows the VA share of line items of reported utilization of each of the top 25 procedures, defined by Current Procedural Terminology (CPT) codes, on the Medicare Physician Fee Schedule (MPFS). We include line items of utilization for any patient in our baseline sample in the 28 days following his ambulance ride. The area of each circle indicates the relative number of line items belonging to each CPT code. For scale, the largest circle represents 1.627 line items per ambulance ride; the smallest circle represents 0.162 line items per ambulance ride. The top 25 procedures represent 57.2% of line items with any CPT code on the MPFS. The gray vertical line indicates the overall VA share of line items of any CPT code on the MPFS.

Figure A.11: VA Shares Within Top Reported Procedure Groups




Note: This figure shows the VA share of line items of reported utilization belonging in each of the top 25 groups of procedures, defined by Current Procedural Terminology (CPT) codes. We form groups based on the list of 115 groups of Category I CPT codes at https://en.wikipedia.org/wiki/Current_Procedural_Terminology, which in turn is based on the organization of CPT codes by the American Medical Association (2017). We include line items of utilization for any patient in our baseline sample in the 28 days following his ambulance ride. The area of each circle indicates the relative number of line items belonging to each CPT code group. For scale, the largest circle represents 4.159 line items per ambulance ride; the smallest circle represents 0.095 line items per ambulance ride. The top 25 groups of procedures represent 65.1% of line items with any Category I CPT code. The gray vertical line indicates the overall VA share of line items of any Category I CPT code.

Figure A.12: Reimbursement and VA Shares of Procedures




Note: This figure shows a binned scatterplot between reimbursement in dollars (on the y-axis) and the VA share of line items corresponding to each of the top 200 Current Procedural Terminology (CPT) codes on the Medicare Physician Fee Schedule (MPFS). Reimbursement for a CPT code is calculated for each year it is on the MPFS by multiplying its year-specific relative value units (RVUs) with the year-specific conversion factor. We then take the median reimbursement across years that the CPT code is on the MPFS. We include line items of utilization for any patient in our baseline sample in the 28 days following his ambulance ride. The top 25 procedures represent 79.3% of line items with any CPT code on the MPFS. We weight each CPT observation by its number of line items in forming the binned scatterplot.

Figure A.13: High-Complexity E/M Utilization in Non-VA vs. VA Providers




Note: This figure shows the odds ratio of high-complexity evaluation and management (E/M) Current Procedural Terminology (CPT) codes billed by non-VA vs. VA providers. We include line items of utilization for any patient in our baseline sample in the 28 days following his ambulance ride. Within each type of E/M code, defined by the setting and the type of patient (e.g., “office or other outpatient visit for the evaluation and management of an established patient” for CPT codes 99211 to 99215), E/M codes are distinguished by “level” of complexity. We calculate the odds of highest to lowest complexity for non-VA providers and for VA providers and present the odds ratio on the x -axis. An odds ratio of one indicates that non-VA and VA providers are equally likely to bill the highest- vs. the lowest-complexity E/M code within the type. An odds ratio greater than one indicates that non-VA providers are more likely to do so. We present results within seven categories of E/M-code types defined by setting. The area of each circle is proportional to the total number of line items in each of these categories.

Figure A.14: Sources of Prior Utilization




Note: This figure shows patterns of prior utilization and ambulance transport among a sample of patients who have some prior utilization either at the VA or affiliated with a non-VA hospital. Panel A shows the percentage of patients in this sample who utilize care associated with different numbers of hospitals. Panel B shows ambulance transport patterns to either the VA or a non-VA hospital depending on whether a patient's modal hospital in prior utilization was associated with the VA or with a non-VA hospital. If the patient's modal hospital utilization was at a non-VA hospital, the figure also shows the percentage of patients who were transported to their modal non-VA hospital or another non-VA hospital. The sample selection for this group of patients is given in Appendix Table A.13.

Figure A.15: Modal Hospital First Stage, Balance, and Reduced Form




Note: Panel A shows a binned scatterplot of arrival at the veteran’s modal hospital against the ambulance leave-out propensity to arrive at that hospital on the x -axis. The figure is a graphical representation of the first-stage regression in Equation (A.30). Panel B shows binned scatterplots of 28-day mortality and predicted 28-day mortality on the y -axis against the ambulance leave-out propensity to arrive at the veteran’s modal hospital on the x -axis. Mortality bin means are shown in solid circles, while predicted mortality bin means are shown in hollow circles. The figure represents the reduced-form regression in Equation (A.31) and the corresponding balance regression replacing mortality with predicted mortality. The sample includes 1,414,217 ambulance rides and 5,716 combinations of ambulance company identifiers and Dartmouth Atlas Hospital Referral Regions (HRRs). The sample includes patients who have some utilization affiliated with a non-VA hospital and no utilization at the VA in the prior year. The selection details of this sample is given in Appendix Table A.13. Controls include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization, which are detailed in Appendix Table A.2.

Figure A.16: Modal Hospital Visual IV




Note: This figure shows the visual IV plot corresponding to the IV regression of the effect of arrival at a patient’s modal hospital on 28-day mortality. For each bin of the instrument, which is the ambulance leave-out propensity to arrive at the patient’s modal hospital, we plot the mean 28-day mortality on the y-axis and the probability that the index patient arrives at his modal hospital on the x-axis. Modal hospital arrival predictions correspond to a first-stage regression in Equation (A.30), and mortality predictions correspond to a reduced-form regression in Equation (A.31). The best-fit line in the visual IV plot replicates the IV estimate of the effect of arrival at a patient’s modal hospital on 28-day mortality, which we perform to obtain the standard error (in parentheses). This IV regression uses 1,414,217 observations and 5,716 combinations of ambulance company identifiers and Dartmouth Atlas Hospital Referral Regions (HRRs). We use the sample of non-VA-only utilizers, given in Appendix Table A.13. Controls include patient zip code dummies, ALS/BLS dummies, source of the ambulance ride, time categories, and patient prior utilization, which are detailed in Appendix Table A.2.

Figure A.17: Modal Hospital OLS and IV Specifications



Note: This figure shows the effect of arrival at a patient’s modal hospital on 28-day mortality estimated from OLS and IV specifications, with progressive sets of controls. Numbered incremental controls correspond to categories or subcategories of variables that are presented in order in Appendix Tables A.2 and A.3. Control sets are as follows: (1) zip code; (2) pickup source; (3) ambulance service; (4) time categories; (5) prior utilization; (6) demographics; (7) socioeconomic status, combat history, and eligibility; (8) extended prior utilization; (9) prior diagnoses; (10) 3-digit ambulance diagnosis codes; (11) co-rider baseline controls; and (12) co-rider hold-out controls. Estimates are shown along solid lines, while 95% confidence intervals are shown in dashed lines. All specification control for hospital identities and use the sample of non-VA-only utilizers, given in Appendix Table A.13.

Figure A.18: Modal Hospital Combinations of Controls



Note: This figure shows IV estimates of the effect of arrival at a patient’s modal hospital on mortality on the y-axis, with first-stage and reduced-form Equations (A.30) and (A.31), varying the number of controls included in the IV regression. Control variables are detailed in Appendix Tables A.2 and A.3. All specifications include the five baseline controls. Therefore, the figure represents $5 + (2^7 - 1) = 132$ specifications. For each number of controls n for $n > 5$, we consider “7 choose $n - 5$ ” specifications. The mean IV estimate is shown with a dashed line; the minimum and maximum IV estimates are shown with a short dashed line. We use the sample of non-VA-only utilizers, given in Appendix Table A.13.

Table A.1: Selection of Baseline Sample

| Sample step | Description | Rides | Patients | Ambulance companies | Hospitals | |
|---|---|-----------|-----------|---------------------|-----------|--------|
| | | | | | VA | Non-VA |
| 1. Build initial sample of ambulance rides to EDs from January 1, 2001, to December 31, 2014. | Require ED visit within 24 hours after ambulance ride, non-missing demographic data, enrollment in Medicare Parts A and B for at least one year, date of death (if non-missing) weakly after the ambulance ride. | 8,952,884 | 2,898,667 | 183,693 | 127 | 7,816 |
| 2. Clean sample | Drop rides linked to more than one ED visit (i.e., visits in different hospitals), with patients younger than 20 years or older than 99 years, with missing Health Referral Region, with missing ambulance diagnosis code, or from VA New Orleans (destroyed in 2005 due to Hurricane Katrina). | 8,828,997 | 2,862,557 | 180,320 | 125 | 7,744 |
| 3. Distance restrictions | Drop patients who do not live within 20 miles of a VA hospital and within 20 miles of a non-VA hospital. Drop rides to a hospital over 50 miles from the patient's home. | 3,465,588 | 1,118,302 | 14,662 | 118 | 3,071 |
| 4. Ambulance restrictions | Drop rides by an ambulance company with fewer than 20 patients in a given zip code. Drop rides by an ambulance company with less than 5% of rides in a given zip code to a VA hospital. Drop rides from zip codes with only one remaining ambulance company. | 1,051,093 | 365,163 | 1,217 | 100 | 1,577 |
| 5. Prior utilization restriction | Drop rides for patients with no VA utilization (inpatient, ED, or primary care) in the prior year. | 491,193 | 188,299 | 1,217 | 99 | 1,404 |
| 6. Prior ride restriction | Drop rides for patients with a prior ride within 30 days. | 401,319 | 188,299 | 1,217 | 99 | 1,386 |

Note: This table details selection steps to create the baseline sample. At each step, the table lists the number of ambulance rides, patients, ambulance companies, and VA and non-VA hospitals. Table 1 shows average patient characteristics among observations at each sample step.

Table A.2: Baseline Control Variables

| Category | Subcategory | Variables |
|-------------------------------------|-------------------------------------|--|
| Location (1,633 indicators) | Zip code (1,630 indicators) | Zip code indicators (1,630 indicators) |
| | Pickup source (3 indicators) | Indicators for whether pickup is from residence, residential (including domiciliary, custodial facility), skilled nursing facility, or scene of accident (omitted category) |
| Ambulance service (3 indicators) | | Indicators for whether ambulance is ALS special (CPT codes A0427, A0330, A0370), ALS non-special (CPT codes Q3019, A0368, A0328), ALS level 2 (CPT code A0433), or BLS (omitted category; CPT codes A0429, A0362, A0322) |
| Time categories (173 indicators) | | Day of the week (6 indicators); Month-year interactions (167 indicators) |
| | Prior utilization (6 indicators) | Indicators for utilization in prior year of Medicare primary care, VA primary care utilization, Medicare ED, VA ED, Medicare inpatient, and VA inpatient services |

Note: This table describes baseline controls variables, denoted as $(z(i), \mathbf{X}_i^0)$ in Condition 1 and throughout the text. We consider our quasi-experiment to be conditional on these variables, and we include these variables as controls in all of our analyses. Numbers of non-collinear indicators are given in parentheses.

Table A.3: Hold-Out Control Variables

| Category | Subcategory | Variables |
|---|--|---|
| Patient background (60 variables) | Demographics (30 indicators) | Age: 5-year age bins from 20-64 years, 2-year age bins from 65-100 years (26 indicators); Male gender; Race: indicators for white, Black, Hispanic, and Asian/other (omitted category) |
| | Socioeconomic status, combat history, and eligibility (22 indicators) | Terciles of income and net worth (4 indicators); Period of combat: WWII, Korean, Vietnam, other (omitted category) (3 indicators); Indicator for aid and attendance for in-home care; Priority group indicators (7 indicators); Service connection: service connected, not service connected, or non-veteran/other (omitted category) (2 indicators); 6 missing indicators for each of the above characteristics |
| | Extended prior utilization (8 variables) | Counts of VA primary care visits, outpatient visits, ED visits, and inpatient visits in prior year; Analogous counts of Medicare visits in prior year |
| Prior diagnoses (93 indicators) | | 31 Elixhauser indicators (dividing hypertension indicator into 2 indicators for complicated and uncomplicated hypertension), in four categories: present in VA data only, present in Medicare data only, and present in both VA and Medicare data ($31 \times 3 = 93$ indicators) |
| 3-digit ambulance diagnosis codes (641 indicators) | | 3-digit ambulance diagnosis (ICD-9) codes (641 indicators) |
| Co-rider characteristics (33 variables) | Co-rider baseline controls (12 variables) | Co-rider pickup source proportions (3 variables); Co-rider ambulance service proportions (3 variables); Co-rider prior utilization proportions (6 variables) |
| | Co-rider hold-out controls (21 variables) | Co-rider average continuous age; Co-rider proportion male gender; Co-rider race proportions (3 variables); Co-rider 1-digit ambulance code proportions (15 variables); Co-rider average predicted mortality |

Note: This table describes hold-out control variables. These variables are used to test robustness of our findings, particularly in Figures 2, A.3, A.18, and A.17. Numbers of non-collinear indicators or variables are given in parentheses.

Table A.4: Robustness of Exclusion Restriction

| | (1) | (2) | (3) | (4) | (5) | (6) |
|---|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| A: Dependent variable: 28-day mortality | | | | | | |
| VA hospital | -0.053 (0.019) | -0.045 (0.018) | -0.039 (0.018) | -0.045 (0.018) | -0.045 (0.018) | -0.045 (0.021) |
| Outcome mean | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |
| B: Dependent variable: 28-day spending | | | | | | |
| VA hospital | -2,421 (897) | -2,805 (876) | -2,144 (809) | -2,549 (814) | -2,598 (820) | -2,257 (974) |
| Outcome mean | 12,265 | 12,265 | 12,265 | 12,265 | 12,265 | 12,265 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |
| Ambulance charges splines | Yes | No | No | No | No | Yes |
| Mileage splines | No | Yes | No | No | No | Yes |
| Out-of-sample mortality | No | No | Yes | No | No | Yes |
| Chosen non-VA hospitals | | | | | | |
| Out-of-sample mortality | No | No | No | Yes | No | Yes |
| Out-of-sample spending | No | No | No | No | Yes | Yes |

Note: This table presents IV estimates of the effect of the VA on 28-day mortality (Panel A) and on 28-day spending (Panel B). In each panel, each column involves including a set of controls for ambulance actions on the specific ride (flexible functions of the charges incurred by the ambulance company, flexible functions of the mileage driven by the ambulance company), for “out-of-sample” outcomes by the ambulance company, and for non-VA hospitals chosen by the ambulance company (“out-of-sample” averages of mortality and spending for these non-VA hospitals). “Out-of-sample” refers to patients outside of the main analytical sample (Appendix Table A.1) because they have no VA utilization in the prior year; specifically, they are computed using patients with only non-VA utilization in the prior year (Panel B of Appendix Table A.13). Regressions are run on the main analytical sample. Further details are given in Appendix A.1.1.

Table A.5: Monotonicity Tests

| First stage sample | Observations | VA share | Instrument | |
|--------------------------------------|--------------|----------|-------------------|----------------------|
| | | | Baseline | Reverse-sample |
| Age \leq 80 | 239,611 | 0.347 | 0.931 (0.038) | 0.497 (0.022) |
| Age $>$ 80 | 161,707 | 0.305 | 0.789 (0.041) | 0.456 (0.022) |
| White | 314,064 | 0.304 | 0.821 (0.037) | 0.221 (0.016) |
| Non-white | 87,176 | 0.426 | 0.992 (0.068) | 0.596 (0.041) |
| Comorbidity count (high) | 167,332 | 0.292 | 0.758 (0.041) | 0.427 (0.019) |
| Comorbidity count (low) | 233,987 | 0.358 | 0.938 (0.039) | 0.553 (0.027) |
| Mental illness or substance abuse | 188,961 | 0.354 | 0.931 (0.040) | 0.514 (0.024) |
| No mental illness or substance abuse | 212,358 | 0.309 | 0.815 (0.037) | 0.456 (0.020) |
| VA visits in prior year (high) | 183,087 | 0.508 | 1.038 (0.050) | 0.710 (0.035) |
| VA visits in prior year (low) | 218,232 | 0.181 | 0.718 (0.031) | 0.284 (0.014) |
| Advanced Life Support | 274,690 | 0.301 | 0.836 (0.036) | 0.249 (0.018) |
| No Advanced Life Support | 126,616 | 0.393 | 0.840 (0.048) | 0.301 (0.032) |
| Predicted VA user (high) | 200,659 | 0.543 | 1.113 (0.054) | 0.865 (0.055) |
| Predicted VA user (low) | 200,660 | 0.117 | 0.559 (0.030) | 0.218 (0.011) |
| Predicted mortality (high) | 200,659 | 0.328 | 0.835 (0.036) | 0.368 (0.019) |
| Predicted mortality (low) | 200,660 | 0.333 | 0.898 (0.046) | 0.502 (0.024) |
| Instrument sample | | | Dual eligibles | Analytical sample |

Note: This table presents first-stage coefficients on different subsamples of patients. For each subsample, we present results for two different instruments: (i) the baseline leave-out instrument, Z_i , given in Equation (1) and calculated from observations among dually eligible veterans (Step 1 of Appendix Table A.1), and (ii) a reverse-sample instrument, \tilde{Z}_i^{-m} , given in Equation (A.2) and calculated from observations in the analytical sample (Step 6 of Appendix Table A.1) that are outside of the regression subsample. Each regression uses baseline controls defined in Appendix Table A.2. Further details are given in Appendix A.1.2.

Table A.6: Monotonicity Tests (Continued)

| First stage sample | Observations | VA share | Instrument | |
|--------------------------------------|--------------|----------|----------------------|----------------------|
| | | | Baseline | In-sample |
| Age \leq 80 | 239,611 | 0.347 | 0.586 (0.021) | 0.525 (0.020) |
| Age $>$ 80 | 161,707 | 0.305 | 0.494 (0.023) | 0.394 (0.022) |
| White | 314,064 | 0.304 | 0.504 (0.019) | 0.513 (0.020) |
| Non-white | 87,176 | 0.426 | 0.676 (0.032) | 0.440 (0.033) |
| Comorbidity count (high) | 167,332 | 0.292 | 0.493 (0.020) | 0.438 (0.021) |
| Comorbidity count (low) | 233,987 | 0.358 | 0.583 (0.022) | 0.504 (0.020) |
| Mental illness or substance abuse | 188,961 | 0.354 | 0.592 (0.021) | 0.518 (0.020) |
| No mental illness or substance abuse | 212,358 | 0.309 | 0.501 (0.020) | 0.426 (0.020) |
| VA visits in prior year (high) | 183,087 | 0.508 | 0.691 (0.026) | 0.572 (0.021) |
| VA visits in prior year (low) | 218,232 | 0.181 | 0.421 (0.018) | 0.445 (0.021) |
| Advanced Life Support | 274,690 | 0.301 | 0.523 (0.020) | 0.518 (0.021) |
| No Advanced Life Support | 126,616 | 0.393 | 0.531 (0.025) | 0.433 (0.024) |
| Predicted VA user (high) | 200,659 | 0.543 | 0.743 (0.028) | 0.619 (0.021) |
| Predicted VA user (low) | 200,660 | 0.117 | 0.331 (0.016) | 0.423 (0.027) |
| Predicted mortality (high) | 200,659 | 0.328 | 0.513 (0.020) | 0.458 (0.019) |
| Predicted mortality (low) | 200,660 | 0.333 | 0.570 (0.023) | 0.479 (0.021) |
| Instrument sample | | | Analytical sample | Analytical sample |

Note: This table presents first-stage coefficients on different subsamples of patients. For each subsample, we present results for two different instruments: (i) the baseline leave-out instrument, \tilde{Z}_i , given in Equation (1), and (ii) a in-sample instrument, \tilde{Z}_i^m , given in Equation (A.2) and calculated from leave-out observations in the same regression subsample. Both instruments are calculated using observations in the analytical sample (Step 6 of Appendix Table A.1). Each regression uses baseline controls defined in Appendix Table A.2. Further details are given in Appendix A.1.2.

Table A.7: Always-Taker and Never-Taker Characteristics

| | Always takers | | Never takers | |
|-------------------------------|---------------------|-----------------------|---------------------|-----------------------|
| | Mean | Ratio | Mean | Ratio |
| Male | 0.961 (0.002) | 1.00 [0.99 - 1.00] | 0.965 (0.001) | 1.00 [1.00 - 1.00] |
| Age | 75.6 (0.158) | 0.99 [0.99 - 1.00] | 76.3 (0.153) | 1.00 [1.00 - 1.01] |
| Black | 0.222 (0.012) | 1.14 [1.02 - 1.26] | 0.184 (0.010) | 0.95 [0.85 - 1.05] |
| Income | \$18,039 (\$200) | 0.86 [0.84 - 0.88] | \$22,397 (\$232) | 1.07 [1.05 - 1.09] |
| Rural zip code | 0.064 (0.015) | 1.27 [0.67 - 1.87] | 0.053 (0.011) | 1.04 [0.62 - 1.46] |
| Residential source | 0.685 (0.011) | 0.97 [0.94 - 1.00] | 0.667 (0.009) | 0.95 [0.92 - 0.97] |
| Comorbidity count | 5.85 (0.046) | 0.95 [0.94 - 0.97] | 6.44 (0.032) | 1.05 [1.04 - 1.06] |
| Mental illness | 0.469 (0.006) | 1.10 [1.07 - 1.13] | 0.420 (0.004) | 0.98 [0.97 - 1.00] |
| Substance abuse | 0.150 (0.005) | 1.04 [0.97 - 1.10] | 0.137 (0.004) | 0.95 [0.90 - 1.00] |
| Prior VA ED visit only | 0.593 (0.007) | 2.02 [1.97 - 2.06] | 0.145 (0.003) | 0.49 [0.47 - 0.52] |
| Prior non-VA ED visit only | 0.032 (0.002) | 0.13 [0.12 - 0.14] | 0.376 (0.005) | 1.52 [1.48 - 1.56] |
| Prior VA and non-VA ED visit | 0.230 (0.006) | 0.98 [0.93 - 1.03] | 0.237 (0.004) | 1.01 [0.98 - 1.05] |
| Ambulance rides in prior year | 2.212 (0.030) | 1.03 [1.00 - 1.05] | 2.210 (0.025) | 1.03 [1.00 - 1.05] |
| Advanced Life Support | 0.576 (0.013) | 0.84 [0.81 - 0.88] | 0.707 (0.010) | 1.03 [1.01 - 1.06] |
| Predicted VA user | 0.969 (0.001) | 1.14 [1.14 - 1.15] | 0.778 (0.002) | 0.92 [0.91 - 0.92] |
| Predicted mortality | 0.103 (0.002) | 1.07 [1.03 - 1.10] | 0.100 (0.001) | 1.03 [1.01 - 1.05] |

Note: This table presents average characteristics for always takers and never takers. Always takers are defined as patients who present to the VA even when they receive a residualized instrument below the 20th percentile; never takers are defined as patients who present to a non-VA hospital even when they receive a residualized instrument above the 80th percentile. To form these residualized instruments, we residualize the baseline instrument, Z_i , given in Equation (1), by baseline controls, described in Appendix Table A.2. Observations are drawn from the baseline sample described in Appendix Table A.1. For each row corresponding to a characteristic, the table presents average characteristics and the ratio between this average and the overall sample average. Overall sample means are given in Table 4. Standard errors are calculated by bootstrap, blocking observations by zip codes, and are shown in parentheses. Corresponding 95% confidence intervals of the ratio are presented in brackets. Further details are given in Appendix A.3.

Table A.8: Treatment Effects from Selection Model

| | Dependent variable: 28-day mortality | | | | |
|---------------------|--------------------------------------|-------------------|-------------------|-------------------|-------------------|
| | (1) | (2) | (3) | (4) | (5) |
| ATE | -0.043 (0.017) | -0.033 (0.006) | -0.033 (0.006) | -0.033 (0.005) | -0.033 (0.005) |
| ATE-LATE difference | 0.003 (0.001) | 0.013 (0.011) | 0.012 (0.011) | 0.012 (0.011) | 0.012 (0.011) |
| Control function | Linear | Cubic | Cubic | Gaussian basis | Gaussian basis |
| Knots | | 3 | 5 | 3 | 5 |
| Outcome mean | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 |
| Observations | 401,319 | 401,319 | 401,319 | 401,319 | 401,319 |

Note: This table presents estimates of the average treatment effect (ATE) from the selection model in Equation (A.21), under different specifications. Column 1 presents results from a control function that is linear in the first-stage residual, corresponding to the regression in Equation (A.23). Columns 2 to 5 present results from semiparametric control functions, corresponding to regressions of the form in Equation (A.25). The columns vary in whether the spline functions are cubic functions or Gaussian basis functions and in the number of knots. In addition to the ATE, each column presents the difference between the ATE and the local average treatment effect (LATE). The LATE is estimated from Equation (A.24) and is numerically equivalent to the LATE from our benchmark analysis in Section 3. We compute standard errors (shown in parentheses) for the ATE and the ATE-LATE difference by bootstrap, blocking by zip codes. Appendix A.4 provides further details.

Table A.9: Heterogeneity by Non-VA Hospital Characteristics

| | Regression estimates | | Characteristic means | |
|---------------------------------------|----------------------|-----------------------------|----------------------|---------------|
| | VA | VA $\times \tilde{I}_{x,i}$ | $I_{x,i} = 0$ | $I_{x,i} = 1$ |
| <i>Volume, Size, and Capabilities</i> | | | | |
| ED visits | -0.046 (0.016) | -0.002 (0.002) | 28,082 | 53,849 |
| Admissions | -0.046 (0.017) | -0.003 (0.002) | 9,664 | 17,859 |
| Total staffed beds | -0.046 (0.017) | -0.004 (0.002) | 199 | 375 |
| Teaching hospital | -0.045 (0.017) | -0.000 (0.002) | 0.02 | 0.51 |
| Trauma center | -0.045 (0.016) | 0.004 (0.002) | 0.28 | 0.93 |
| Advanced cardiac care | -0.046 (0.017) | -0.000 (0.002) | 0.64 | 1.00 |
| Stroke center | -0.045 (0.017) | 0.001 (0.002) | 0.03 | 0.65 |
| <i>Staffing</i> | | | | |
| ED staff per 1,000 ED visits | -0.045 (0.017) | -0.001 (0.002) | 0.30 | 0.75 |
| Nurses per 1,000 patient-days | -0.046 (0.016) | 0.006 (0.002) | 4.13 | 6.58 |
| Physicians per 1,000 patient-days | -0.045 (0.017) | 0.002 (0.002) | 4.36 | 10.79 |
| Hospitalists per 1,000 patient-days | -0.045 (0.017) | 0.003 (0.002) | 0.12 | 0.39 |
| Intensivists per 1,000 patient-days | -0.045 (0.017) | 0.003 (0.002) | 0.05 | 0.23 |

Note: This table presents regression results investigating heterogeneous treatment effects along binary indicators of average non-VA hospital characteristics associated with each zip code. For each zip code, hospital characteristics are averaged with weights proportional to the number of rides going to each non-VA hospital from the zip code. We then divide observations i , based on whether their zip codes $z(i)$ have below- vs. above-median averages, denoted by $I_{x,i} = 0$ and $I_{x,i} = 1$, respectively. Regression results correspond to Equation (A.26). The coefficient on VA represents the LATE of going to the VA, and the coefficient on VA $\times \tilde{I}_{x,i}$ represents the difference in the LATE between observations with $I_{x,i} = 1$ and observations with $I_{x,i} = 0$. Appendix Table A.10 presents results for additional characteristics. Appendix A.5 provides further details on the hospital characteristics.

Table A.10: Heterogeneity by Non-VA Hospital Characteristics (Continued)

| | Regression estimates | | Characteristic means | |
|------------------------------|----------------------|-----------------------------|----------------------|---------------|
| | VA | VA $\times \tilde{I}_{x,i}$ | $I_{x,i} = 0$ | $I_{x,i} = 1$ |
| <i>Spending and Outcomes</i> | | | | |
| Relative spending | -0.045 (0.017) | -0.002 (0.002) | 0.97 | 1.04 |
| Mortality rate | -0.045 (0.017) | -0.003 (0.002) | 11.62 | 12.89 |
| Readmission rate | -0.045 (0.017) | -0.002 (0.002) | 17.30 | 18.90 |
| <i>Organization and IT</i> | | | | |
| Network or hospital system | -0.045 (0.017) | -0.002 (0.002) | 0.65 | 1.00 |
| HMO or ACO | -0.045 (0.017) | -0.002 (0.002) | 0.00 | 0.47 |
| Health IT | -0.046 (0.016) | -0.002 (0.002) | 0.00 | 0.80 |
| Share of non-VA rides (max.) | -0.045 (0.017) | 0.002 (0.002) | 0.42 | 0.73 |

Note: This table presents regression results investigating heterogeneous treatment effects along binary indicators based on non-VA hospital characteristics associated with each zip code. For “Share of non-VA rides (max.)”, we take the maximum non-VA hospital share of non-VA rides for each zip code as the zip code characteristic. For the remaining characteristics, hospital characteristics are averaged within each zip code with weights proportional to the number of rides going to each non-VA hospital from the zip code. We then divide observations i , based on whether their zip codes $z(i)$ have below- vs. above-median statistics, denoted by $I_{x,i} = 0$ and $I_{x,i} = 1$, respectively. Regression results correspond to Equation (A.26). The coefficient on VA represents the LATE of going to the VA, and the coefficient on $VA \times \tilde{I}_{x,i}$ represents the difference in the LATE between observations with $I_{x,i} = 1$ and observations with $I_{x,i} = 0$. Appendix Table A.9 presents results for additional characteristics. Appendix A.5 provides further details on the hospital characteristics.

Table A.11: Heterogeneity by VA Hospital Characteristics

| | Regression estimates | | Characteristic means | |
|---------------------------------------|----------------------|-----------------------------|----------------------|---------------|
| | VA | VA $\times \tilde{I}_{x,i}$ | $I_{x,i} = 0$ | $I_{x,i} = 1$ |
| <i>Volume, Size, and Capabilities</i> | | | | |
| ED visits | -0.045 (0.017) | -0.001 (0.002) | 8,625 | 23,111 |
| Admissions | -0.044 (0.016) | -0.003 (0.002) | 3,247 | 8,148 |
| Total staffed beds | -0.044 (0.017) | -0.007 (0.002) | 139 | 463 |
| Teaching hospital | -0.045 (0.017) | -0.003 (0.002) | 0.00 | 0.93 |
| Trauma center | -0.052 (0.018) | 0.006 (0.004) | 0.00 | 1.00 |
| Advanced cardiac care | -0.051 (0.018) | -0.004 (0.002) | 0.00 | 1.00 |
| <i>Staffing</i> | | | | |
| ED staff per 1,000 ED visits | -0.050 (0.022) | -0.001 (0.003) | 0.19 | 1.21 |
| Nurses per 1,000 patient-days | -0.045 (0.017) | 0.003 (0.002) | 3.80 | 8.60 |
| Physicians per 1,000 patient-days | -0.050 (0.022) | -0.000 (0.003) | 1.12 | 7.95 |
| Hospitalists per 1,000 patient-days | -0.051 (0.022) | 0.006 (0.003) | 0.03 | 0.30 |
| Intensivists per 1,000 patient-days | -0.050 (0.022) | 0.001 (0.003) | 0.00 | 0.15 |
| <i>Spending and Outcomes</i> | | | | |
| Relative spending | -0.045 (0.016) | -0.002 (0.002) | 0.95 | 1.22 |
| Mortality rate | -0.045 (0.017) | 0.005 (0.003) | 7.11 | 7.98 |
| Readmission rate | -0.045 (0.017) | -0.003 (0.002) | 11.70 | 12.70 |

Note: This table presents regression results investigating heterogeneous treatment effects along characteristics of the VA hospital associated with each zip code. For each VA hospital characteristic x , we divide observations i , based on whether x is below vs. above the median, denoted by $I_{x,i} = 0$ and $I_{x,i} = 1$, respectively. Regression results correspond to Equation (A.26). The coefficient on VA represents the LATE of going to the VA, and the coefficient on VA $\times \tilde{I}_{x,i}$ represents the difference in the LATE between observations with $I_{x,i} = 1$ and observations with $I_{x,i} = 0$. Appendix A.5 provides further details on the hospital characteristics.

Table A.12: Heterogeneity by Patient Characteristics

| | Regression estimates | | Characteristic means | |
|-----------------------------------|----------------------|-----------------------------|----------------------|---------------|
| | VA | VA $\times \tilde{I}_{x,i}$ | $I_{x,i} = 0$ | $I_{x,i} = 1$ |
| Older than 80 | -0.047 (0.017) | 0.004 (0.003) | 0.00 | 1.00 |
| Black | -0.043 (0.017) | -0.002 (0.003) | 0.00 | 1.00 |
| Hispanic | -0.045 (0.017) | -0.008 (0.008) | 0.00 | 1.00 |
| Income | -0.044 (0.017) | 0.003 (0.002) | \$10,651 | \$31,159 |
| Comorbidity count | -0.044 (0.016) | -0.014 (0.002) | 3.90 | 9.28 |
| Mental illness or substance abuse | -0.045 (0.017) | -0.005 (0.002) | 0.00 | 1.00 |
| VA visits in prior year | -0.044 (0.017) | -0.004 (0.002) | 2.15 | 11.88 |
| Ambulance rides in prior year | -0.043 (0.017) | -0.008 (0.002) | 1.00 | 3.55 |
| Advanced Life Support | -0.046 (0.017) | -0.013 (0.002) | 0.00 | 1.00 |
| Predicted VA user | -0.044 (0.017) | -0.005 (0.003) | 0.70 | 1.00 |
| Predicted mortality | -0.045 (0.016) | -0.018 (0.002) | 0.04 | 0.15 |

Note: This table presents regression results investigating heterogeneous treatment effects along patient characteristics. For each VA hospital characteristic x , we divide observations i , based on whether x is below vs. above the median, denoted by $I_{x,i} = 0$ and $I_{x,i} = 1$, respectively. Regression results correspond to Equation (A.26). The coefficient on VA represents the LATE of going to the VA, and the coefficient on VA $\times \tilde{I}_{x,i}$ represents the difference in the LATE between observations with $I_{x,i} = 1$ and observations with $I_{x,i} = 0$.

Table A.13: Selection of Alternative Samples

| Sample step | Description | A: Sample for Descriptive Utilization Patterns | | | Hospitals | |
|--|---|--|-----------|---------------------|-----------|--------|
| | | Rides | Patients | Ambulance companies | VA | Non-VA |
| 3. Start from distance restrictions in baseline sample | See step #3 in Table A.1. | 1,051,093 | 365,163 | 1,217 | 100 | 1,577 |
| 4. Prior utilization restriction | Keep rides for patients with some non-VA or VA utilization (inpatient, ED, or primary care). | 977,826 | 340,371 | 1,217 | 100 | 1,565 |
| 5. Prior ride restriction | Drop rides for patients with a prior ride within 30 days. | 794,940 | 340,371 | 1,217 | 100 | 1,548 |
| B: Non-VA-Only Sample | | | | | | |
| 2. Start from clean sample | See step #2 in Table A.1. | 8,828,997 | 2,862,557 | 180,320 | 125 | 7,744 |
| 3. Distance restrictions | Drop rides to a hospital over 50 miles from the patient's home. Drop zip codes without at least two non-VA hospitals within 20 miles that receive at least 5% from that zip code. | 6,424,120 | 2,131,152 | 29,100 | 122 | 5,498 |
| 4. Ambulance restrictions | Drop rides by an ambulance company with fewer than 20 patients in a given zip code. Drop rides from zip codes with only one remaining ambulance company. | 3,919,572 | 1,372,499 | 5,716 | 119 | 3,999 |
| 5. Prior utilization restriction | Keep only rides for patients with some non-VA utilization (inpatient, ED, or primary care) but no VA utilization in the prior year. | 1,735,141 | 644,917 | 5,716 | 97 | 3,812 |
| 6. Prior ride restriction | Drop rides for patients with a prior ride within 30 days. | 1,414,217 | 644,917 | 5,716 | 96 | 3,799 |

Note: This table details selection steps to create two alternative samples. Panel A shows selection steps for the sample that we use to study descriptive utilization patterns in Appendix Figure A.14. Panel B shows selection steps for the sample of patients with only non-VA prior utilization, which we use in Section 5.3 to study the effect of receiving care at a modal non-VA hospital. At each step, the table lists the number of ambulance rides, patients, ambulance companies, and VA and non-VA hospitals. Table A.14 shows average patient characteristics among observations at each sample step.

Table A.14: Characteristics of Non-VA-Only Sample

| Restrictions | Sample characteristics | | | | |
|-------------------------------|------------------------|--------------------|---------------------|-----------------------------------|----------------------------|
| | Dually eligible | Add zip × hospital | Add zip × ambulance | Add non-VA-only prior utilization | Add no ride in prior month |
| Male | 0.899 | 0.898 | 0.897 | 0.824 | 0.825 |
| Age | 77.04 | 77.12 | 77.32 | 77.68 | 78.05 |
| Black | 0.111 | 0.124 | 0.129 | 0.125 | 0.118 |
| Income | \$21,724 | \$21,763 | \$22,253 | \$22,800 | \$23,393 |
| Rural zip code | 0.255 | 0.169 | 0.125 | 0.120 | 0.120 |
| Residential source | 0.610 | 0.619 | 0.657 | 0.614 | 0.636 |
| Comorbidity count | 6.53 | 6.62 | 6.60 | 6.96 | 6.57 |
| Prior VA ED visit only | 0.048 | 0.052 | 0.052 | 0.000 | 0.000 |
| Prior non-VA ED visit only | 0.607 | 0.606 | 0.602 | 0.797 | 0.752 |
| Prior VA and non-VA ED visit | 0.088 | 0.089 | 0.085 | 0.000 | 0.000 |
| Ambulance rides in prior year | 2.77 | 2.83 | 2.82 | 3.13 | 2.28 |
| Advanced Life Support | 0.696 | 0.695 | 0.699 | 0.676 | 0.684 |
| Weekend rate | 0.272 | 0.271 | 0.271 | 0.270 | 0.269 |
| 28-day mortality | 0.115 | 0.116 | 0.113 | 0.117 | 0.112 |
| Present at VA | 0.044 | 0.049 | 0.049 | 0.002 | 0.002 |
| Number of patients | 2,862,557 | 2,131,152 | 1,372,499 | 644,917 | 644,917 |
| Number of ambulance rides | 8,828,997 | 6,424,120 | 3,919,572 | 1,735,141 | 1,414,217 |

Note: This table presents characteristics of observations remaining at each step of creating the sample of patients with only non-VA prior utilization, which we use in Section 5.3 to study the effect of receiving care at a modal non-VA hospital. Each step is detailed in Panel B of Appendix Table A.13.

Table A.15: Modal Hospital Mechanisms

| | Dependent variable: 28-day mortality | | | | | |
|-----------------------|--------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | (1) | (2) | (3) | (4) | (5) | (6) |
| | A: OLS | | | | | |
| Modal hospital | -0.005 (0.001) | -0.006 (0.001) | | -0.012 (0.005) | -0.006 (0.001) | -0.008 (0.003) |
| × Adoption | | | -0.006 (0.001) | | | -0.006 (0.001) |
| × No adoption | | | | | | |
| | B: IV | | | | | |
| First stage | 0.745 (0.011) | 0.689 (0.008) | | 0.506 (0.026) | 0.703 (0.007) | |
| Modal hospital | -0.015 (0.009) | -0.004 (0.006) | | -0.011 (0.034) | -0.006 (0.005) | -0.015 (0.019) |
| × Adoption | | | -0.015 (0.006) | | | -0.006 (0.005) |
| × No adoption | | | | | | |
| Outcome mean | 0.106 | 0.113 | 0.112 | 0.107 | 0.112 | 0.112 |
| Observations | 338,313 | 1,075,528 | 1,414,197 | 58,968 | 1,354,196 | 1,413,573 |
| Fixed effects | | | | | | |
| Hospital identities | Yes | Yes | No | Yes | Yes | No |
| Hospital ever adopted | N/A | N/A | Yes | N/A | N/A | Yes |
| Sample | IT adoption | No IT adoption | Full | ACO adoption | No ACO adoption | Full |

Note: This table shows OLS and IV estimates of the effect of presenting to a veteran’s modal hospital on 28-day mortality, depending on whether the modal hospital has adopted health IT or whether the modal hospital has joined an Accountable Care Organization (ACO). Columns 1 and 2 show results estimated in subsamples defined by whether the modal hospital has adopted health IT or not. Columns 5 and 6 show results estimated in subsamples defined by whether the modal hospital has joined an ACO or not. The first-stage and reduced-form equations for the IV estimation (Panel B) are given in Equations (A.30) and (A.31); while this table presents results with hospital fixed effects, results do not qualitatively depend on the inclusion of hospital fixed effects. Columns 3 and 6 present results estimated on the overall sample with interactions for adoption status; these specifications are described in detail in Appendix A.9. We include baseline controls defined in Appendix Table A.2. The overall sample is the same alternative sample designed to study choice among non-VA hospitals for patients with only non-VA utilization in the prior year. Details of the sample selection are given in Appendix Table A.13, Panel B.